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Cancer is still one of the most frequent causes of morbidity and mortality in Western 
countries. Although today part of the cancer patients may be cured using novel therapeutics 
(chemotherapy etc.), in many cases, except for hematological malignancies, surgical resection 
of the primary tumor still remains the main option. Once a tumor has disseminated to other 
organs, in the majority of the cases it is impossible to cure the patient.  In such cases, 
chemotherapy and radiotherapy are frequently used as additional therapeutic regimens. 
Animal models have been of utmost importance for gaining insight into the biology of tumor 
growth and metastasis: the patho-physiological steps of tumor growth and metastasis can be 
studied under defined laboratory conditions, which is for ethical reasons impossible in human 
beings1. The experimental setting also allows the development of new therapies and 
diagnostic tools. Although many theories and hypotheses on the mechanisms of tumor growth 
and dissemination are up to now based on tumor models 2, it is important to realize that such 
models are not necessarily valid for the different malignancies. Nevertheless, such models do 
offer the possibility to elucidate processes that are incompletely understood. 
In this thesis, studies on human melanoma cell lines in nude mouse xenograft models 
and mechanisms of development and growth of metastases are described with a focus on 
tumor angiogenesis. In these studies, preclinical data on diagnostic (radiological) and 
therapeutical (anti-angiogenic) interventions are presented and discussed. As melanoma is a 
highly malignant type of cancer, it is easy to transplant it in animals. Although the 
characteristics of only one type of malignancy are described here, many of the results and 
conclusions may also be extrapolated to other types of malignancies in patients, because these 
characteristics described are frequently mirrored in human tumor material. 
 
 
 
Human melanoma 
Melanoma is known as one of the most aggressive tumors in humans. The tumor originates 
from melanocytes that are derived from the neural crest. Although most melanomas arise in 
the skin, they may also arise in mucosal surfaces or at other sites to which neural crest cells 
have migrated. The incidence of  melanoma has been steadily increasing over the past years, 
making it a serious problem for healthcare systems in several countries, e.g. Australia, Canada 
and the USA (www.cancer.gov). 
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Fortunately, most melanomas are detected early and are excised as thin lesions. At this stage 
the probability of tumor dissemination is low. Most patients with a thin melanoma are 
therefore cured by excision of the lesion with an adequate tumor-free margin3,4.  
A more serious oncological problem are larger sized (thick) melanoma lesions: these tumors 
tend to spread via lymphogenous and hematogenous routes. The chances of curing such a 
patient are low. 
Frequent sites of distant metastasis are the lungs, the liver and the brain; moreover, it is the 
distant metastases that are fatal for the patients. The high affinity of melanoma to metastasize 
to the central nervous system (CNS) may be due to its neuroectodermal origin: the micro-
environmental conditions in the brain harbouring (a cocktail of) CNS-specific growth factors 
may facilitate the growth of melanoma cells5. 
 
Central nervous system metastasis 
The incidence of CNS metastasis in patients with melanoma ranges from 10% to 40% in 
clinical studies, while in autopsy series CNS involvement was identified in up to two thirds of 
the patients with metastatic melanoma6. This means that among cancer patients with advanced 
(disseminated) disease, melanoma patients have a high-risk for developing CNS metastasis7. 
This site of metastasis is life threatening for the patient. In a large series with more than 700 
melanoma patients with brain metastases, the median overall survival was 3.8 months7,8. 
Brain metastases in general are difficult to treat6 because of anatomical and physiological 
reasons: surgical excision is often limited to solitary lesions at locations that allow surgical 
intervention and do not involve vital areas of the brain. Radiation dose is limited because of 
vulnerability of the CNS for irradiation. Chemotherapy efficiency  is limited as melanoma is 
relatively insensitive to cytotoxic agents. Furthermore, the blood-brain barrier may prevent 
adequate delivery of some of the cytotoxic agents to the brain parenchyma.  
The CNS consists of parenchyma with neuronal and glial cells, and  a delicate branched 
network of brain microvessels is present that is characterized by a specific vascular-astrocytic 
functional unit, representing the blood-brain barrier. The CNS is surrounded by the meninges 
(pachymeninx (dura mater) and leptomeninges). In cancer patients metastases occur both in 
the meninges and the brain parenchyma. 
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Angiogenesis 
Angiogenesis is the formation of a neovascular bed in physiological (e.g. embryogenesis, 
menstrual cycle) and pathological conditions9 (e.g. wound healing). Angiogenesis is now for 
more than two decades a major focus of interest in the field of oncology. Judah Folkman 
postulated that growth of a tumor beyond a certain size (1-2 mm3)  depends on the formation 
of new blood vessels. Such vessels facilitate the supply of oxygen and nutritients to the 
tumor10. This hypothesis seems straight forward, as healthy normal tissue also depends on a 
vasculature, which is the result of physiological angiogenesis during organogenesis11. 
Therefore, the hypothesis of Folkman provided a dogmatic view for the scientists working in 
the field of tumor angiogenesis. 
To date there is abundant data that angiogenesis occurs in human tumors12,13. Studies in 
animal models have shown that tumor-induced angiogenesis is essential for tumor growth, as 
inhibition of angiogenesis resulted in diminished tumor growth rates in such models12-15. 
Physiological angiogenesis is a tightly regulated multistep process. Only tumors that 
have the repertoire to induce the full program of angiogensis will be vascularized by 
functional, mature vessels. The most prominent and most potent angiogenic factor is vascular 
endothelial growth factor (VEGF)16. This factor is also known as vascular permeability factor 
(VPF) 17 because of its potency to induce vascular leakage. It is a secreted protein and occurs 
as different isoforms. The human isoforms described to date consist of 121, 144, 165, 189 and 
206 amino acids18; three well characterized murine counterparts lack one amino acid resulting 
in sequences of 120, 164, 188 amino acids19. VEGF acts via VEGF-receptors: VEGFR1, 
VEGFR2 and VEGFR3. Among these, VEGFR2 plays a crucial role in the induction of 
angiogenesis, whereas the role of VEGFR1 and VEGFR3 in the process of angiogenesis is not 
fully clear yet 20. VEGFR3 is thought to be involved in lymphangiogenesis21. Besides these 
VEGF receptors, there are co-receptors that bind to VEGF and may enhance VEGF 
signalling. Neuropilin-1 is such a co-receptor22. The different VEGF-isoforms were found to 
have a different impact in vascular patterning in physiological and tumor angiogenesis 
because of a different capacity to induce co-signalling via such associated receptors23.  
 
 
Metastasis 
Tumor dissemination in cancer patients usually results (sooner or later) in death of these 
patients. The current concept of tumor growth and dissemination may be briefly described as 
follows: a tumor grows to a macroscopically relevant size. The induction of angiogenesis is 
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crucial for this growth. During this process, tumor cells may gain the capacity to migrate and 
penetrate blood- and lymph vessels. Such tumor cells may reach distant organs or lymph 
nodes via the blood stream or lymphatic drainage and can develop into larger metastatic 
lesions if they again succeed to induce angiogenesis. 
This cascade is thought to represent a micro-evolutionary process in which tumor cells are 
selected by acquiring the capacity to induce angiogenesis, to migrate and invade vessels, to 
adhere in vessels of distant organs and to develop there into metastases2,24-26. In Darwinian 
terms: survival of the most malignant species with optimal fitness to perform the different 
steps just mentioned. In this context, different tumor subclones may preferentially metastasize 
to different organs because of varying microenvironmental conditions. Examples of such 
microenvironmental factors are the presence of certain adhesion molecules in the local 
vasculature and parenchyma, and the presence of local growth factors at these sites. This idea 
is in fact based on the ‘seed and soil’ hypothesis described by Paget more than 100 years 
ago27. More recently,  Fidler and co-workers substantially contributed to the unravelling of 
these mechanisms and promoted Paget’s hypothesis26.  
It is generally accepted that increased angiogenesis correlates with an increased metastatic 
potential15.  Theoretically angiogenesis facilitates different pro-metastatic conditions in the 
process of dissemination:  
- increase in the tumor mass, enhancing the probability of a spontaneously developed tumor 
subclone that is able to leave the tumor via (blood) vessel invasion. 
- increase in the vessel density, resulting in a higher chance that migratory tumor cells 
encounter and invade vessels and leave the tumor. 
Furthermore, a disseminated tumor cell with an angiogenic phenotype has a higher probability 
to develop into a larger, clinically relevant metastasis. 
 
 
Animal models 
Animal models were essential for developing the above-mentioned theories on angiogenesis 
and metastasis. They allowed investigation of the influence of defined factors on tumor 
biology and behavior. A major part of oncological research is performed in mice and rats. 
Mice are especially suitable and used for several reasons: they are small, highly reproductive 
animals with extensively characterized different strains (the ‘Drosophila’ for oncological 
research). Furthermore, mice are easy to handle, they are less expensive than rats, and their 
housing is easy as well. 
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Tumor animal models can be divided into syngenic and xenogenic models. In syngenic 
models, tumors are studied that develop from the animal tissue itself because of exogenous 
(e.g. radiation, etc. ) or endogenous (e.g. tumor oncogene mutation) influence in the animal. 
Another syngenic model is the transplantation of  a tumor cell line derived from the animal 
strain studied. Xenograft models, on the other hand, are models in which tumor cells from a 
different species are introduced into animals (e.g. human tumor cells into mice). 
Based on the site of tumor growth in animals the models can be classified orthotopic versus 
heterotopic. For example human astrocytic brain tumors studied in the mouse brain 
parenchyma are orthotopic models. However, heterotopic brain tumor models in which  
astrocytic tumor cells are inoculated into the subcutaneous space in mice are also used.  
The relevance of data from animal experiments for the understanding of the tumor biology 
depends on the exact model that is used. The micro-environmental circumstances between 
subcutaneous space and brain parenchyma are very different. 
For simulation of metastasis, there are also different model types:  
- direct tumor cell inoculation into the organ of interest (e.g. transcranial (through skin and 
skull) inoculation of tumor cells into the brain parenchyma). 
- colonization models: tumor cells are inoculated into the blood stream proximal to the organ 
of interest (e.g. internal carotid artery injection to induce CNS metastasis). 
- spontaneous metastasis: a primary (e.g. subcutaneous) tumor is inoculated into the animal 
and distant organs are examined for metastatic deposits after a period of tumor growth. 
Again Fidler and co-workers did pioneering work on this aspect of basic oncology: they 
developed different orthotopic tumor models, closely mimicking the human situation28 in 
order to prevent a situation that ‘mice tell lies’. 
 
Additional questions 
The concepts of angiogenesis and metastasis mentioned above are clear, comprehensive and 
in line with the paradigm of evolution in all kind of processes in (medical) biology. However, 
these concepts may be somewhat oversimplified. 
 
Angiogenesis:  
Are all tumors really angiogenesis dependent? Astrocytic brain tumors, for example, are 
characterized by highly infiltrative growth29. Tumor cell infiltration is an essential criterion 
for neoplastic malignancy. There is a dilemma here: if malignant tumors infiltrate normal 
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healthy tissue, why is angiogenesis necessary? Are pre-existent vessels not enough to sustain 
tumor growth, especially in a highly vascularized organ as the brain?       
The initially promising results of anti-angiogenic therapy in animal models could so far not be 
reproduced in human patient trials. What is the reason for the discrepancy between data from 
animal models and that from patient trials? How valid are the tested models, what are the 
limitations of extrapolating animal data to patients? Are there valid (diagnostic)  parameters 
for detecting angiogenesis in mice and men?  
 
Metastasis: 
There is no clear-cut correlation between circulating single tumor cells and metastasis30, 
showing that pure intravascular tumor load of single tumor cells is not the rate limiting factor 
in metastasis. Is metastasis always a phenomenon of survival of the fittest, i.e. a clonal 
selection at single cell level? Interestingly, in the experience of a pathologist tumor emboli, 
rather than single cells are frequently seen in the vasculature of the primary tumor and in the 
vessels at the site of metastases. Are multicellular tumor (tissue) fragments rather than single 
tumor cells involved in metastasis? If so, the pattern of metastasis of these fragments could be 
more dependent on anatomical/mechanical circumstances. What is exactly the contribution of 
mechanical conditions and what of  ‘biochemistry’ (adhesion molecules etc.) to the site of 
metastasis?  
 
 
General outline of the thesis: 
 
This thesis describes different aspects of angiogenesis and metastasis in nude mice human 
melanoma xenograft models and deals with different unanswered questions, controversial 
hypotheses and translation of experimental data to the human situation. 
 
In chapter 2 the development of a human melanoma metastasis xenograft model in nude mice 
brains (orthotopic colonization model) is described. Different patterns of metastasis to the 
CNS are encountered and the role of the αvß3 integrin expression in tumor cells and the 
impact of tumor cell clusters versus single tumor cells in this process are investigated. 
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In chapter 3 a possible mechanism of  metastatic growth of human melanoma in the model 
described in chapter 2 is presented: vascular co-option - no need for an angiogenic switch. 
The role of VEGF secretion in this situation is also demonstrated. 
 
The clinical, especially diagnostic impact of the model described in chapter 3 is presented in 
chapter 4: growth patterns of metastases have direct consequences for their appearance in 
contrast-enhanced MRI. A new iron oxide based contrast agent is compared with gadolinium 
diethylenetriaminepenta-acetic acid (Gd-DTPA) and potential advantages of this agent are 
investigated.  
 
The role of the three most frequent VEGF-isoforms in metastatic growth is described in 
chapter 5: differences in the morphology of tumor vascularization and their radiological 
consequences are presented. 
 
Experimental anti-angiogenic therapy in the brain metastasis model is investigated in studies 
described in chapter 6: ZD 6474 is a small compound inhibiting the VEGF receptor-signalling 
pathway; therapeutical and radiological consequences of this treatment are presented. 
 
In chapter 7 a new concept on spontaneous formation of metastasis is introduced. The 
colonization model described in chapters 2-6 is compared with the development of 
spontaneous metastasis from the subcutaneous space. 
 
Finally, a summarizing discussion and future perspectives are presented in chapter 8. 
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Abstract 
We investigated the effect of integrin αvβ3 expression on the metastatic pattern of human 
melanoma cells in the central nervous system (CNS). For this purpose, we developed a 
hematogenous CNS melanoma metastasis model in nude mice using a modified internal 
carotid artery infusion technique. This protocol revealed 2 different patterns of CNS 
metastasis. The integrin αvβ3-expressing melanoma lines Mel57 and Zkr nearly exclusively 
produced metastases in the brain parenchyma, whereas cells of the BLM and MV3 lines, 
devoid of integrin αvβ3 expression, preferentially metastasized to dura mater and 
leptomeninges. Treatment with hyaluronidase to obtain single BLM cell suspensions did not 
influence the metastatic pattern, indicating that this was not simply the result of entrapment of 
tumor cell aggregates in large-sized leptomeningeal vessels. The role of integrin αvβ3 
expression in the process of metastasis was tested by transfection of BLM, but did not lead to 
an altered pattern of metastasis. We did observe, however, slower growth of the transfected 
tumors, although the in vitro growth rate was unaltered, indicating a reduction in 
tumorigenicity. We conclude from our findings that CNS metastasis of melanoma cells in the 
mouse xenograft model occurs in at least 2 different but very reproducible patterns. Although 
it is predicted that adhesion of tumor cells to endothelial cells plays a role in this 
phenomenon, tumor cell integrin αvβ3 expression per se does not explain the difference in 
metastatic behavior in the CNS. We assume that other, as yet unknown factors, must be 
involved 
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Introduction 
The capacity of tumors, including malignant melanoma, to form central nervous system 
metastases is an increasing problem in clinical oncology 1. The special biology of the CNS 
blood-brain barrier (BBB), that is impermeable for a number of therapeutics, together with the 
vulnerability of the brain for irradiation and surgery, form main obstacles for treatment. Since 
it is unclear why some tumors preferentially metastasize to the CNS, investigation of the 
molecular mechanisms involved is needed. Various molecules may be involved, because 
different CNS compartments show differences in vascularity, extracellular matrix (ECM) 
composition 2, immune surveillance3 and growth factor expression 4. Interestingly, dura mater 
and leptomeninges contain almost the same ECM components as most peripheral organs and 
their vessels do not form a tight BBB. The ECM of the brain parenchyma on the other hand, is 
completely different from that found in the meninges 5 and other parts of the human body. 
Recently, it was proposed that integrins expressed on the tumor cell membrane play a 
dominant role in determining the site of metastasis 6-8. In particular, the integrin αvβ3 was 
assumed to facilitate melanoma metastasis in general 9-14. Besides mediating adhesion to ECM 
components 5-6, intercellular adhesion via this integrin between tumor cells and, e.g. capillary 
endothelial cells, may play a role as well 8,15-16. 
To test whether integrin αvβ3 expression is involved in determining the metastatic behavior to 
the CNS, we developed a model of hematogenous metastasis formation in the CNS of nude 
mice by modification of a previously described internal carotid artery tumor cell injection 
technique 17. We used melanoma cell lines with metastatic behavior in nude mice, and with 
differences in integrin αvβ3 expression 18-19. 
Finally, we investigated whether the metastatic pattern of an integrin αvβ3-negative 
melanoma cell line was changed by introduction of expression of this molecule via gene 
transfection. 
 
Materials and Methods  
Mice  
Specific pathogen-free (SPF) male, 6 to 8 weeks old BALB/c nu/nu mice weighing 18-25g 
were purchased from the central university animal facility. A maximum of 5 mice were 
housed per cage under SPF conditions (temperature 20-24°C; relative humidity 50-60%; 15 
air changes per hour; light-dark periods 14hr/10hr). Water and food (RMH, Hope Farms, The 
Netherlands) were available to the animals ad libitum. 
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Cell lines  
Melanoma cell lines included: Mel57 and Zkr, the latter derived from a melanoma brain 
metastasis (αvβ3 positive) and BLM(20) and MV3 21, both lacking integrin αvβ3 expression 
(18-19). All cell lines were cultured in Dulbeccos Modified Eagles Medium (DMEM), 
supplemented with 10% fetal calf serum (FCS), streptomycin, penicillin and glutamate at 
37°C. Cultures were free of Mycoplasmata. 
Microsurgical injection procedure  
For tumor cell injection cell cultures were trypsinized (trypsin 0.125%; EDTA 0.1% and 
glucose 0.1%) and cell suspensions were counted on a Coulter counter. Cells were washed 
and resuspended in phospate-buffered saline (PBS). For hyaluronidase treatment, cell 
suspensions were incubated with 10 U/ml enzyme (EC 3.2.1.35; Sigma, Zwijndrecht-The 
Netherlands) for 10 min at 20 °C. Cells were then washed, resuspended in PBS and counted 
again. 
Mice were anaesthetised by neuroleptanalgesia consisting of fluanisone, fentanyl and 
midazolam via subcutaneous injection. 
Animals were fixed on the operation table and the heads were stabilized by a band placed 
between the teeth of the upper jaw. The neck was prepared for surgery by alcohol 
desinfection, and the skin was cut by a medial incision. After blunt dissection the pretracheal 
muscles were exposed. The muscles at the right side were longitudinally separated. The 
exposed right common carotid artery including the carotidal bifurcation was separated from 
the vagal and hypoglossal nerves. Internal carotid, external carotid and occipital artery were 
exposed. A ligature of 7-0 silk suture was placed around the origin of the common carotid 
artery. A second ligature was placed proximal to the carotidal bifurcation but was not closed 
immediately. The blood flow between both ligatures was temporarily stopped by lifting the 
second ligature, and in this part the artery was nicked with a pair of microscissors. A 
polyethylene tube connected to a syringe containing the cell suspension was filled with 20-40l 
physiological salt solution to prevent tumor cell contamination. The tube was inserted into the 
common carotid artery and the second ligature was tightened around it to prohibit leakage to 
the operation field. After tube insertion both the external carotid and occipital artery were 
temporarily compressed with a forceps and 100µl of the tumor cell suspension was slowly 
injected into the open left internal carotid artery. The external carotid and occipital artery 
were kept closed for 15 sec after injection. To prevent tumor cell reflux into the external 
carotid and occipital artery and subsequent local tumor cell spread, a small amount of blood 
was aspirated from the internal carotid artery into the tube after the 15s interval. Then, the 
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tube was removed and the second ligature was closed permanently. The operation wound was 
rinsed three times with physiological salt solution to wash out a possible tumor cell 
contamination and the skin was closed by sutures. 
Transfection with integrin 3 subunit  
Full length cDNA for the integrin 3 subunit 22, provided by Dr. Ruoslahti (La Jolla, CA), was 
cloned into the polylinker of the mammalian expression vector pBJ1neo 23, provided by Dr. R. 
de Waal-Malefijt (La Jolla, CA). Twenty g of this construct was used for stable transfection of 
BLM cells via the calcium phosphate precipitation method 24, using the Calcium Phosphate 
Transfection System (Life Technologies, Breda, The Netherlands). After 48h of recovery, 
stably transfected cells were selected by culture in the presence of 1 mg/ml G418 (Life 
Technologies) for two weeks. Single cell sorting was done on an Epics Elite flow cytometer 
using the anti- αvβ3 mAb LM609 (see also below). Cells were cultured in medium containing 
200mg/ml G418 and regularly monitored for αvβ3 expression. Expression levels of αvβ3 
were determined by FACS analysis using LM609 mAb and were similar for Mel57 and BLM-
3 (data not shown). BLM transfected with the empty vector pBJ1neo (BLM Neo) was used as 
control. 
Histology  
Mice were sacrificed in case of severe cachexia, acutely developing neurological deficits, or 
visible tumor masses. Brain, meninges and skull were inspected macroscopically using an 
operation microscope. 
Material for immunohistochemistry was snap-frozen in liquid nitrogen. Lung, heart, kidney, 
spleen and other tissues were fixed in buffered formalin, and embedded in paraffin. After 
euthanasia some heads were perfused via the left carotid artery with buffered formalin, fixed, 
decalcified and paraffin-embedded. Sections of 4 m underwent standard H&E staining. 
Immunohistochemistry (IHC)  
Mouse anti-human αvβ3 integrin monoclonal antibody LM609 (Merck, Darmstadt, 
Germany)(25) was diluted in PBS with 1% BSA. Frozen 4 m sections were fixed in acetone 
for 10 min, dried and incubated at room temperature with mAb for 1 h. After washing with 
PBS, bound Ab was detected with a horse anti-mouse Ig Ab (Vector Laboratories, 
Burlingame, CA) in a dilution of 1/200 in PBS with 1% BSA for 30 min. After washing, the 
bound Abs were visualized using the peroxidase-based Vectastain elite ABC kit (Vector 
Laboratories, Burlingame, CA) using 3-amino-9-ethylcarbazole as a chromogen. Sections 
were counterstained with hematoxylin. 
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Results  
Different metastatic patterns of human melanoma cell lines to the CNS  
In initial experiments mice received injections with varying amounts of cells to determine the 
threshold of reproducible tumorigenicity. Data are shown in Table I.  
 
 
Table I. Metastasis Formation by Human Melanoma Cell Lines in Mice 
After Internal Carotid Artery Injection 
 
Incidence of metastasis  
 
CNS (primary site)  
 
Visceral  
 Cell line (injected cell 
number) 
Survival time (days) range 
(median) Parenchyma Meninges Lung Heart 
 
Me157 (0.5 × 105) 22-35 (29.5) 4/4 0/4 0/4 0/4 
Me157 (1 × 105) 29-36 (30) 3/3 0/3 0/3 0/3 
Me157 (2.5 × 105) 26-27 (26.5) 4/4 1/4 1/4 0/4 
Me157 (5 × 105) 21-27 (25.5) 4/4 0/4 0/4 0/4 
Zkr (2.5 × 105) 35-61 (48) 4/4 1/4 0/4 0/4 
MV3 (2.5 × 105) 34 and 54 0/21 1/2 0/2 0/2 
MV3 (5 × 105) 27-38 (33) 0/31 3/3 0/3 0/3 
BLM (1 × 105) 23-25 (23) 0/31 3/3 3/3 0/3 
BLM (2.5 × 105) 18-30 (22) 0/61 6/6 3/6 0/6 
BLM hyaluronidase (2.5 × 
105) 
20-28 (21) 0/51 5/5 3/5 1/5 
BLM- 3 (1 × 105) 33-48 (41) 0/7
1 6/7 1/7 0/7 
BLM-Neo (1 × 105) 29-35 (33) 0/51 5/5 2/5 0/5 
 
  1 Indicated is the primary site of CNS involvement. Secondary parenchymal involvement was frequently 
observed. 
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Clinical signs of tumor growth differed between the cell lines. In mice receiving BLM or 
MV3 cells, macroscopically visible destruction of skull bone by tumor, disconnection of skull 
sutures by elevated intracranial pressure and loss of general activity and focal neurological 
deficits were observed. Cachexia was a minor symptom. In contrast, clinical signs of tumor 
growth in Mel57 and to a lesser extent in Zkr carrying mice were severe cachexia, and 
sometimes focal neurological deficits like slight hemipalsy or hemiataxia. In general, cachexia 
was the reason for euthanasia of mice with Mel57 and Zkr metastases. 
Metastases formed by either MV3 or BLM involved the meninges (dura mater (fig.1a) and 
leptomeninges (fig.1b), frequently followed by secondary brain parenchyma involvement by 
tumor cell invasion along the vessels via the Virchow-Robin space (fig.1c). In cases with 
extensive parenchymal involvement, we could not exclude primary involvement, but based on 
the findings in animals bearing less tumor mass, occurrence of secondary involvement of the 
parenchyma was beyond doubt. Occasionally, lesions were found in the ventricles of the 
brain. 
In contrast, all animals injected with Mel57 and Zkr cells showed primary metastatic 
involvement of brain parenchyma (fig.1d and 1g). Micrometastases and somewhat larger 
lesions presented with an infiltrative rather than solid growth pattern, whereas bulky lesions 
often had a central aspect of solid tumor formation, although an invasive front into the brain 
parenchyma was always present. Mice injected with a smaller number of tumor cells 
developed cachexia only slightly later. Nevertheless, larger individual metastases were found 
more often in animals injected with a small number of tumor cells. Leptomeningeal and dural 
Mel57 and Zkr metastases occurred rarely and were of microscopic size. Mel57 and Zkr 
metastases in the pituitary gland, pineal gland and ganglion gasseri were occasionally 
observed, which was not seen with BLM or MV3 cells. To detect integrin αvβ3 expression in 
situ by IHC, murine anti-human αvβ3 Ab LM609 was used to highlight membranous staining 
of single Mel 57 and Zkr (αvβ3 positive) tumor cells in the parenchyma (fig. 1e and 1g). 
Normally, antibodies raised in mice can not be used for staining purposes, as the secondary 
anti-mouse antiserum will bind with host (mouse) immunoglobulins (Ig) that are omnipresent 
in mouse tissues. However, host Ig only poorly pass the BBB. Therefore, mouse Ig levels in 
brain parenchyma are extremely low, which allows for the use of anti-mouse secondary 
antibodies in immunostaining of mouse brain tissue. Vessel lumina, containing plasma Ig, 
were visible as small red spots. 
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In contrast to Mel57, ZKr and MV3, BLM frequently produced pulmonary metastases after 
internal carotid artery injection (Table I). However, these were of a negligible size compared 
to the CNS lesions. 
Hyaluronidase treatment does not affect the metastatic behavior of BLM melanoma cells  
Cell suspensions obtained by trypsin treatment of BLM and MV3 cells often contained large 
amounts of multicellular aggregates that may be associated with high hyaluronic acid 
production26. Since hyaluronic acid production levels are correlated with spontaneous 
metastasis in melanoma xenograft models, embolism of larger sized meningeal vessels 
causing inhibition of further transport to smaller sized parenchymal capillaries might explain 
the predominant meningeal involvement. To test this possibility, BLM cell suspensions were 
treated with hyaluronidase after trypsin treatment, resulting in a single cell suspension. No 
differences in metastatic pattern were observed between BLM cells with or without 
hyaluronidase treatment. Again, a predominant meningeal involvement was observed, 
eventually followed by secondary parenchymal invasion. 
BLM-3 and BLM-Neo melanoma lines show metastatic behavior identical to BLM  
To investigate the involvement of integrin αvβ3 in metastasis formation in BLM cells, we 
transfected BLM cells with 3 cDNA, resulting in surface expression of αvβ3 protein. These 
cells, or cells transfected with empty vector only (BLM-Neo), were injected into mice, and 
metastatic patterns in the CNS were analysed. 
Both transfected cell lines involved the meninges (fig. 1f), but general examination of the 
H&E stained slides suggested that the extent of invasion into the parenchyma of the 
transfected cells was less than that of untransfected cells. Expression of the αvβ3 transgen in 
the metastatic lesions in vivo was shown by immunohistochemical analysis (fig. 1f). BLM-
Neo injected mice developed signs of tumor growth earlier than the BLM-3 injected ones 
(Table I). In vitro growth rates, determined by BrdU uptake, were similar for BLM, BLM-3 
and BLM-Neo (data not shown). 
 
 
 
Fig.1:  
a) Meningeal (dura mater)  metastasis of BLM human melanoma cell line. T=tumor, P=brain parenchyma, S=skull. Original 
magnification x40. H&E staining. 
b) Meningeal metastasis of MV3 human melanoma cells in the leptomeninges of the cerebellum. SG=stratum granulosum, T=tumor. 
Original magnification x100. H&E staining. 
c) Leptomeningeal metastasis: BLM human melanoma cells invading the brain along the Virchow-Robin space. E=nucleus of vessel 
cell, T=tumor cell. Original magnification x250. H&E staining. 
d) Parenchymally infiltrating brain metastasis of Mel57 human melanoma cell line. Original magnification x100. H&E staining. 
e) Parenchymal brain metastasis of Mel57 human melanoma cell line. Immunohistochemical staining of the αvβ3 integrin with mAb 
LM609 on the cell membrane. Counterstaining: hematoxylin. Original magnification x100.  
f) Leptomeningeal metastasis of BLMβ3 human melanoma cell line in the cerebellum. Immunohistochemical staining of the 
transfected αvβ3 integrin with mAb LM609 on the cell membrane. Counterstaining: hematoxylin. Original magnification x250. 
g) Parenchymal brain metastasis of Zkr human melanoma cell line. Immunohistochemical staining of the αvβ3 integrin with mAb 
LM609 on the cell membrane. Counterstaining: hematoxylin. Original magnification x250. See also colour display page 149. 
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Discussion 
Metastases of malignant melanoma to the CNS represent a complication of considerable 
relevance in clinical oncology. Reports on experimental data dealing with the pathobiological 
characteristics of this type of metastatic disease are scarce. 
In this study we investigated the mechanisms involved in metastasis formation in the CNS in 
a human melanoma xenograft model. To parallel the patient situation, where melanoma 
metastasis formation to the CNS occurs exclusively via the hematogenous route, tumor cell 
application into the blood stream is a prerequisite. Internal carotid artery injection 17, 27-28 
prevents the extensive visceral metastasis formation that is frequently observed in left cardiac 
ventricle injections 29. In contrast to the human situation, the internal carotid artery (ACI) in 
rodents like mice and rats supplies the dura mater as well as brain parenchyma and 
leptomeninges 30-31. This explains why in our model after ACI injection of tumor cells, 
metastases were found in all these compartments. 
Interestingly, the different melanoma cell lines reproducibly metastasized to different 
compartments of the CNS. Similar results were described by Schackert et al. 32, who showed 
that human melanoma lines derived from non-CNS metastases predominantly produced 
meningeal involvement, whereas cell lines derived from brain metastases more frequently 
caused parenchymal metastases. The three cell lines used in the present study, Mel57, BLM 
and MV3, are all derived from non-CNS melanoma metastases. The reason for the observed 
differences in metastatic spread is not clear. Studies with radiolabeled tumor cells carried out 
by Schackert et al. showed that already the initial arrest of tumor cells was different among 
these cell lines. To exclude any effects of tumor cell embolism in large-sized leptomeningeal 
vessels by multicellular aggregates at the site of subsequent metastasis formation, we prepared 
single cell suspensions by hyaluronidase treatment. This treatment, however, had no effect on 
metastatic behavior, and, moreover, indicated that hyaluronic acid components on the cell 
surface are not directly involved in metastasis formation. 
Several studies have described the role of cell adhesion molecules in melanoma progression 9, 
33-35. The acquirement of integrin αvβ3 expression is supposed to be an important step in 
melanoma progression, and has been described to be responsible for melanoma lymph node 
metastasis 12. Integrin αvβ3 mediates adhesion of cells to various ECM molecules5, 6, 25, 33, 36 
via the RGD-amino acid sequence 5-6. Although the function of integrin αvβ3 in cell-cell 
adhesion is not completely clear, it may be involved in tumor cell adhesion to endothelial 
cells and migration through vessel walls8, 15. 
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Initially, it appeared that αvβ3 expression had a strong effect on the metastatic pattern in our 
model since the αvβ3 positive and αvβ3 negative cell lines metastasized towards completely 
different locations. Our transfection data, however, did not support a role for αvβ3 in this 
process, since induction of αvβ3 expression did not lead to a change in metastatic pattern. 
Possibly, Mel57 and Zkr on the one hand and BLM and MV3 on the other, express adhesion 
molecules other than integrin αvβ3 that interact with specific counterstructures present on 
parenchymal and meningeal vessels, respectively. 
Both 3-transfected BLM cells as well as untransfected cells presented with meningeal 
involvement, but the results indicated a lower degree of tumorigenicity in comparison to the 
wild type BLM cells. The animals developed symptoms of tumor growth later, coinciding 
with a decreased intracranial tumor mass. Also, one out of 7 animals did not develop CNS 
metastasis at all, whereas the corresponding inoculum of wild type BLM cells was always 
tumorigenic, indicating a decrease in aggressiveness due to αvβ3 integrin expression. The in 
vitro growth was not affected by transfection. More likely, however, the lower tumorigenicity 
of the 3 -transfected line may be explained by disturbances of cellular functions by the 
transfected protein35, 37-38 or the transfection procedure itself, since the empty vector-
transfected BLM-Neo cell line was less aggressive as well. 
Another experimental approach could have been masking of the αvβ3 integrin on Mel57 and 
Zkr cells, e.g. with help of an antibody like LM609, but this procedure may interfere with 
other cellular functions like induction of tumor cell apoptosis, and therefore, via other 
unrelated mechanisms, prevent metastasis to occur. 
In summary, we postulate that selective receptors are present on brain capillary endothelium 
and/or tumor cells, which facilitate tumor cell adhesion and metastasis formation at restricted 
sites. Our results indicate that the metastatic pattern of human melanoma cells in our CNS 
metastasis model is not dependent on hyaluronic acid or integrin αvβ3 expression. 
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Abstract 
We investigated the mechanisms of vascularization in a brain metastases model of malignant 
melanoma. Parenchymal metastases expressing little Vascular Endothelial Growth Factor-A 
(VEGF-A) co-opted the pre-existent brain vasculature, leading to an infiltrative phenotype. 
Metastases of the human melanoma cell line Mel57, engineered to express recombinant 
VEGF-A165 showed accelerated growth in a combined expansive and infiltrative pattern with 
marked central necrosis. This difference in growth profile was accompanied by dilatation of 
co-opted intra- and peritumoral vessels with concomitant induction of vascular permeability. 
Our data show that modulation of pre-existent vasculature can contribute to malignant 
progression without induction of sprouting angiogenesis.  
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Introduction 
Brain metastases of malignant melanoma are a life-threatening complication of this disease. 
Primary and metastatic tumors of the central nervous system (CNS) are generally highly 
vascularized, therefore anti-angiogenic therapy has been considered promising 1. However, 
the brain itself has a dense vascular bed and primary CNS tumors often show a highly 
infiltrative growth pattern. This raises the question whether the vessels in such tumors are 
formed by neo-angiogenesis or are pre-existent ones 2. Indeed, employment of pre-existent 
vessels in early metastatic outgrowth in the brain, a process referred to as co-option, has been 
reported 3-5, which was followed by a switch to an angiogenic phenotype. Vessel co-option as 
a mean of tumor vascularization might have important consequences for diagnosis and 
therapy. For example, in contrast-enhanced magnetic resonance imaging (CE-MRI), tumor 
lesions are visualized by virtue of tumor-induced vascular changes like hyperpermeability, 
leading to extravasation of contrast agent. Although vascular hyperpermeability is considered 
to be a characteristic of tumor neovasculature, it is unclear whether co-opted vessels in CNS 
malignancies are modified in this respect. Secondly, vessel co-option obviously will have 
important consequences for application of tumor therapies using angiogenesis inhibitors. In 
this regard, it is important to realize that most studies with anti-angiogenic compounds have 
been carried out in animal models where tumors are grown subcutaneously (s.c.). Especially 
for CNS tumor biology, s.c. models have only limited clinical relevance because the 
subcutaneous space is essentially avascular. S.c. tumors will therefore be artificially selected 
to grow in an angiogenesis-dependent fashion while the microenvironmental conditions that 
exist in highly vascularized tissues like the brain are bypassed.  
In previous work we showed that the human melanoma cell line Mel57 metastasizes to mouse 
brain parenchyma after injection into the internal carotid artery 6-8. In vitro, Mel57 expresses 
very low amounts of Vascular Endothelial Growth Factor-A (VEGF-A)9.  We report here on 
the mechanisms of tumor vascularisation in this model and on the effects of VEGF165 
expression on tumor growth and vascular parameters. We show that expression of VEGF165 
induced significant progression of tumor growth, which was not associated with classical (i.e. 
sprouting) angiogenesis but caused by architectural and functional changes of the co-opted 
pre-existent brain vasculature. 
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Materials and methods 
Mice 
Specific pathogen-free (SPF) male, 6 to 8 weeks old BALB/c nu/nu mice weighing 18-25g 
were purchased from the university central animal facility. Per cage 5 mice were housed 
under SPF conditions (temperature 20-24 °C; relative humidity 50-60%; 15 air changes per 
hour; light-dark periods 14 h/10 h). Water and food (RMH, Hope Farms, the Netherlands) 
were available to the animals ad libitum. Experiments were carried out in accordance with the 
national animal protection laws. 
Cell lines, transfections and microsurgical injections 
Human melanoma cell lines Mel57, M14 and 530 were cultured in Dulbecco’s Modified  
Eagle’s Medium (DMEM, Life Technologies, Breda, The Netherlands), supplemented with 
10% fetal calf serum (FCS), streptomycin and penicillin at 37 °C. Mel57 cells were 
transfected using Fugene (Roche, Mannheim, Germany) with plasmid pVEGF-IRESneo or 
pEGFP-IRESneo (enhanced green fluorescent protein) as a control, according to the 
manufacturer’s guidelines. pVEGF-IRESneo carries the cDNA for human VEGF165 cloned in 
the EcoR1-BamH1 sites of vector pIRESneo (Clontech, Palo Alto, California) under control 
of the CMV promoter. Two days after transfection, selection of transfectants was started using 
400 µg/ml G418. The use of an internal ribosome entry site (IRES) to generate neomycin 
resistance led in our hands to more than 95% positivity for the recombinant protein in G418-
resistant cells. Therefore, after two weeks of selection, colonies of transfected cells were 
pooled, expanded and frozen. Levels of recombinant VEGF in conditioned media were 
determined using western blot analysis as described 9. Metastasis was induced as described 
previously 6 by microsurgical injection of tumor cell suspensions into the right internal carotid 
artery of anaesthetised nude mice 
Histological and immunohistochemical analysis 
Mice were sacrificed after development of severe cachexia or acute neurological deficits. For 
immunohistochemistry, material was snap-frozen in liquid nitrogen or fixed in formaline and 
embedded in paraffin. Sections of 4 µm underwent conventional H&E staining. The brains of 
animals bearing lesions of the Mel57 cell lines, sacrificed 20-22 days after tumor cell 
injection were cut semi-serially and lesion sizes were determined using measurement oculars. 
Antibodies used were anti-murine CD31 (Mec 7.46; Hycult Biotechnology, Uden, The 
 35 
Netherlands), anti-mouse tight junction protein ZO1 (mAB1520; Chemicon, California), 
rabbit anti-mouse Ki-67 (Dianova, Hamburg, Germany), mouse anti-human α-smooth muscle 
actin (α-Sm1, Sigma, Zwijndrecht, The Netherlands), anti-Glut-1 (Dako, Glostrup, Denmark), 
rabbit anti-KDR (Santa Cruz Biotechnology, Santa Cruz, California), rabbit anti-angiopoietin 
I (Santa Cruz Biotechnology, Santa Cruz, California) and rabbit anti-angiopoietin II (Santa 
Cruz Biotechnology, Santa Cruz, California). Frozen 4 µm sections were fixed in acetone for 
10 min, dried and incubated with Ab for 1 h at room temperature in phosphate-buffered saline 
containing 1% bovine serum albumin (PBS/BSA). After washing with PBS, bound Abs were 
detected with a peroxidase-conjugated secondary Ab (Vector, Burlingame, California) using 
the Vectastain elite ABC kit (Vector, Burlingame, California). Sections were counterstained 
with hematoxylin. Integrity of the blood-brain barrier (BBB) was investigated by staining for 
extravasated mouse immunoglobulins as described previously 10. In all stainings a negative 
control was included in which primary antibodies were omitted. These controls were always 
negative. 
 
Tumor cell proliferation assays 
The S-phase marker bromodeoxyuridine (BrdU) (Sigma, Zwijndrecht, The Netherlands) was 
administered intraperitoneally at a dose of 100 mg/kg in 0.5 ml 0.9% NaCl 15 min. prior to 
sacrifice. The proliferation index of individual Mel57-lesions (n=3) and Mel57-VEGF-lesions 
(n=6) in different mice was determined in frozen brain sections by quantification of 
incorporated BrdU as described previously 11. Tumor cell proliferation in vitro was 
determined as follows: 5x103 cells were seeded in six-well culture plates and cultured in 
serum-free medium. After 2, 3 and 4 days cells were trypsinized and counted using a Coulter 
counter. All experiments were performed in triplicate. 
 
 
Results 
  
Growth of Mel57 lesions in brain parenchyma 
Three to five weeks after injection of Mel57 cells in the right internal carotid artery, animals 
started to suffer from cachexia. Morphological analysis showed that numerous parenchymal 
lesions with diameters up to 3 mm were present in each brain with preferential localization in 
the right side of the brain (cerebrum, cerebellum and brain stem). These tumors exhibited an 
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infiltrative growth pattern in the parenchyma (Fig. 1A). Tumor cells exploited the pre-existent 
brain vessels by growing in the space of Virchow-Robin (forming lesions containing remnants 
of pre-existent brain parenchyma (Fig. 1A, inset)). Tumor growth in the space of Virchow-
Robin was also seen in metastases derived from the human melanoma cell lines M14 and 530 
(Fig.1E and F). The cell line Mel57 was chosen for further studies. We did not detect 
differences between the vasculature within the lesions and that in the surrounding normal 
brain tissue with regard to vessel diameter (Fig. 1C), activation status of the endothelium 
(assessed by KDR/Flk-1, Fig. 2G and CD105 expression, not shown) and maturation status 
(assessed by pericyte coverage, Fig. 2I). Also, intratumoral vessels still had all characteristics 
of an intact blood brain barrier (BBB) as demonstrated by unaltered morphology (Fig. 1C), 
lack of mouse IgG extravasation (Fig. 2A) and the presence of endothelial glucose transporter 
1 (Glut-1) (Fig. 2C) and zonula occludens ZO-1 (Fig. 2E) at levels similar to those found in 
normal brain parenchyma. Vessel density within the lesions was slightly lower than in the 
surrounding normal brain parenchyma (Fig. 1C) indicating that there was no angiogenic 
compensation for the tissue volume increase at the lesion site. This lack of angiogenesis was 
in line with the overall absence of vascular changes. Despite the absence of neo-
vascularization, necrosis was scarce in these lesions, implying that the blood supply from the 
pre-existent vascular bed sufficed to provide the tumor cells with oxygen and nutrients. 
Although injection of higher numbers of cells led to a proportionally higher number of 
lesions, the morphology of the individual lesions was not affected (not shown). All together, 
the infiltrative character, the low intratumoral vessel density and the intact BBB strongly 
suggested that these lesions grew by mere vessel co-option without induction of an angiogenic 
switch.  
There were neither qualitative nor quantitative differences in tumor growth patterns between 
parental Mel57 and control Green Fluorescent Protein (EGFP) transfectants (data not shown). 
 
Fig. 1 – Growth patterns of Mel57 (A,C), Mel57-VEGF165 (B,D), M14 (E) and 530 (F) melanoma brain metastases. H&E 
staining (A,B) and CD31 staining (C,D) of brains containing Mel57 lesions (A,C) and Mel57-VEGF165 lesions (B,D). The 
insets in A and B show that tumor cells invade the brain parenchyma along the brain vessels in the space of Virchow-Robin. 
The inset in D shows a decrease of vessel dilatation with distance to a small sized lesion. Note the vessel dilatation in Mel57-
VEGF165 lesions and the presence of central necrosis in Mel57-VEGF165 lesions (B) but not in Mel57 lesions (A). The cell 
lines M14 and 530, producing low amounts of VEGF in vitro, also display an infiltrative growth pattern by vascular co-
option in brain metastases. Note the Glut-1 blood-brain barrier marker on co-opted vessels in (E). T=tumor, N=necrosis, 
V=vessel. See also colour display page 150. 
 
 37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mel57 
A 
C 
1 mm 
T
T 
D
N
V
T
T 
Mel57-VEGF165
B
1 mm
NN
N
H&E
CD31
T 
T 
1.5 mm 
FE
1 mm 
lateral 
ventricle 
M14 530
H&E 
Mel57 Mel57-VEGF165
Glut-
Figure 1 
 38  
Effects of VEGF165 on growth of Mel57 lesions 
Since Mel57 produces low levels of VEGF in vitro (approximately 30 pg/106 cells/24 hrs, 
data not shown), and sprouting angiogenesis was absent in Mel57 CNS-lesions, we were 
interested in the effects of expression of this potent angiogenic factor in this model. To this 
end, we created stable transfectants of Mel57 which produced high levels of VEGF165 
(approximately 30 ng/106 cells/24 hr) and analysed the growth profile. Mel57-VEGF165 
developed a growth pattern that was completely different from parental tumor cells. These 
lesions had a more solid and expansive rather than infiltrative growth pattern (Fig. 1B) 
although at the tumor rim infiltration into the parenchyma, again along pre-existing vessels, 
was still present (Fig. 1B, inset). Like in Mel57 lesions, the intratumoral vessel density was 
lower than in the surrounding brain parenchyma (Fig. 1D). However, now there were marked 
differences between intra/peri-tumoral vessels and extratumoral vessels. (Peri-)tumoral 
vessels were irregularly dilated (Fig. 1D) and showed upregulation of KDR (Fig. 2H) and 
CD105 expression (not shown), indicating that VEGF had induced an activated state of the 
endothelium. Vessel dilatation gradually decreased with increasing distance from the lesion 
(see Fig. 1D, inset) pointing at tumor-derived VEGF as the causative factor. Staining for 
mouse immunoglobulins indicated high permeability of blood vessels in the tumor and at the 
tumor periphery (compare Fig. 2B to 2A). The dilated vessels still stained positive for the 
BBB markers Glut-1 and ZO-1 (Fig. 2D, F), indicating that these vessels are truely pre-
existent and not neo-angiogenic. Interestingly, Glut-1 expression on the endothelium in 
intratumoral vessels was markedly decreased as compared to that in normal brain vessels 
(compare Fig. 2D to 2C and note the Glut-1 negative vessel indicated by the arrow in Fig. 
2D). 
Staining for alpha-smooth muscle actin revealed a high grade of pericyte coverage of tumor 
vessels (Fig. 2J), indicating the presence of a mature phenotype. Despite the lack of sprouting 
angiogenesis, both endothelial cells and pericytes responded to VEGF by proliferation, as 
these cells frequently stained positive for (murine) nuclear antigene Ki-67 (MIB-1, Fig. 2L). 
This was clearly a VEGF effect since vascular cells in Mel57 parental lesions were quiescent 
(Fig. 2K). Despite all the vascular changes observed, we did not see induction of angiogenesis 
in terms of sprouting and branching of new capillaries in Mel57-VEGF165 lesions.  
Average diameters of Mel57-VEGF165 lesions were increased approximately 2-fold as 
compared to parental Mel57 lesions (Fig. 3A), while the proliferation index of the Mel57-
VEGF165 lesions was more than 4-fold higher than that of control tumors (Fig. 3B). 
Proliferation was boosted by factors from the tumor environment since there was no 
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difference in growth rate between the Mel57 transfectants and the parental line in vitro 
(results not shown). The high proliferation rate, in combination with the lack of sprouting 
angiogenesis in the Mel57-VEGF165 lesions led to evident hypoxia as shown by upregulation 
of Glut-1 in tumor cells themselves (Fig. 2D and (12)) and subsequently to necrosis, even in 
small lesions (Fig. 1B). In immunohistochemistry we detected no differences in expression of 
both angiopoietins I and II between tumors from Mel57 and Mel57-VEGF165 cells, both 
angiopoietins were expressed (not shown). 
 
Discussion 
Tumors are considered to start as avascular masses that become vascularized by sprouting 
angiogenesis, a process that is induced by tumor-derived factors such as VEGF. However, 
several groups have reported that tumors can also utilize the pre-existent vasculature in the 
host tissue. Holash et al. 3 described initial growth of a brain tumor by vessel co-option, which 
was followed by vessel regression and induction of classical angiogenesis via upregulation of 
VEGF and angiopoietin-2 3, 4. Li et al. described a subcutaneous model of early tumor 
outgrowth where vasodilatation was followed by sprouting angiogenesis in lesions as small as 
a few thousand cells 5.  
Here we show in a brain microenvironment that tumors consisting of several hundreds of 
thousands of cells can grow without induction of sprouting angiogenesis, even in the presence 
of high levels of VEGF. Obviously, the capillary network of the brain parenchyma is one of 
the densiest in the mammalian body. Thus, in such an environment tumors can thrive in an 
angiogenesis-independent manner and produce lesions that in the murine brain can reach 
diameters of up to 3 mm (approximately 14 mm3), far beyond Folkman’s angiogenic switch 
threshold of 2 mm3 13.  
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Fig. 2 – Effect of VEGF165 on blood-brain barrier function. Brains containing Mel57 lesions (A,C,E) or Mel57-VEGF165 
lesions (B,D,F) were stained for mouse IgG (A,B), Glut-1 (C,D) or ZO-1 (E,F) as described in the text. Only vessels in and 
around Mel57-VEGF165 lesions are leaky as demonstrated by the presence of extravasated IgG (B). Dilated vessels in Mel57-
VEGF165 lesions express the BBB markers ZO-1 (B) and Glut-1 (D) although expression on vessels within the lesions is 
clearly downregulated. The arrow in (D) points at a Glut-1 negative vessel. Glut-1 is expressed in tumor cells adjacent to 
necrosis, indicating hypoxia (D,*). Activation of vascular endothelium by VEGF165. Immunostaining of Mel57 (G,I,K) and 
Mel57-VEGF165 (H,J,L) lesions for VEGFR-2/Flk-1 (G,H), α-smooth muscle actin (α-SMA) (I,J) and Ki-67 (K,L). VEGFR-
2/Flk-1 is upregulated on vessels in and around the Mel57-VEGF165 lesions, indicating an activated state of the endothelium. 
These vessels display a mature phenotype as indicated by the high pericyte coverage (J) compared to vessels in lesions from 
the parental cell line (I). Although VEGF-A165 in these tumors induces proliferation of endothelial cells, as demonstrated by 
Ki-67 staining (L), this is not accompanied by vascular sprouting. V=vessel, T=tumor. See also colour display page 151. 
 
 
 
 
 
 
 
 
Fig. 3 – Effects of VEGF165 expression on lesion size and proliferation. A) Size of Mel57 and Mel57-VEGF165 lesions, 
expressed as diameter (mm). Lesions in 5 mice brains were used in this analysis. Mice were sacrificed 21±1 days after 
intracarotid injection of tumor cells. Lesions were measured as described in the text. Sizes differed significantly between the 
groups (P<0.001, Students T-test). B) Tumor cell proliferation index  in vivo as determined by BrdU incorporation (see text). 
Data are expressed as fraction of labelled tumor cell nuclei (P<0.001, Students T-test). Error bars represent standard 
deviations. 
 
 
 
 
 
Mel57 Mel57-VEGF165
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
le
si
on
 s
iz
e 
(m
m
)
Mel57 Mel57-VEGF165
0.00
0.05
0.10
0.15
0.20
0.25
0.30
n=3
n=6
la
be
lli
ng
s 
in
de
x
A B Figure 3 
 42  
In vitro, Mel57 produces minimal amounts of angiogenic factors like VEGF, bFGF, IL-8 and 
PDGF 9. The absence of vascular changes in Mel57 and Mel57-EGFP lesions demonstrates 
that VEGF was not upregulated in vivo as well. In a previous paper we reported low 
expression levels of VEGF in melanoma lines M14 and 530 as well 9. Brain metastases 
derived from these cell lines behaved comparably to those derived from Mel57, showing that 
the phenomenon of vascular co-option is not restricted to one cell line.  
Based on several criteria, we conclude that there were neither morphological nor functional 
differences between intratumoral and distant vessels in Mel57 or Mel57-EGFP lesions. The 
blood brain barrier was intact, as demonstrated by the absence of extravasated 
immunoglobulins and by the presence of Glut-1 and ZO-1. From these results we conclude 
that VEGF production was not essential for the formation of brain metastases. Clearly, the 
capacity to metastasize to the brain in the absence of VEGF may be tumor type-dependent, 
since Yano et al. showed that anti-sense VEGF cDNA transfection of human carcinoma cell 
lines decreased the metastatic capacity to the brain of these cells 14. 
In contrast to the prevailing idea that VEGF165 induces sprouting angiogenesis, brain 
metastases of stable VEGF165 -transfectants of Mel57 did not have a classical angiogenic 
phenotype: despite a high proliferation rate of endothelial cells and pericytes, there was no 
branching or sprouting of the otherwise extensively dilated capillaries in these tumors. This is 
in accordance with recent reports on VEGF effects in non-tumorous settings 10, 15. Another 
remarkable observation was that VEGF severely deteriorated BBB function leading to 
vascular hyperpermeability, which is in line with previous reports 16-18. 
Despite the lack of classical (i.e. sprouting) angiogenesis, VEGF165 expression did lead to 
tumor progression, which was reflected by increased tumor cell proliferation rates and larger 
lesion sizes. This resulted in a more solid, expansive growth of the lesions with lack of blood 
supply in the center of the lesions, often causing central necrosis, even in relatively small 
lesions. 
Since the growth rates of the different tumor cell lines in vitro were equal, the overall 
increased tumor growth of the Mel57-VEGF165 tumors must have been caused by modulation 
of the pre-existent vascular bed. The dilatation of the blood vessels may have led to elevated 
perfusion thereby providing the lesions with a better blood supply. This, however, occurred 
predominantly in the peritumoral zone. The inability to induce sprouting angiogenesis caused 
a lack of neovasculature within the tumor lesions and subsequent local necrosis. Our data 
therefore suggest that tumor-derived factors, other than VEGF165, are required for sprouting 
angiogenesis to occur. Angiopoietins have been reported to play an important role in 
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angiogenesis too 3, 4, 19. IHC staining for angiopoietins I and II demonstrated that these factors 
were produced by both parental Mel57 and Mel57-VEGF165 cells, implying that the 
angiopoietin/Tie2 system probably is not of significance in this model. It has also been 
reported that expression of the larger VEGF-isoforms by tumors correlates with poor 
prognosis 20. We are currently investigating the effects of expression of these isoforms in our 
model. 
Most data on tumor growth, angiogenesis and angiogenesis inhibition are derived from 
experimental settings in which tumors are grown in the largely avascular subcutaneous space 
and therefore are selected for angiogenic capacity. In our model we closely mimick the human 
situation of hematogenous CNS metastasis formation 8. We show that mere vessel co-option 
can account for providing tumor blood supply in highly vascularized organs. Constitutive 
VEGF expression per se does not lead to classical angiogenesis but may promote tumor 
growth by functional modulation of the co-opted vessels. Thus, the irregularly shaped and 
dilated vessels that are often found in human CNS malignancies may not always represent 
newly formed vessels, but morphologically and functionally altered pre-existent ones.  
Our results might have clinical relevance with regard to diagnosis and therapy. As in CE-MRI 
tumors are detected on the basis of vascular changes (e.g. hyperpermeability), the absence 
thereof, such as we observed in the Mel57 lesions, will hamper tumor detection. With regard 
to therapy, our results show that anti-angiogenic treatment of brain tumors like glioblastoma 
multiforme, high-grade astrocytomas and metastases with vascular changes may give a 
benefit in that tumor progression might be slowed down. However, an important unwanted 
side effect might be that blockade of VEGF leads to a non-permeable tumor vasculature, 
potentially with a concomitant resistance to chemotherapeutic treatment. These issues are 
currently under investigation in our lab.  
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Abstract 
We have previously shown that the dense vascular network in mouse brain allows for growth 
of human melanoma xenografts (Mel57) by co-option of pre-existent vessels. Overexpression 
of recombinant VEGF-A by such xenografts induced functional and morphological alterations 
of pre-existent vessels. We now describe the effects of VEGF-A expression on visualization 
of these brain tumors in mice by magnetic resonance imaging (MRI), using gadolinium 
diethylenetriaminepenta-acetic acid (Gd-DTPA) and ultra small paramagnetic iron oxide 
particles (USPIO) as contrast agents.  
Brain lesions derived from (mock-transfected) Mel57 cells were undetectable in MRI after 
Gd-DTPA injection. However, the majority of such lesions became visible after injection of 
USPIO, due to the lower vascular density in the lesions as compared to the surrounding 
parenchyma. In contrast, VEGF-A-expressing lesions were visualized using Gd-DTPA-
enhanced MRI by a rapid circumferential enhancement, due to leaky peritumoral vasculature. 
USPIO-enhanced MRI on these tumors corroborated the immunohistochemical finding that 
peritumorally located, highly irregular and dilated vessels were present while intratumoral 
vessel density was low.  
This study shows that VEGF-A is a key factor in imaging of brain neoplasms. Our data also 
demonstrate that, at least in brain, blood-pool agent-enhanced MRI may be a valuable 
diagnostic tool to detect malignancies that are not visible on Gd-DTPA enhanced MRI. 
Furthermore, the involvement of VEGF-A in MRI visibility suggests that care must be taken 
with MRI-based evaluation of anti-angiogenic therapy, as anti-VEGF treatment might revert a 
tumor to a co-opting phenotype, resulting in loss of contrast enhancement in MRI. 
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Introduction 
Primary brain tumors and brain metastases of various origins are important clinical problems1.  
In patients with advanced malignant melanoma the cause of death is frequently related to 
brain metastasis and accompanying neurological complications 2. For diagnosis as well as 
planning and evaluation of therapy, imaging techniques like computer-assisted tomography 
(CT) and (contrast-enhanced) magnetic resonance imaging (CE-MRI) are invaluable tools. In 
CE-MRI, contrast enhancement of tumor tissue is usually accomplished by extravasation and 
subsequent accumulation in the interstitium of small contrast agents like gadolinium 
diethylenetriaminepenta-acetic acid (Gd-DTPA). Tumor vessels generally are more leaky than 
normal vessels and will thus permit faster extravasation. Hence, dynamic CE-MRI 
measurements allow identification of suspected malignancies by highlighting regions with 
increased rates of wash-in and wash-out of contrast agents 3. The difference between tumor 
and normal vessels is especially pronounced in brain, since the blood-brain barrier function of 
normal brain vessels precludes extravasation of these agents 4. 
Unfortunately, not all patients with brain tumors are recognized as such in contrast-enhanced 
MRI. Examples are infiltratively growing brain tumors like low grade diffuse astrocytomas 
(WHO grade II) and gliomatosis cerebri, which generally do not enhance in MRI after Gd-
DTPA adminstration because they grow without increasing vessel permeability 5, 6. On the 
other hand, the most malignant astrocytic tumor, i.e. glioblastoma multiforme (WHO grade 
IV) is readily detectable in MRI because in these tumors the blood vessels are tortuous and 
leaky. Nevertheless, Gd-DTPA often fails to identify the exact tumor boundary since 
enhancement may also occur at some distance from the tumor. In addition, in such tumors, 
which generally have a very heterogeneous morphology, regions can be found that are 
characterized by infiltrative growth and lack of Gd-DTPA-enhancement in MRI. 
One of the candidate factors responsible for detectability in Gd-DTPA-enhanced MRI is 
Vascular Endothelial Growth Factor-A (VEGF-A) which is also well known for its potency to 
induce vessel permeability 7. VEGF-A is regarded as the most potent angiogenic factor and in 
preclinical tumor models, inhibition of VEGF-A-signaling leads to inhibition of tumor 
angiogenesis and tumor growth 8-10. A number of compounds that target VEGF-A or its 
cognate receptors have made it to phase III clinical trials (see internet page 
http://www.cancer.gov/clinical_trials/). However, results so far are disappointing and some 
compounds (e.g. SU5416, a potent inhibitor of VEGF receptor-2) have been withdrawn from 
trial because of lack of response. One possible explanation for the discrepancy between 
clinical and preclinical results might be that the clinical targets, i.e. metastatic tumors that 
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typically grow in organs with high vascular densities such as liver, lung and brain, are less 
dependent on angiogenesis than tumors grown in preclinical mouse models where tumor cells 
are injected in the, largely avascular, subcutaneous space. Indeed, there is increasing evidence 
that some (metastatic) human tumors can grow without inducing an angiogenic switch 11-14. 
Therefore, it is important to develop a clinical tool that is able to predict which tumors are 
angiogenesis-dependent and thus susceptible to anti-angiogenic therapy and which tumors are 
not. CE-MRI could qualify as such because it is a non-invasive technique that allows 
detection of the vascular functional abnormalities associated with angiogenesis. CE-MRI 
modifications detecting angiogenesis-independent tumors still need to be identified, however. 
We recently showed that some human melanoma cell lines, like Mel57, express very low 
levels of VEGF-A and have low angiogenic potential in a mouse model of hematogenous 
brain metastasis 15. For blood supply and growth, these tumors co-opted the dense vascular 
bed in the brain parenchyma, allowing tumor growth in the absence of angiogenesis 16. 
Interestingly, vessel density and vascular volume within these lesions were lower than in the 
surrounding brain tissue, due to the increase of tumor volume in between pre-existent vessels 
without accompanying compensating angiogenesis. Remarkably, these tumors had a 
phenotype, at least partially resembling that of diffuse infiltrative, low grade gliomas: highly 
infiltrative tumor growth and no influence on blood-brain barrier function 15. However, when 
Mel57 tumors were grown that were engineered to express VEGF-A, a phenotype frequently 
seen in glioblastoma multiforme developed, i.e. combined expansive and infiltrative growth 
with highly dilated, irregularly shaped and leaky vessels.   
The differences in vascular phenotypes between Mel57 and Mel57-VEGF tumors led us to 
investigate whether these were reflected in patterns of contrast enhancement in MRI. Our data 
implicate VEGF-A as a crucial factor for the detection of brain tumors in MRI. They  also 
suggest that USPIO-enhanced MRI might provide additional diagnostic information in 
patients in whom Gd-DTPA CE-MRI was inconclusive.  
 
Materials & Methods 
 
Cell lines and transfections  
Mel57 cells were cultured at 37°C in Dulbecco’s modified  Eagle’s Medium (DMEM, Life 
Technologies, Breda, The Netherlands), supplemented with 10% fetal calf serum (FCS), 
streptomycin and penicillin. Plasmid pEGFP-IRESneo was from Clontech (Palo Alto, CA, 
USA). Human VEGF-A121 cDNA was cloned in plasmid pIRESneo. Transfections were 
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performed using Fugene reagent (Roche, Mannheim, Germany) according to the 
manufacturer’s guidelines. Transfected cells were selected in medium containing 400 µg/ml 
G418 (Roche, Mannheim, Germany) and maintained in medium containing 200 µg/ml G418. 
Cell clones were expanded, pooled and frozen. Cells were not individually cloned since the 
use of the IRES for G418-resistance warrants that close to 100% of the cells are positive for 
the transgene. Levels of recombinant VEGF-A in conditioned media were determined by 
western blot analysis as described 17.  
 
Animal experiments  
Specific pathogen-free (SPF) male, 6 to 8 weeks old BALB/c nu/nu mice were purchased 
from the university central animal facility. Five mice per cage were housed under SPF 
conditions (temperature 20-24 °C; relative humidity 50-60%; 15 air changes per hour; light-
dark periods 14 h/10 h). Water and food (RMH, Hope Farms, the Netherlands) were available 
to the animals ad libitum. Experiments were carried out in accordance with the national 
animal protection laws and approval was obtained from the Animal Experimental Committee. 
Brain metastases were induced as described previously 18. Briefly, cells were trypsinized, 
washed twice with phosphate-buffered saline (PBS) and counted using a Coulter Counter. For 
each cell line, a volume of 100 µl containing 1x105 cells was microsurgically injected into the 
right internal carotid artery of anesthetized nude mice. After development of cachexia 
(typically after 22-25 days for control tumors and 18-20 days for VEGF-expressing tumors) 
CE-MRI was performed according to the protocol described below. Groups of 5 mice were 
used in this study for each cell line. 
 
Contrast-enhanced magnetic resonance imaging 
Mice were anaesthetized (1.3% isoflurane; 1:1 (v/v) N2O/O2 mixture), catheterized in the tail 
vein, and placed in an MR spectrometer (S.M.I.S. console equipped with a Magnex Scientific 
7T/200mm horizontal bore magnet and a 150mT/m gradient set). Body temperature was 
maintained by placing the mice on a 37oC circulating warm water bed. A 12 mm diameter 
radiofrequency surface coil was positioned over the skull. After initial monitoring of the brain 
with fast gradient-echo scout images, 20 contiguous high-resolution coronal MR images were 
acquired with T2-weighted multislice spin-echo imaging (echo time = 50 ms; repetition time = 
3000 ms; number of averages = 1; field of view = 40x40 mm; matrix size = 512x512; slice 
thickness = 1 mm). This imaging protocol was repeated 2 minutes after intravenous injection 
of USPIO (Sinerem®, Guerbet, France) 19 at a dose of 12.5 mg/kg. Due to a shortening of T2-
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relaxation, injection of Sinerem leads to a signal decrease in this spin-echo sequence. In case 
of Gd-DTPA contrast enhancement, 16 contiguous images were acquired with a T1-weighted 
multislice gradient-echo sequence (TE= 8 ms; TR = 100 ms; flip angle = 90º; number of 
averages = 1; field of view = 25x25 mm; matrix size = 256x256; slice thickness = 1 mm) 
before and 1, 2, 10 and 20 minutes after injection of Gd-DTPA (Magnevist®, Schering, 
Germany) at a dose of 0.2 mmol/kg. Each animal received a single intravenous bolus injection 
of either Sinerem® or Magnevist®. For each contrast agent and tumor cell line, 5 mice were 
imaged. For quantification of data, voxels were selected that encompassed a complete lesion 
and intensity within a voxel was measured pre-contrast and at different time points post 
contrast, using the S.M.I.S. software package. In this way, signal intensities of 9 lesions in 5 
mice were measured  
 
Histological and immunohistochemical analysis 
After MRI, mice were sacrificed and brains removed and formalin-fixed. Brains were cut in 
coronal slices and embedded in paraffin. Sections of 4 µm were subjected to conventional 
H&E staining or immunostained for the endothelial marker CD34. MRI images were matched 
to histology as closely as possible, although a perfect match was impossible because of the 
difference between thicknesses of MRI and histology slices (1 mm vs. 4µm). 
 
Results 
Parental and mock-transfected Mel57 cells 
We have previously shown that metastatic Mel57 lesions grow in mouse brain parenchyma by 
co-option of pre-existing brain vessels. The presence of tumor did not affect the integrity of 
the brain vascular bed as illustrated by intactness of the blood-brain barrier 15.  In precontrast 
T1-weighted images these tumors could not be recognized, even after having reached 
considerable size (compare the image in Figure 1A to the matched H&E staining in Figure 
1C). In line with intact blood-brain barrier function, these lesions were not highlighted in Gd-
DTPA-enhanced MRI experiments as well (Figure 1B and figure 3). Note in this figure that 
large meningeal and/or skull blood vessels were contrast-enhanced, showing that Gd-DTPA 
had entered the circulation. This same result was obtained in all ten mice carrying parental 
and mock-transfected Mel57 tumors. 
In T2-weighted spin-echo images, parental Mel57 lesions were also not visible (compare the 
image in Figure 1D with the matched H&E-stained section in Figure 1F). However, after 
intravenous injection of the USPIO Sinerem, most of the lesions became visible as 
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hyperintense regions, compared to healthy brain parenchyma (compare Figure 1E to Figure 
1F, the arrows point at lesions). Comparison of post- to pre-contrast images revealed that this 
effect was due to a signal decrease in the highly vascularized normal brain parenchyma while 
inside the lesions MR signal intensity was less affected. Identical results were obtained using 
both contrast agents with EGFP-transfected control tumors (data not shown). In all mice 
carrying parental- or mock-transfected tumors we did not detect any tumor in CE-MRI 
although we were able to prove histologically that tumors were abundantly present in every 
mouse.  
 
VEGF-A expressing  Mel57 tumors 
In brains containing VEGF-A-expressing Mel57 tumors a completely different pattern of 
contrast enhancement was observed, both with T1-weighted Gd-DTPA and T2-weighted 
USPIO MRI. Although small lesions were not detected in precontrast T1-weighted images, 
large lesions became faintly visible as hyperintense regions (compare the image in Figure 2A 
to its matched histological counterpart in Figure 2C). Intravenous administration of Gd-DTPA 
resulted in a marked, predominantly circumferential contrast enhancement of all lesions 
(Figure 2B). Acquisition of MR images at different time points post injection revealed that 
wash-out of the contrast agent occurred rapidly. MR signals in the tumor tarted to decline as 
soon as 2 minutes post injection (figure 3). Twenty minutes post injection, tumors could not 
be distinguished anymore on MR images (not shown). At that time, extravasated Gd-DTPA 
had redistributed through the entire brain, including tumor, leading to overall higher MR 
signal intensities than pre-contrast (see also figure 3). Again, this result was very reproducible 
as all five Mel57-VEGF carrying mice showed circumferential enhancement after Gd-DTPA 
injection. 
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Fig 1. CE-MRI of mouse brain metastases of parental Mel57 human melanoma cells. T1-weighted gradient-echo images 
were acquired before (A) or directly after (B) injection of the contrast agent Gd-DTPA. Note that the contrast agent reached 
the brain as is evidenced by signal increase in the skull. C) Histology (H&E staining) of the slice corresponding to that in (A) 
and (B). Note that the lesions that are evident in C) are  not recognized on the MR images, both pre- and post-contrast. In a 
different mouse, T2-weighted spin-echo MR images of brain, containing parental Mel57 tumors were acquired  before (D) 
and after (E) injection of USPIO. The histology of the corresponding section is displayed in (F). Note that before contrast 
injection no lesions are visible, whereas after USPIO injection most lesions are visible as hyperintense regions (arrows in 
figure 1E and 1F). The inset shows a CD34 staining of the boxed tumor in C). Note also that the images, acquired in the MRI 
represent 1 mm slices while for H&E staining 4 µm slices are used. Perfect matching is therefore hardly possible. See also 
colour display page 152. 
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Fig 2. CE-MRI of Mel57 brain metastases, expressing VEGF-A. T1-weighted gradient-echo images were acquired before (A) 
or directly after (B) injection of the contrast agent Gd-DTPA. C) Histology (H&E staining) of the slices corresponding to that 
in (A) and (B). A CD34-immunostaining of the boxed tumor in (C) is shown to highlight the vasculature. Note that in (B) a 
strong peritumoral contrast enhancement is present, corresponding to dilated peritumoral, leaky vessels (inset in C). In a 
different mouse, T2-weighted spin-echo MR images of mouse brain Mel57-VEGF-A  tumors were acquired before (D) and 2 
minutes after (E) injection of USPIO. Histology of the corresponding section is displayed in (F). The arrowhead points at an 
intracerebral hemorrhage. Before injection of USPIO, lesions are detectable as hyperintense lesions while after injection 
lesions are strongly demarcated by peritumoral signal decrease. Intratumoral signal decrease is weaker than in the 
surrounding brain tissue, reflecting lower vessel density (F). See also colour display page 153. 
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Regions with contrast enhancement corresponded mainly to dilated vessels which were 
located at the tumor rim and in the peritumoral zone, adjacent to the main tumor mass. This 
conclusion is based on our histological finding that high numbers of irregular and highly 
dilated vessels were present in this peritumoral zone (Figure 2C, inset). We have previously 
demonstrated that these vessels were leaky by staining tissue sections for extravasated mouse 
immunoglobulins 15 and confirmed the permeability of these dilated vessels in all the VEGF-
tumors investigated here (not shown). Therefore, these vessels must be the ones from which 
Gd-DTPA extravasates. The observation that contrast enhancement was mainly confined to 
the tumor rim/peritumoral zone and did occur only limited in the central parts of the lesions 
was in line with our previous finding that intralesional vessel density in these tumors was low 
15. Individual intratumoral, dilated and leaky vessels could also be recognized after Gd-DTPA 
injection as hyperintense spots. 
In pre-contrast T2-weighted spin echo images, Mel57-VEGF lesions were visible as hyper-
intense areas (Figure 2D). Also, some lesions appeared as hypo-intense, presumably because 
of  large haemoglobin concentrations and/or hemorrhages (arrow in figure 2D,F). After 
USPIO injection, the signal intensity of the peritumoral regions markedly decreased (Figure 
2E), corroborating our previous histological finding that these regions contained highly 
dilated blood vessels 15. Occasionally, within the lesions dot-shaped signal decreases were 
observed that corresponded to dilated individual intratumoral vessels (not shown).  
Like in Gd-DTPA imaging, in USPIO-enhanced MRI the signal intensity change in Mel57-
VEGF-A tumor-containing brains was confined to the peritumoral areas. Comparable to 
parental Mel57 tumors, the post-contrast signal intensity of the tumor mass was higher than 
that of the surrounding brain parenchyma, due to a lower intravascular volume inside the 
tumor (Figure 2C,F and inset).  
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Fig 3. Semi-quantification of signal intensities after Gd-DTPA injection and wash out from mock-transfected or parental 
control tumors ( ) or tumors expressing VEGF-A (◊). 
Voxels containing tumor were selected and signal intensities measured over time. Values are depicted as mean of 9 lesions 
(in 5 different mice) +/- the standard deviation with the intensity of the pre-contrast voxels set at 100%.  Note that, within this 
time frame, post contrast intensities do not return to pre-contrast levels, probably due to diffusion of Gd-DTPA through the 
brain. Differences in signal intensities between Mel57-VEGF and parental Mel57 tumors after Gd-DTPA injection were 
highly significant (p<0.001 for all time points examined).  
 
 
Discussion 
In a previous study we analyzed patterns of vascularization in a mouse model of 
hematogenous brain metastasis, utilizing the human melanoma cell line Mel57 15. Upon 
intracarotid injection, this cell line which produces minimal amounts of VEGF-A, grew in 
brain parenchyma solely by vascular co-option, i.e. without induction of an angiogenic 
switch. In Mel57 brain metastases that expressed high levels of the angiogenic factor VEGF-
A we found that co-opted vessels, situated predominantly at the tumor periphery, were altered 
functionally and morphologically as they were irregularly dilated and permeable for large 
plasma proteins like immunoglobulins.  
Here we have used two contrast agents with different properties to investigate the 
consequences of the different tumor vessel characteristics on radiological behavior in CE-
MRI experiments. Gd-DTPA is a small, paramagnetic molecule which extravasates from 
leaky vessels into the surrounding interstitium. The rate and extent at which this occurs 
depend on several parameters, such as blood flow, vascular surface area, vessel permeability, 
interstitial pressure and extravascular space 3, 20. In clinical practice, Gd-DTPA is used to 
detect vascular abnormalities that frequently occur in malignancies. The other contrast agent 
is an USPIO consisting of superparamagnetic iron oxide particles, coupled to polydextrane 
(Sinerem). Due to its relatively large size, USPIOs are regarded as blood pool agents 19, 21, 
especially immediately after i.v. injection 22. The ironoxide causes T2 and T2* relaxation 
effects 23, of which the latter can be measured using gradient-echo MR sequences. Since at 7 
T, spin-echo images were of better quality in our hands, we chose to acquire T2-weighted 
spin-echo images for Sinerem measurements.  
When mice carrying parental Mel57 brain lesions were subjected to T1-weighted MRI, lesions 
were not visible, even after injection of Gd-DTPA. This is consistent with our previous 
observation that vessels in these tumors are pre-existent brain capillaries in which the blood-
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brain barrier is not affected 15. On spin echo images after i.v. injection of USPIO, Mel57 
lesions were visible as hyperintense regions due to lower vessel density than in the 
surrounding brain parenchyma.  
There is clear clinical relevance to this finding. Low grade diffuse glial tumors also infiltrate 
brain parenchyma without inducing significant vascular changes 24. Consequently, 
radiological diagnosis of these malignancies is often difficult, due to a lack of contrast 
enhancement by Gd-DTPA 5, 6. Otherwise, tumors like glioblastoma multiforme often have a 
heterogeneous phenotype with areas lacking the vascular changes, considered typical for such 
tumors. The presence of such regions often leads to radiological underestimation of tumor 
size 25. Our observations suggest that differences between vessel densities of tumor tissue and 
surrounding brain parenchyma, which often exist, are readily detectable using USPIO-
enhanced MRI. This may therefore be a valuable additional tool for diagnosis of vessel co-
opting brain tumors that do have altered vascular densities but lack functional vascular 
changes and thus are not detected using standard Gd-DTPA enhanced MRI. 
In contrast to parental Mel57 brain lesions, large VEGF-A- producing lesions were frequently 
detected in both T1-weighted gradient echo images and T2-weighted spin echo images, 
probably due to hyperpermeability-induced edema in or around the tumor or to higher water 
contents in the tumor (e.g. due to larger interstitial space). Also, the increased concentration 
of haemoglobin, a result of vessel dilatation associated with Mel57-VEGF-A tumors, might 
have contributed to the appearance of these tumors in pre-contrast images (see also the 
appearance of the hemorrhage in figure 2D and F (arrow)). After Gd-DTPA injection, strong 
circumferential contrast enhancement readily demarcated these lesions. This contrast 
enhancement was transient, as within 10 minutes most of the contrast agent had spread 
through the brain tissue. The ring-shaped contrast enhancement was in line with our 
histological observation that dilated, hyperpermeable vessels were abundantly present 
immediately adjacent to the tumor lesions, in the tumor rim/peritumoral zones15. 
Clinical studies have already shown a correlation between VEGF-A production by tumors and 
Gd-DTPA contrast enhancement in MRI in primary and metastatic brain neoplasms 26, 27, but 
direct evidence for such a correlation has been lacking so far. Our data provide solid proof 
that VEGF-A, also known as Vascular Permeability Factor (VPF) 7, is a key factor that 
determines whether a tumor is visible in Gd-DTPA-enhanced MRI.  
Interestingly, the pathology (growth pattern, central necrosis) and radiological behavior (ring-
shaped contrast enhancement) of Mel57-VEGF-A lesions partly resembled that typical for 
high grade gliomas like glioblastoma multiforme (GBM), tumors that are infamous for high 
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VEGF-A expression levels. Our findings with Mel57-VEGF-A brain xenografts might also 
provide an explanation for the fact that in GBM, Gd-DTPA-enhancement frequently occurs at 
some distance from the tumor mass: VEGF-A, secreted by the tumor might diffuse over small 
distances from the tumor through the brain and cause permeability of vessels at the tumor rim 
and adjacent peritumoral vessels. In this respect it is important to realize that in our study we 
have used VEGF-A121, the isoform of VEGF that can diffuse freely since it lacks affinity for 
extracellular matrix components like heparan sulfate proteoglycans (HSPGs) 28. We are 
currently investigating whether expression of the larger VEGF isoforms, that are at least 
partially retained by the extracellular matrix, leads to different patterns of contrast 
enhancement. 
The low intratumoral vessel density in Mel57-VEGF-A metastases was also evident from 
USPIO-enhanced MRI. The lesions did not show the signal decrease that was observed in 
distant brain tissue. In line with the high vascular volume at the tumor periphery, due to 
highly dilated vessels, the peritumoral zone displayed a very strong signal decrease. This 
demonstrated that these peritumoral vessels were perfused, supporting our hypothesis that 
enhanced tumor growth of Mel57-VEGF-A, as compared to parental Mel57 lesions, was due 
to a higher blood supply via dilated peritumoral vessels 15. 
Interestingly, macromolecular contrast agents like USPIO have been used to improve MRI 
visualization of gliomas in a protocol where imaging was performed 12 hours post injection 
of contrast agent 29. Whether at this stage the agent still can be considered blood-pool 
restricted is not clear since USPIOs may be phagocytosed by tumor cells or macrophages 30. 
Performing MRI scans at an earlier time point may yield additional information.  
Our observations have a number of important consequences:   
1) In patients, suffering from vessel-co-opting brain tumors, in whom radiological diagnosis 
proves difficult due to low or absent Gd-DTPA enhancement, USPIO-enhanced MRI might 
yield valuable additional diagnostic information based on lower vessel densities within the 
tumor. Evenmore, it would also be worthwhile to subject patients, already diagnosed with 
GBM, to USPIO-enhanced MRI since vessel-co-opting regions within the tumor which do not 
enhance using Gd-DTPA may be identified as such. 
2) Prudence is in order in CE-MRI follow-up of anti-angiogenic therapy, aimed at inactivation 
of VEGF-A. Tumors may initially become (partially) invisible in Gd-DTPA enhanced MR 
images, not because the lesion was irradicated, but because it was converted to a co-opting 
phenotype. We have recently demonstrated that this indeed occurs (manuscript in 
preparation). Otherwise, an anti-angiogenic treatment might be considered effective because 
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during MRI follow-up the tumor did not seem to have progressed, while it actually may have 
done so via vessel co-option. Recently, such adaptation of a tumor in response to anti-VEGF 
treatment has indeed been described 10, 31. Also in these cases USPIO-enhanced MRI follow-
up might be informative. We are currently testing this hypothesis by investigating the effects 
of anti-angiogenic therapies in our model. 
3) From combined Gd-DTPA and USPIO– enhanced MRI images one might be able to 
predict whether anti-angiogenic treatment of tumors will be succesfull. Our data suggest that 
non-Gd-DTPA enhancing tumors will not be susceptible to anti-VEGF therapy.  
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Abstract 
We previously described that VEGF-A expression by Mel57 human melanoma cells leads to 
tumor progression in a murine brain metastasis model in an angiogenesis-independent fashion 
by dilation of co-opted pre-existent vessels and concomitant enhanced blood supply1. Here, 
we compare the activities of the 121, 165 and 189 VEGF-A isoforms in this model by 
transfecting Mel57 cells with the respective cDNAs and injecting the resulting stably 
transfected cell lines in the internal carotid artery of nude mice (n=10 for each isoform). 
Although the three isoforms had similar potency to induce endothelial cell proliferation, 
VEGF121 expression did not result in sprouting angiogenesis, but rather led to extensive 
vasodilation and increased permeability of pre-existent, predominantly peritumoral vessels. 
Sometimes, proliferating endothelial cells accumulated in vessel lumina, giving these a 
microvascular glomeruloid-proliferation-like appearance. Expression of VEGF165 or VEGF189 
was associated with induction of an intratumoral neovascular bed. In VEGF165-expressing 
tumors, daughter endothelial cells were distributed among newly formed vessels which were 
heavily dilated. This also occurred in VEGF189-tumors but there, vasodilation was less 
pronounced. Using contrast-enhanced magnetic resonance imaging (CE-MRI), the different 
vascular phenotypes were reflected by characteristic radiological images. VEGF165 expression 
was the most unfavorable of the three: mice carrying VEGF165 tumors became moribund 
earlier than those carrying VEGF121 expressing tumors (16+/- 4 days vs. 22 +/- 3 days).  
Our data demonstrate that VEGF-A-isoforms differ in angiogenic properties which can be 
visualized by CE-MRI.
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Introduction 
Angiogenesis, the formation of new blood vessels from pre-existing ones, is a complex 
process that is regulated by a vast array of stimulators and inhibitors. Of these, Vascular 
Endothelial Growth Factor-A (VEGF-A) is regarded as the most potent pro-angiogenic factor. 
Via binding and activation of the tyrosine kinase receptors VEGFR1 and VEGFR2 (also 
named Flt-1 and KDR/Flk-1, respectively), endothelial cell proliferation, migration, and 
expression of Tissue Factor and proteases are induced2,3. These concerted actions lead to 
blood vessel permeability, followed by extravascular deposition of a fibrin network which 
serves as a provisional matrix for newly formed daughter endothelial cells 4.  
VEGF-A is member of a family of growth factors also comprising VEGF-B,C,D,E, Placental 
Growth Factor (PlGF) and the platelet derived growth factors (PDGF-A and B) 2. Alternative 
splicing of VEGF-A pre-mRNA leads to secretion of six variants of this homodimeric 
molecule consisting of 121, 145, 165, 183, 189 and 206 amino acid residues, respectively 5,6. 
In mice these isoforms have one amino acid residue less. With the exception of VEGF121, 
these proteins have affinity for heparin and heparan sulphate proteoglycans (HSPGs) that 
increases with length due to the presence of positively charged domains, encoded by exon 7 in 
VEGF165 and exons 6 and 7 in VEGF189 and VEGF206 7,8. The exon 7-encoded sequence also 
confers affinity upon VEGF165 for the co-receptors neuropilin 1 and 2. In cell culture 
VEGF189, and to a lesser extent VEGF165, are sequestered by HSPGs on the cell surface. It is 
assumed that in this way the extracellular matrix functions as a reservoir of biologically 
inactive VEGF-A which, when needed, can be released quickly as aminoterminal bio-active 
fragments by the action of proteases 9-11. 
Although VEGF121 itself does not bind to heparin or HSPGs, the latter are required for 
efficient receptor activation 7. Both VEGFR1 and VEGFR2 have heparin binding domains, 
suggesting that receptor-bound HSPGs stabilize the ligand-receptor complex 12-14. In vitro, 
VEGF121 binds to VEGFR1 with 20-fold lower affinity than VEGF165 15 and it is also less 
potent in activating VEGFR2 11. Remarkably, VEGF121 and VEGF165 have been reported to 
have similar angiogenic activities in vivo 16,17. The presence of ligand-receptor complex-
stabilizing HSPGs in vivo that are absent in vitro may account for the apparent difference in 
VEGF121 potencies in both settings. 
In vitro studies have unraveled in detail the molecular biology and cell biology of 
VEGF/VEGFR signaling. However, it is only since recently that attention is paid to in vivo 
activities of individual VEGF-A isoforms. Data obtained by the group of Carmeliet using 
knock-in mice that selectively express individual VEGF-A isoforms in cardiac muscle showed 
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that VEGF164 is sufficient for normal embryonic vascular development. In hearts where only 
VEGF188 was expressed, arterial development was significantly affected, while venous 
development appeared normal. Exclusive VEGF120 expression led to lethal disturbances in 
vascular development 18,19. 
Contradictory reports exist towards the functional importance of VEGF121 in tumor biology.  
When overexpressed in a colon tumor xenograft model, VEGF121 increased vascularity and 
enhanced tumor growth 20 while in recent reports expression of VEGF165 and VEGF189, but 
not VEGF121, correlated with increased vascular density and poor prognosis 21-23. 
Interestingly, Guo et al. described that the ability of VEGF121 to induce angiogenesis 
depended on the site of tumor growth: VEGF121 minimally enhanced angiogenesis in and 
growth of subcutaneous gliomas, whereas in brain the same VEGF121-expressing tumor 
generated an angiogenic response 24. Some reports described that VEGF121 and VEGF165 
expression in brain tumor models led to cerebral hemorrhage and VEGF189 caused sprouting 
angiogenesis, while other reports stated that VEGF189 lacks any angiogenic activity 25,26. 
We previously described that the human melanoma cell line Mel57 has low background 
production of angiogenic factors and grew in murine brain parenchyma by co-option of pre-
existent brain vessels, i.e. without inducing an angiogenic response and without notably 
affecting pre-existing vessels 1. In these tumors, even after having reached considerable size, 
hardly any hypoxia developed. This makes this system particularly convenient to study 
angiogenic activities of different factors, since results are not biased by upregulation of 
endogenous VEGF-A, an event known to occur in response to hypoxia. Using this model, we 
previously described that recombinant VEGF-A was not able to induce an angiogenic 
response but instead modulated pre-existent vessels by dilation, induction of 
hyperpermeability, loss of blood-brain barrier markers and upregulation of a number of 
molecules, characteristic for activated endothelial cells 1 . In contrast-enhanced magnetic 
resonance imaging (CE-MRI) scans, VEGF-A-expressing tumors were easily recognized, 
while parental Mel57 tumors were undetectable 27.  
Here we report on the vascular phenotypes and MRI behaviour of Mel57 brain tumors 
expressing either of the three VEGF-A isoforms. 
 
Materials and Methods 
Cell lines and transfections. Mel57 human melanoma cells were maintained in Dulbecco’s 
Modified Eagles Medium (DMEM, Life Technologies, Breda, The Netherlands) 
supplemented with 10% fetal calf serum (FCS) and penicillin/streptomycin. cDNAs encoding 
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the 121, 165 and 189 aa VEGF isoforms (human origin) were cloned in vector pIRESneo 
(Clontech) to generate plasmids pIRESneoVEGF121 , pIRESneoVEGF165 and 
pIRESneoVEGF189. All sequences were verified by DNA sequencing (AbiPrism, Applied 
Biosystems). Plasmid pIRESneoVEGF165 was different from the VEGF165 construct published 
before 1 as the cDNA in that plasmid had a slightly modified 3’ end. Plasmids were stably 
transfected into Mel57 cells as described 1. Presence of recombinant proteins in conditioned 
media was confirmed by SDS-PAGE and western blotting experiments using antibody VEGF-
A20 (Santa Cruz). In case of VEGF189, 5 IU/ml heparin (Leo systems, Breda, The 
Netherlands) was included in the culture medium prior to analysis. VEGF concentrations were 
also determined using an in-house developed ELISA28. 
 
Animal experiments. All experiments were approved by the Animal Experiment Committee of 
the Nijmegen University. The hematogenous brain metastasis protocol has been described 
previously 29. In short, 105 Mel57 (transfectant) cells were microsurgically injected into the 
right internal carotid artery of BALB/C nude mice (n= at least 10 for each cell line). After 14-
21 days, depending on which isoform was expressed, animals became moribund, due to 
cachexia or development of neurological defects. At this stage, CE-MRI was performed (see 
below) after which animals were killed by intravenous injection of an overdose barbiturates. 
Brains were removed and either fixed in formalin or snap-frozen in liquid nitrogen. 
 
3D-reconstruction of tumor vessels by ink perfusion. Moribund tumor-bearing mice (three 
from each group) were anaesthesized and microsurgically injected into the supra-aortic 
branches with 5 ml of indian ink, containing 5,000 U/ml heparin. After this procedure, brains 
were removed, fixed in buffered formalin for 24 hrs and 0.5 mm sections were cut and 
examined under a transmission microscope with bright light. By focussing through different 
layers of the section a good impression of the 3D vascular structure was obtained. 
 
Immunohistochemistry. Immunostainings were performed using antibodies directed against 
murine Ki67 as a proliferation marker (Dianova, Hamburg, Germany), the endothelial 
markers CD31 and CD34 (Hycult, Uden, The Netherlands), VEGFR2 (Santa Cruz, CA, USA) 
and the blood brain barrier marker Glut-1 (DAKO, Glostrup, Denmark). Antibodies against 
the pericyte marker α-smooth muscle actin were obtained from Sigma (Zwijndrecht, The 
Netherlands). Extravascular mouse immunoglobulins were detected with a biotin-labeled anti-
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mouse IgG. Secondary biotin-labeled antibodies were visualized by ABC staining according 
to standard protocols (VECTOR, Burlingame, CA, USA). 
 
Magnetic resonance imaging. Mice were anaesthetized (1.3% isoflurane; 1:1 (v/v) N2O/O2 
mixture), catheterized in the tail vein, and placed in an MR spectrometer (S.M.I.S. console 
equipped with a Magnex Scientific 7T/200mm horizontal bore magnet and a 150mT/m 
gradient set). Body temperature was maintained at 37oC with a circulating warm water bed. 
After initial monitoring of the mouse brain with fast gradient-echo scout images using a 12 
mm surface coil, twenty contiguous high-resolution coronal MR images were acquired with 
T2-weighted multislice spin-echo imaging (TE = 50 ms; TR = 3000 ms; FOV= 40x40 mm; 
matrix size = 512x512; slice thickness = 1 mm) before and 2 minutes after intravenous 
injection of 0.2 ml of USPIO (ultrasmall superparamagnetic iron oxide-coated dextran, 
Sinerem®, Guerbet, France) (12.5 mg/kg). In case of Gd-DTPA (gadolinium 
diethylenetriaminepenta-acetic acid) contrast enhancement, 16 contiguous images were 
acquired with a T1-weighted multislice gradient-echo sequence (TE= 8 ms; TR = 100 ms; field 
of view = 25x25 mm; matrix size = 256x256; slice thickness = 1 mm) before and at several 
time points (0, 2, 10 and 20 minutes) after bolus injection (0.2 ml; 0.2 mmol/kg) of 
Magnevist® (Schering, Germany). 
 
Results  
Effects of VEGF-A isoforms on growth of Mel57 brain lesions. To examine the effects of the 
121, 165 and 189 isoforms of VEGF-A on tumor growth in mouse brain, we generated stable 
transfectants of the human melanoma cell line Mel57, expressing either isoform in vitro at 
levels of 30-100 ng/ml/106 cells/48 hrs (as determined by ELISA, not shown). Recombinant 
proteins were of the correct molecular weights as determined by western blotting (not shown). 
Before transfection, this cell line expresses very low endogenous levels of angiogenic factors, 
especially VEGF-A 30,31. After intracarotid injection of parental Mel57 cells, metastatic 
lesions formed in the parenchyma that grew infiltratively by vascular co-option without 
notable vascular changes 1,27. In tumors expressing either VEGF-A isoform we found 
upregulation of the endothelial markers CD31, CD34, VEGFR2 and the activated pericyte 
marker α-smooth muscle actin (figure 1A-C and not shown). There was no significant effect 
of VEGF-A isoform expression on the number of lesions that developed (not shown). All 
isoforms induced proliferation of endothelial cells, as demonstrated by mouse-specific 
immunostaining for the proliferation marker Ki67 (figure 1J-L). Furthermore, staining for 
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murine IgGs, that normally do not pass the blood brain barrier, revealed that all isoforms 
caused extravasation of macromolecules indicating vessel hyperpermeability (figure 1G-I). 
Besides these common VEGF-A effects, striking differences were found between vascular 
morphologies as described below. In situ hybridization with an antisense VEGF-A RNA 
probe revealed that also in vivo, expression levels of the three isoforms were comparable (not 
shown), indicating that the differences were qualitative. 
 
VEGF121 
After injection of Mel57-VEGF121 cells, tumors developed with a combined infiltrative and 
expansive phenotype. Animals were moribund due to cachexia or neurological defects 
reproducibly three to four weeks after injection of tumor cells. Immunostaining for the 
endothelial marker CD34 revealed that in the peritumoral zone irregularly dilated vessels 
were present (figure 1A). Tumor cells could often be observed along these vessels indicating 
migration in the perivascular space (arrow in figure 1A, inset). Vessel densities within tumor 
nests were relatively low as was demonstrated by CD34 immunohistochemistry (figure 1A) 
and by 3D visualization established by ink perfusion (figure 2B). The low intratumoral vessel 
density and the morphology of peritumoral vessels indicated a lack of sprouting angiogenesis. 
In some tumors, the low intratumoral vessel density resulted in central hypoxia and necrosis 
(figure 1D, note that Glut-1, besides being a marker for the blood brain barrier (see below), 
also is upregulated on hypoxic cells). Although VEGF121 clearly lacked the capacity to induce 
sprouting angiogenesis, it was yet a strong inducer of endothelial proliferation (see the murine 
Ki67 staining in figure 1J). Focally, glomeruloid-like microvascular proliferations consisting 
of endothelial cells and pericytes were present (arrow in figure 1J), resembling a phenotype 
that is often encountered in high grade glial brain tumors like glioblastoma multiforme 32. 
Glucose transporter-1 (Glut-1) is a membrane protein that is specifically expressed on 
endothelial cells of brain vessels and is regarded as a blood-brain barrier marker 33. The 
dilated vessels in and around VEGF121 lesions had a mosaic Glut-1 phenotype, some 
endothelial cells being positive and others negative (figure 1D), consistent with a loss of 
blood-brain barrier function.  
VEGF121-induced peritumoral vascular effects were reflected in CE-MRI. Intravenous 
injection of the paramagnetic, low molecular weight compound Gd-DTPA in mice carrying 
VEGF121-expressing lesions led to predominantly circumferential signal increase immediately 
after injection, whereas centrally in tumor nests no notable enhancement was observed (figure 
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3A). Peritumoral enhancement was entirely due to expression of VEGF121, since it was absent 
in mice carrying parental Mel57 lesions 27. A similar pattern of enhancement was obtained 
after intravenous injection of USPIOs that, due to large size, are assumed to remain 
intravascularly 34. Again predominantly circumferential enhancement occurred (figure 3B), 
although individual, dilated, intratumoral vessels were also highlighted (note that the nature of 
MR sequence used, causes a drop of signal intensity). This enhancement pattern lasted for up 
to 4 hours post injection, while Gd-DTPA enhancement was much more transient, having 
disappeared within 20 minutes post injection (not shown). 
 
VEGF165 and VEGF189 
When VEGF165 or VEGF189 was expressed by Mel57 brain tumors, mice developed terminal 
cachexia and neurological defects approximately two and three weeks post injection, 
respectively. The tumor vasculature that had formed was very different from that induced by 
VEGF121. Now, extensive neo-angiogenesis had occurred (see CD34 staining in figure 1B,C 
and 3D visualization in figures 2C,D) while peritumoral vascular effects were hardly 
observed, in contrast to the VEGF121 situation (figure 2B). VEGF165-expressing lesions 
displayed prominent vessel dilation and permeability with numerous proliferating endothelial 
cells (figure 1B,E,K). Consistent with the high vascular volume in these tumors, necrosis was 
never observed. In the border regions of these tumors, vessels were partly Glut-1 negative 
(figure 1E, thin arrowhead) while this protein was completely absent in vessels in the tumor 
centre (bold arrowhead). In the VEGF189-expressing metastases, a dense network of 
microcapillaries had formed that were leaky and had diminished Glut-1 expression, whereas 
vessel dilation was minimal. Consistent with the high intratumoral vascular volumes, 
VEGF165- or VEGF189-expressing tumor nests were entirely contrast-enhanced in Gd-DTPA 
and USPIO-enhanced MR images (figure 3C-F). The wash-out rates of Gd-DTPA were not 
notably different from that of the VEGF121-expressing tumors, since 10-20 minutes post 
injection signals had returned to basal levels (not shown). Due to the earlier time point at 
which mice carrying VEGF165 -lesions became moribund, these lesions were generally smaller 
than VEGF121 lesions. 
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Fig 1 – Immunohistochemical analysis of mouse brain Mel57 lesions, expressing VEGF isoforms as indicated. A-C: CD34 
endothelial staining, D-F: staining for Glut-1, a blood-brain barrier specific protein, G-I: staining for murine IgG, showing 
cumulative leakage of immunoglobulins from permeable vessels, J-L: staining for the murine proliferation marker Ki67. The 
arrow in J) points at a glomeruloid-like vascular proliferation, while in K) and L) daughter endothelial cells are redistributed 
over newly formed vessels. Note the predominantly peritumoral effects on the vasculature by VEGF121 (A) while expression 
of the two other isoforms lead to predominantly intratumoral vascular effects (B,C). The arrows in E) point at Glut-1 negative 
(arrow) and mosaic vessels (small arrowhead). H=hypoxia, which manifests as Glut-1 positivity . The bars represent 0.5 mm. 
See also colour display page 154. 
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Fig 2 –3D visualization of brain tumor vasculature. Mice carrying parental Mel57 (A), Mel57-VEGF121 (B), Mel57-
VEGF165 (C) and Mel57-VEGF189 (D) tumors were perfused with indian ink as described in Materials and Methods. Brains 
were cut into 0.5 mm sections and examined under a transmission light microscope. Lesions were easily identified on basis of 
different optical breaking indices compared to normal brain tissue. White areas in A and B represent the (poorly vascularized) 
lesions. Microscope magnifications were 50x and 200x (insets). Since mice carrying VEGF165-lesions became moribund 14 
days post injection of the tumor cells, i.e. one week earlier than the other mice (see text), VEGF165 lesions were relatively 
small. Due to the amount of light needed to visualize these relatively small, very dark lesions, the surrounding brain tissue is 
hardly visible in C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3 – Contrast-enhanced MRI of murine brains carrying Mel57 lesions expressing the different VEGF-isoforms. T1-
gradient echo (A,C,E) or T2-spin echo sequences (B,D,F) were used to detect Gd-DTPA and USPIOs respectively. The 
images shown are acquired 2 minutes after intravenous bolus injection of both contrast agents. 
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Discussion 
We report here that, in striking contrast to VEGF165 and VEGF189, VEGF121 is not able to 
induce angiogenic sprouting in metastatic melanoma in mouse brain. Rather, the small 
isoform caused extensive dilation and permeability of pre-existent blood vessels, a phenotype 
which is very similar to what we described previously for VEGF165 1. However, in that study 
we used a VEGF165 molecule that carried a mutation of the carboxyl terminus. At that time we 
considered this a wild type protein as the carboxyl terminus had not been recognized in the 
literature as functionally important. Furthermore, this protein was indistinguishable from 
commercially obtained wtVEGF165 in a number of in vitro functional and receptor binding 
assays. To our surprise we have now found that when the carboxyl terminus was unmodified, 
a different vascular phenotype developed than we previously described, indicating that the 
carboxyl terminus is critical for full VEGF activity. These findings imply that different 
biological activities of VEGF165 can be dissected using these mutants (manuscript in 
preparation).  
Interestingly, in a recent report Bates et al. described the identification of VEGF165b, a splice 
variant which lacks the carboxyterminal exon 8 sequence 35. Despite intact binding domains 
for VEGFR1, VEGFR2 and neuropilins, this protein behaved as a VEGF receptor antagonist, 
thus confirming the importance of the carboxyl terminus for VEGF activity. How exactly 
exon 8-encoded sequences contribute to VEGF-A activity is still enigmatic.  
In contrast to VEGF121 , VEGF165 and VEGF189 induced extensive sprouting angiogenesis in 
our model. The phenotypes of tumors expressing these larger isoforms could also be 
distinguished since VEGF165 induced profound vasodilation, whereas VEGF189 failed to do so. 
Interestingly, expression of VEGF165 appeared to correlate with worse clinical outcome since 
we consistently found that mice carrying VEGF165-expressing brain tumors became 
symptomatic already after approximately two weeks, one week earlier than those expressing 
VEGF121 or VEGF189. The reason for this difference is not clear: it is not likely to be a result 
of enhanced growth of the VEGF165-expressing tumors. In a time-matched experiment, we 
found no significant differences between the sizes of the various brain lesions, although 
within individual animals tumor sizes showed a high degree of heterogeneity (not shown). 
Possibly the combination of extensive vasodilation and hyperpermeability induced by 
VEGF165 led to more severe edema in the surrounding brain tissue than that induced by the 
other isoforms. We have not examined this in detail.  
In all VEGF-expressing tumors, irrespective of the isoform, the blood brain barrier marker 
Glut-1 was absent or only partially expressed on vessels. Whether VEGF-A actively 
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downregulates Glut-1 expression on pre-existing brain vessels, or newly formed endothelium 
simply does not express this brain endothelium-specific protein, is not completely clear. The 
fact that in VEGF165-lesions intratumoral vessels were completely negative for Glut-1 while at 
the tumor rim mosaic vessels were found, is in favor of the second option: at the tumor rim, 
pre-existent vessels become gradually influenced by tumor-derived VEGF-A leading to a 
mixture of mother endothelial cells (Glut-1 positive) and daughter cells (Glut-1 negative). As 
endothelial cell proliferation continues, Glut-1-negative endothelial cells will become more 
and more abundant until in the intratumoral vessels, they prevail.  
Depending on which VEGF-isoform was expressed, tumors had distinct patterns of contrast-
enhancement in MRI experiments. Tumors that expressed VEGF121 characteristically showed 
a circumferential enhancement, due to a peritumorally located, dilated and leaky vasculature, 
combined with low intratumoral vessel density. The larger isoform-expressing tumors showed 
a more homogeneous, bulky enhancement. These MR images were in good agreement with 
our morphological findings. Peritumoral Gd-DTPA enhancement in the VEGF121-expressing 
tumors indicated the presence of leaky vessels outside the main tumor mass from which the 
contrast agent could extravasate and accumulate in the surrounding tissue, while the strong 
signal drop after USPIO injection was in accordance with the high density of dilated vessels, 
causing a high local vascular volume. The relatively low intratumoral vessel density 
accordingly led to low levels of enhancement of the lesion itself, both with Gd-DTPA and 
USPIOs. The bulky enhancement seen in VEGF165 and VEGF189 lesions was also in 
accordance with the high vascular volume of these tumors. Whether CE-MR images of human 
tumors can be correlated to VEGF isoform expression is not known. If so, it may be of help 
for prognosis and possibly for selection of patients that are candidates for anti-VEGF therapy. 
In a preliminary study we found that the heterogeneity in expression levels of the different 
VEGF-isoforms in human tumors makes this question difficult to answer. 
Differential effects of the various VEGF-A isoforms have only recently received attention in 
the literature. Via targeted disruption of specific VEGF exons, Carmeliet et al. have generated 
mice that selectively express VEGF120. VEGF120 could not substitute for the larger isoforms 
as during development these mice developed severe angiogenesis-related abnormalities 36,37. 
These defects might in fact be related to vasculogenesis rather than angiogenesis, since 
VEGF121 and VEGF165 are equally effective in inducing angiogenesis in the chick 
chorioallantoic membrane angiogenesis assay and collateral formation in ischemic rabbit 
hindlegs 17. In a recent report, VEGF120 was described to be relatively incapable of inducing 
branching of blood vessels in various organs during development 38. 
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In tumors, controversial observations have been reported regarding VEGF isoform activities. 
VEGF-null fibroblasts have been generated and used to establish fibrosarcomas expressing 
each individual VEGF isoform 39. Analysis of subcutaneous tumors grown from these cell 
lines revealed that only VEGF164 could compensate for the lack of the endogenous VEGF 
gene while VEGF120 had a negligible angiogenic effect. In this model VEGF188 expression led 
to highly vascularized, yet small, tumors. From these data the hypothesis emerged that 
VEGF120 diffuses away from the tumor and recruits vasculature from surrounding tissue, 
while the ECM-binding isoform VEGF188 induces local branching and sprouting angiogenesis. 
In this model, the VEGF164 isoform has intermediate activity. This model is consistent with 
our current findings: whereas VEGF121 failed to induce an intratumoral neovascular bed, 
VEGF189 expression in our brain model led to highly vascularized and relatively large tumors. 
This largely confirms results from other groups 24,25 and  might be explained by the fact that in 
the vessel-dense brain there is no need for extra recruitment of blood vessels from the 
surroundings 1.  
The difference between VEGF121 and VEGF165 is the presence of the exon 7-encoded domain 
in VEGF165, which is responsible for neuropilin and HSPG binding. Neuropilin 1 potentiates 
the activity of the VEGF-A/VEGFR2 complex 40 and HSPGs can act as chaperone for 
VEGF165 41 or even transmit VEGF165 signals 42. In this light it was a remarkable observation 
that VEGF121 induced extensive endothelial cell proliferation, a VEGFR2-mediated response, 
in pre-existent vessels to an extent that at least equaled that induced by the larger VEGF 
isoforms. This suggests that neuropilin 1- enhanced VEGFR2 binding can not account for the 
difference between the in vivo activities of the 121 and 165 -isoforms. A second argument 
against a role for neuropilin and HSPGs in the VEGF165-induced tumor phenotype can now be 
found in our previous study, in which we used a VEGF165 mutant (see above) 1. This mutant 
did contain the intact exon 7 sequence and therefore had intact neuropilin and HSPG affinity. 
Nevertheless, it did not induce sprouting angiogenesis but led to a VEGF121-like vascular 
phenotype.  
An interesting observation was that VEGF121 was an efficient inducer of endothelial cell 
proliferation in the absence of sprouting angiogenesis. This shows that activation of VEGFR2, 
the receptor that is responsible for proliferation, occurred but was not sufficient for 
angiogenesis in this model, contrary to what is generally believed. Obviously, endothelial 
proliferation via VEGFR2 activation is a critical step in the initial stages of angiogenesis, but 
is not sufficient for completion of this process: migration, adhesion and protease activities 
obviously are necessary as well. Remarkably, in a recent report it was shown that VEGF121, in 
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contrast to the larger VEGF-A isoforms, was unable to mediate endothelial migration in vitro 
43, possibly because extracellular matrix-bound VEGF-A is needed for migration. Whether 
this concept also explains our in vivo results remains to be established. Alternatively, certain 
signals, induced by VEGF165 and VEGF189 may fail to occur in the VEGF121-induced signal 
transduction cascade, thereby rendering VEGF121 unable to induce sprouting angiogenesis. It 
would be interesting to know the nature of these signals and the receptors from which they 
emerge, since apparently the differences between VEGF121 and VEGF165 activities can not be 
solely attributed to differential binding to neuropilins, VEGFR2 and HSPGs. 
These issues are currently under investigation in our lab. 
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Abstract 
Purpose - In brain, tumors may grow without inducing angiogenesis, via co-option of the 
dense pre-existent capillary bed. The purpose of this study was to investigate how this 
phenomenon influences the outcome of anti-angiogenic therapy. 
Experimental design - Mice carrying brain metastases of the human, highly angiogenic 
melanoma cell line Mel57-VEGF-A were either or not treated with different dosages of 
ZD6474, a VEGFR2 tyrosine kinase inhibitor with additional activity against EGFR. Effect of 
treatment was evaluated using contrast-enhanced MRI and (immuno)morphological analysis. 
Results – Placebo-treated Mel57-VEGF-A brain metastases evoked an angiogenic response 
and were highlighted in contrast-enhanced (CE)- MRI. Following treatment with ZD6474 
(100 mg/kg), CE-MRI failed to detect tumors, either in prevention or therapeutic treatment 
regimens. However, (immuno)histological analysis revealed the presence of numerous small, 
non-angiogenic lesions. Treatment with 25 mg/kg ZD6474 resulted also in efficient blockade 
of vessel formation, but did not fully inhibit vascular leakage, thereby still allowing 
visualization in CE-MRI scans. 
Conclusions - Our data show that, although angiogenesis can be effectively blocked by 
ZD6474, in vessel-dense organs this may result in sustained tumor progression via co-option, 
rather than in tumor dormancy. Importantly, blocking VEGF-A may result in undetectability 
of tumors in CE-MRI scans, leading to erroneous conclusions about therapeutic efficacy 
during MRI follow-up. The maintenance of VEGF-A-induced vessel leakage in the absence of 
neovascularization at lower ZD6474 doses may be exploited to improve delivery of 
chemotherapeutic agents in combined treatment regimens of anti-angiogenic and 
chemotherapeutic compounds. 
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Introduction 
The continuously increasing demand for oxygen and nutrients of growing solid tumors can be 
met by induction of a neovascular bed. This is accomplished by an hypoxia-driven 
mechanism, which results in expression of a number of effector molecules among which is 
Vascular Endothelial Growth Factor-A (VEGF-A), the most potent angiogenic factor known 
to date 1. The notion that abrogation of the blood supply to a tumor will prevent further 
outgrowth and induce dormancy, has led to the development of numerous compounds that 
target one of the events in the multi-step process of angiogenesis. These include: naturally 
occurring angiogenesis inhibitors such as tumstatin, endostatin and angiostatin (proteolytic 
fragments of collagen IV, XVIII and plasminogen respectively) 2-9; protease inhibitors that 
prevent degradation of the basal lamina of blood vessels 10; and compounds that interfere with 
adherence of endothelial cells to matrix proteins (eg via blockade of  αvβ3 integrin) 11,12. 
However, since VEGF-A by itself has the potency to initiate most, if not all, necessary steps 
in the angiogenic process, most research has focused on targeting VEGF-A or its receptors 
VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). This has resulted in the development of VEGF 
antagonists 13,14, humanized antibodies against VEGF-A 15,16 or VEGFR-2 17,18, and soluble 
chimeric VEGF receptor ectodomains 19, compounds with tumor growth inhibitory activities 
in a number of animal models 19,20. One novel class of compounds targeting VEGF comprises 
small molecule agents that  can be administered orally against the tyrosine kinase moieties of 
VEGF receptors 21-23. Included in this class is ZD6474, which selectively inhibits VEGFR-2 
kinase activity and has additional inhibitory activity against epidermal growth factor receptor 
(EGFR) tyrosine kinase. It has previously been shown that this compound has potent 
antitumor activity against a broad spectrum of histologically diverse subcutaneous tumor 
xenografts in mice 21.  
These promising preclinical data have led to high expectations for anti-angiogenic approaches 
in the clinic. However, it seems unlikely that inhibition of VEGF-dependent angiogenesis will 
demonstrate the same pan-tumor activity in the clinic that has been seen in preclinical models. 
There are several reasons to expect discrepancies in results between preclinical models and 
clinical trials in man. First, slowly growing, large human tumors may differ in their sensitivity 
towards angiogenesis inhibitors from the rapidly growing tumors that are often used in mouse 
models of cancer, and human tumors may have regions with relatively mature and stable 
tumor vessels that are less susceptible to anti-VEGF therapy. Indeed, in Rip-Tag mice (a 
transgenic mouse model of spontaneous pancreatic islet carcinoma formation) it was shown 
that targeting VEGFRs resulted in inhibition of tumor angiogenesis and growth only in early 
 84  
stages of tumor development. Affecting vessel integrity, by targeting platelet-derived growth 
factor receptors (PDGFRs) leading to pericyte loss, resulted in regression of vessels in more 
established tumors. In this model simultaneous targeting of VEGFRs and PDGFRs was more 
efficient than targeting of either receptor alone 24. Secondly, candidate patients for Phase I 
trials with anti-angiogenic therapy are predominantly patients with disseminated cancer, in 
which other therapeutic options are no longer available, and one may ask the question whether 
disseminated tumors have the same angiogenesis-dependency as the originating tumor: since 
tumor metastasis occurs through lymph and blood vessels, outgrowth of metastases mostly 
will occur in vessel dense organs like lung, liver and brain. In these organs tumors (both 
primary and metastatic) may grow independently of angiogenesis via a process of co-option 
of pre-existent vessels 25-28. This implies that, whereas compounds may be efficient inhibitors 
of angiogenesis and tumor growth in angiogenesis-dependent tumors (such as subcutaneous 
tumor xenografts), their effects may be limited in tumors, growing in tissues with an intrinsic 
vascular density that allows for co-option by infiltrative tumors. 
Here we investigated this hypothesis by treating mice, carrying brain tumors of the human 
melanoma cell line Mel57, with the anti-angiogenic agent ZD6474. While parental Mel57 
xenografts grow in brain parenchyma of immunocompromized mice exclusively via co-option 
of brain capillaries, Mel57 tumors stably expressing VEGF-A165 evoke a fulminant 
angiogenic response 29. In contrast to parental tumors, those expressing VEGF-A are readily 
detected in CE-MRI due to VEGF-induced vascular leakage 30. Here we show that ZD6474 is 
a potent inhibitor of angiogenesis in this tumor model. However, this inhibition does not lead 
to tumor regression, or increased survival. Tumor growth is able to continue via co-option of 
pre-existent vessels, a growth pattern that is not detected by Gd-DTPA-enhanced MRI. 
Intermediate doses of ZD6474 inhibited new vessel formation but not VEGF-A-induced 
vessel leakage, still allowing MRI detection of treated tumors. 
These data indicate that in clinical settings where switching to vessel co-option is possible,  
the interpretation of CE-MRI data to monitor antitumor effects should be used with caution. 
Decreases in CE-MRI signal can effectively determine if an agent reduces tumor vessel 
permeability, but may be a poor indicator of antitumor response, particularly if the tumor can 
adopt a vessel co-option phenotype. 
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Materials and Methods 
 
Cell lines and transfections  
Culture of the Mel57 human melanoma cell line and generation of stably transfected Mel57 
cell lines, expressing enhanced green fluorescent protein (EGFP) or VEGF-A165 has 
previously been described 27,29. EGFP and VEGF-A165 cDNAs were under control of the 
CMV promoter, and expression of the proteins of interest was linked to that of the neomycin-
resistance gene product via an internal ribosome entry site, enabling effective selection for 
EGFP or VEGF-A- expressing cells.  
 
Animal experiments  
Specific pathogen-free (SPF) male BALB/c nu/nu mice were purchased from the university 
central animal facility breeding program. Experiments were carried out in accordance with the 
national animal protection laws and approval was obtained from the Animal Experimental 
Committee. To establish brain metastases, 7 week-old mice were anaesthesized (1.3 % 
isoflurane/O2/N2O) and tumor cells (1x105 Mel57-EGFP or Mel57-VEGF-A165 cells in 100 µl 
phosphate buffered saline [PBS]) were injected in the right internal carotid artery as 
previously described 31. Three sets of experiments were performed. In one experiment, mice 
carrying Mel57-VEGF-A165 brain lesions were treated with 100 mg/kg ZD6474 (n=9) or 
placebo (n=10) starting at day 2 or 10 post tumor cell injection. In a second experiment, 
tumor-bearing mice (n=10) were treated with 50 mg/kg ZD6474, starting at day 1, 5, 9, 13 or 
17 post injection (n=2 for each time point). Finally, an experiment was performed in which a 
1:1 mixture of Mel57-VEGF-A165 and Mel57-EGFP cells was injected to compare the effects 
of ZD6474 on angiogenic and co-opting lesions within one animal (n=10). In this case, mice 
were treated with 25 mg/kg starting at day 2 post-injection. ZD6474 (as a suspension in 1% 
polysorbate-80) or placebo (1% polysorbate-80) was administered p.o. once daily in a volume 
of 100 µl. After 16-20 days when clinical symptoms due to tumor growth were apparent 
(weight loss, neurological defects), CE-MRI was performed according to the protocol 
described below.   
 
Contrast-enhanced magnetic resonance imaging 
CE-MRI was performed as previously described 30. Briefly, mice were anaesthesized (1.3% 
isoflurane; 1:1 (v/v) N2O/O2 mixture), catheterized in the tail vein, and placed in an MR 
spectrometer (S.M.I.S. console equipped with a Magnex Scientific 7T/200mm horizontal bore 
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magnet and a 150mT/m gradient set). Body temperature was maintained by placing the mice 
on a 37oC circulating warm water bed. A 12 mm diameter surface coil was positioned over the 
skull. After initial monitoring of the brain with fast gradient-echo scout images, 16 contiguous 
images were acquired with a T1-weighted multislice gradient-echo sequence (TE= 8 ms; TR = 
100 ms; flip angle = 90º; number of averages = 1; field of view = 25x25 mm; matrix size = 
256x256; slice thickness = 1 mm) before and 1, 2, 10 and 20 minutes after bolus injection of 
Gd-DTPA (Magnevist®, Schering, Germany) at a dose of 0.2 mmol/kg.  
 
Histological and immunohistochemical analysis 
After MRI, mice were sacrificed by injecting an overdose of barbiturate and brains removed 
and fixed in buffered formalin. Brains were cut coronal slices and embedded in paraffin. 
Sections of 4 µm were processed for conventional H&E staining or immunostaining for 
mouse IgG (to examine the presence of extravasated proteins), the endothelial marker CD34 
(Hycult, Uden, The Netherlands), GLUT-1 (as a blood-brain barrier marker and a hypoxia 
marker, DAKO, Glostrup, Denmark), MIB-1 (anti-human Ki67, DAKO, Glostrup, Denmark) 
and anti-mouse Ki67 (Dianova, Hamburg, Germany). MRI images were matched to histology 
as closely as possible. To confirm stable VEGF-A expression, tumors were also subjected to 
VEGF in situ hybridization (ISH) using a digoxigenin-labeled VEGF-A antisense RNA probe. 
The corresponding sense probe was used as a control. 
 
Results 
We have recently described that Mel57 tumors grow in mouse brain via co-option of pre-
existent vessels without inducing an angiogenic switch, whereas the same tumors, engineered 
to express VEGF165, evoked a fulminant angiogenic response 25,29. Parental Mel57 lesions 
were invisible in Gd-DTPA-enhanced MRI scans, whereas VEGF-A165-induced vessel 
leakage led to clear MRI visibility 30. To investigate the effects of the anti-VEGF therapy on 
MRI representation and tumor phenotype, we treated mice carrying highly angiogenic Mel57-
VEGF-A165 brain tumors with ZD6474. Treatment with 100 mg/kg, starting early during 
tumor development (2 days post-injection of tumor cells), led to complete inhibition of 
VEGF-A effects. In treated animals, tumors grew via co-option of pre-existent vessels as was 
evident from a number of observations. First, vessel dilatation as observed in placebo-treated 
controls was absent in the treated tumors (Figure 1A and F). Secondly, the upregulation of a 
number of endothelial markers such as CD34, which was evident in placebo-treated Mel57-
VEGF-A165 tumors (Figure 1B), was absent in ZD6474- treated tumors (Figure 1G). 
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Furthermore, in contrast to tumor vessels in placebo-treated animals, tumor vessels in treated 
animals expressed GLUT-1, a characteristic property of the highly specialized blood-brain 
barrier, suggesting that these vessels were pre-existent rather than newly formed (compare 
Figures 1C and H). Vessels were not leaky, as evidenced by absence of extravasated mouse 
immunoglobulins (not shown). Also, VEGF-A-induced proliferation of mouse endothelial 
cells, which occurred abundantly in the control animals, failed to appear in the treated animals 
(see mouse-specific Ki67 stainings in Figures 1D and I). Importantly, in both the control and 
the ZD6474-treated animals, tumor cells had a high proliferation index (see MIB-1 
immunostaining in Figures 1E and J) indicating that blood supply from co-opted pre-existent 
brain capillaries was sufficient for tumor progression. This was also evident from the fact that 
hypoxia and necrosis were never observed in these tumors. Importantly, using the intracarotid 
injection technique, multiple lesions develop in brain parenchyma. Typically, 20-50 lesions 
are found in each brain. All lesions responded to therapy in a similar manner. 
Mel57 cells express VEGFR-2  but do not respond to VEGF-A by increased proliferation 
(unpublished results). The high proliferation index in ZD6474-treated tumors (figure 1J) 
confirms that the effects of  ZD6474 are indeed the result of inhibition of VEGFR-2 on 
endothelial cells rather than a direct effect on the tumor cells.   
The absence of vessel leakage in ZD6474-treated tumors was reflected in MRI: treated tumors 
were not visible (Figure 2B) whereas lesions in control-treated animals were clearly enhanced 
after injection of Gd-DTPA (Figure 2A). To exclude the possibility that the co-opting 
phenotype of ZD6474-treated tumors was due to incidental loss of VEGF-A expression, we 
performed ISH with an antisense VEGF-A probe which demonstrated that the co-opting 
phenotype was caused by ZD6474 treatment and not by incidental loss of VEGF-A 
exppression (Figure 1K). 
In this tumor model, 12 days after tumor cell injection small lesions were present that already 
exerted marked effects on the vasculature such as vasodilatation and vessel leakage, as 
demonstrated by IgG leakage around the lesions (not shown), and which were detectable by 
Gd-DTPA in MRI as small hyperintense spots (Figure 2D, arrows). To investigate the effects 
of ZD6474 on tumors in which VEGF-A effects are already distinct, mice were injected with 
Mel57-VEGF-A cells and treatment with 100 mg/kg ZD6474 was initiated 10 days later. 
After another five days, mice were  subjected to Gd-DTPA-enhanced brain MRI and 
sacrificed. Again, tumor lesions grew by vascular co-option, with some lesions showing 
remnants of dilated vasculature (not shown). Vessels were, however, not leaky as illustrated 
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by an absence of Gd-DTPA extravasation (Figure 2C).  This was confirmed once more by the 
presence of only very little extravasated mouse immunoglobulin (not shown). 
At a dose of 100 mg/kg, ZD6474 very efficiently prohibited the development of an angiogenic 
tumor phenotype, forcing tumor cells to grow by co-option of pre-existent vessels, much like 
parental Mel57 tumors. In order to understand the switch to a vessel co-option phenotype 
better we tested the effects of lower doses of ZD6474 (25 and 50 mg/kg) in this model. 
Mice that were treated with 50 mg/kg ZD6474 starting at day 2 after tumor cell injection 
showed a strikingly different tumor phenotype compared with the 100 mg/kg treatment group. 
Now, tumors had an expansive appearance and were poorly vascularized. In approximately 
50-70% of the lesions, central hypoxia (evidenced by GLUT-1 staining of tumor cells, arrow 
in Figure 3C) and necrosis (Figure 3A) were observed. At the tumor rims, cells co-opted pre-
existent, GLUT-1 positive, vessels (Figure 3C). Surprisingly, a similar tumor phenotype was 
observed when 50 mg/kg treatment was initiated 1, 5, 9 and 13 days post tumor cell injection 
(Figure 4 and data not shown). Only when treatment was given for 2 days, starting at day 17 
post-tumor cell injection, was a tortuous, dilated and leaky tumor vasculature without 
apparent signs of hypoxia or necrosis observed (Figure 3E-G and Figure 4D). While in these 
tumors, cells proliferated abundantly, as demonstrated by anti-pan Ki67 stainings, 
proliferating mouse endothelial cells in the dilated vasculature were only sparsely detected 
(data not shown). This suggests that ZD6474 treatment for as little as 2 days led to marked 
inhibition of endothelial cell proliferation.  
 
Fig 1 – Effects of 100 mg/kg ZD6474 on Mel57-VEGF-A165 brain tumor morphology. 
Mice were injected in the internal carotid artery with Mel57-VEGF-A165 cells and oral treatment with placebo (A-E) or 100 
mg/kg ZD6474 (F-J) was intiated 2 days post injection. Sixteen days post injection of tumor cells mice were sacrificed and 
brains removed and fixed in formalin. Four-µm sections were stained with conventional H&E (A,F), and with antibodies 
against the anti-endothelial marker CD34 (B,G), the brain-endothelium marker GLUT-1 (C,H), Ki67 (proliferation antigen, 
mouse specific, D,I) and with MIB-1 (anti-pan Ki67 E,J). In treated tumors, GLUT-1 was expressed on tumor vessels (arrow 
in H), whereas it was absent on placebo-treated tumors (arrow in C points at a tumor vessel). Note the absence of 
proliferating mouse endothelial cells in the ZD6474-treated tumors (I), while numerous proliferating (endothelial) cells are 
present in placebo-treated tumors. By contrast, tumor cell proliferation was not inhibited by ZD6474 (compare MIB staining 
in E and J), and ZD6474-treated tumors progressed by vascular co-option. Treated tumors were highly invasive but still 
expressed VEGF-A as demonstrated by ISH using an anti-sense VEGF probe (K). ISH using a sense control probe was 
negative (not shown). See also colour display page 155. 
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Although at 50 mg/kg ZD6474 effectively inhibited angiogenesis, it did not completely 
prevent vascular leakage as evidenced by the presence of extravasated mouse 
immunoglobulins around the lesions (Figure 3D) and the fact that tumors were readily 
detected in Gd-DTPA-enhanced MRI as ring-enhancing lesions (Figure 4). The ring-
enhancement observed in Figures 4A-C corrobated the histological finding that within these 
tumor lesions the vessel density was low, leading to central (non-enhancing) necrosis. The 
bulky enhancement of the lesions in Figure 4D (arrows) is in agreement with the absence of 
necrosis and the high vessel density in these tumors (Figure 3E-G). 
Lowering the dose even further to 25 mg/kg yielded similar results: vessel leakiness was not 
inhibited in contrast to angiogenesis, again resulting in central necrosis in approximately 50% 
of the lesions (not shown). 
In our brain tumor model, lesions arise by clonal expansion (manuscript submitted for 
publication). This enabled us to compare the effects of ZD6474 on angiogenic Mel57-
VEGF165 tumors and co-opting Mel57-EGFP tumors within one animal, by making use of 
EGFP-expression to discrimate between the different Mel57 transfectants. Similar 
experiments have been recently published in which clonality of metastases was determined 
using this approach 32. In a time-matched experiment, a 1:1 mixture of Mel57-EGFP and 
Mel57-VEGF165 was injected in carotid arteries and treatment with 25 mg/kg ZD6474 or 
placebo was initiated 2 days later (n=5 for each group). Again, tumors were analysed at day 
20 post injection.  
EGFP staining of brain tissue revealed that necrosis only occurred in Mel57-VEGF-A tumors, 
and never in Mel57-EGFP tumors (arrow in Figure 4E), indicating that co-opting Mel57-
EGFP lesions were not notably affected by ZD6474 treatment. As in the 50 mg/kg 
experiment, ZD6474 treatment led to a ring-shaped appearance of tumors in Gd-DTPA 
enhanced MRI, presumably because of the presence of central, non-enhancing necrosis (not 
shown). 
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Fig 2 – Effects of ZD6474 treatment of Gd-DTPA-enhanced MRI. 
Before sacrifice, control-treated (A) and ZD6474-treated (B,C) mice were subjected to CE-MRI as described in the text. 
Treatment was initiated at day 2 (B) or day 10 (C) post-injection. The images shown were acquired before (upper panels) and 
2 minutes after injection of Gd-DTPA in the tail vein. Note the enhancement in meningeal vessels in B and C, indicating that 
Gd-DTPA did enter the circulation in these mice. (D) MRI image of mouse brain containing Mel57-VEGF-A lesions, 
recorded 12 days post-injection of tumor cells. Image was taken immediately after injection of  Gd-DTPA. Arrows indicate 
small lesions. 
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Fig 3 – Effects of 50 mg/kg ZD6474 on Mel57-VEGF-A brain lesions.  
ZD6474 (50 mg/kg) was administered daily to nude mice carrying Mel57-VEGF-A165 tumors in their brains. Treatment was 
initiated at day 5 (A-D) or day 17 (E-G) post-injection of tumor cells, and mice were sacrificed 20 days after tumor 
inoculation. Intratumoral vessel density was low (B) and almost no proliferating endothelial cells could be detected within 
treated tumors (not shown), resulting in large areas of central necrosis (n) in approximately 70% of lesions. Tumor cells 
surrounding the necrosis stained positive for GLUT-1, indicating that local hypoxia due to insufficient neovascularization 
resulted in necrosis (C). Despite effective inhibition of neovascularization, vessels were still leaky as indicated by the 
presence of extravasated IgG (D). When treatment was initiated at day 17 post injection of tumor cells, a high vessel density 
still could be observed (E and F) and no necrosis was observed. Intratumoral vessels were glut-1 negative (G) indicating that 
these were newly formed. See also colour display page 156. 
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Fig 4 – Brain MRI of tumor-bearing mice treated with 50 mg/kg ZD6474 from day 1, 5 , 9 or 17 post-inoculation of tumor 
cells as indicated. T1-weighted Gd-DTPA-enhanced images were acquired at day 20, before (upper panels) and directly after 
intravenous injection of the contrast agent. Clearly, at this dose of ZD6474, VEGF-induced vessel leakage is not inhibited. 
Note the ring enhancement of the tumors when treatment is started at earlier time points, while bulky enhancement was 
observed in the group treated from day 17 to 19. The enhancement patterns correlate with the histology of the lesions (see 
figure 3), where tumor centers are very poorly vascularized and often necrotic leading to poor enhancement.  
Panel (E) EGFP immunostaining on brain of a mouse, carrying both EGFP and VEGF-A-expressing Mel57 tumors, and 
treated with 25 mg/kg ZD6474. Note that co-opting Mel57-EGFP tumors were not affected by ZD6474 treatment (arrow) 
whereas the VEGF-expressing tumors display central necrosis (n). See also colour display page 157. 
 
 
Discussion 
ZD6474 has been shown to be a promising anti-angiogenic agent, which inhibits VEGFR-2 
tyrosine kinase activity and has additional activity against EGFR tyrosine kinase 21. It 
prevents tumor growth in a wide range of histologically diverse tumor models, and is 
currently being evaluated in Phase II clinical trials. It is generally accepted that tumor growth 
is heavily dependent on angiogenesis, but a number of reports have been published that now 
suggest that angiogenesis is not always a prerequisite for tumor growth, as tumor cells may 
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exploit pre-existent vasculature, a process known as vascular co-option 25-28,33. In this report 
we investigated the effects of ZD6474 on tumor behavior in a mouse model of brain 
colonization by the human melanoma cell line Mel57. This cell line homes to brain 
parenchyma 31 where it grows rapidly to relatively large, vital infiltrative tumors by co-option 
of pre-existent vessels. Blood supply from these brain vessels was adequate for tumor growth, 
as no hypoxia developed in the lesions 27. Consequently, the trigger for upregulation of 
VEGF-A expression and the angiogenic switch did not occur. Furthermore, co-opted blood 
vessels were not notably affected by the tumor, as the blood-brain barrier remained intact 30. 
In contrast, stably transfected Mel57 cells expressing human VEGF165, evoked a fulminant 
angiogenic response in which the conceptual hallmarks of angiogenesis were present: tumor 
vessels were dilated and tortuous, and contained numerous proliferating endothelial cells. 
Furthermore, the blood-brain barrier was disrupted, enabling Gd-DTPA-enhanced detection in 
MRI. Importantly, the fact that these tumors induce angiogenesis does not preclude co-option: 
in fact, at the tumor rim co-option of vessels can be observed. 
When treatment with 100 mg/kg ZD6474 was initiated 2 days post-carotid injection, VEGF-A 
effects were completely abrogated, whereupon the tumor adopted the pre-existing vessel co-
opting phenotype in which the blood-brain barrier remained intact. Accordingly, treated 
tumors were invisible in Gd-DTPA-enhanced MRI. Importantly, these co-opting tumors still 
expressed high levels of VEGF-A, excluding the possibility that the development of this 
phenotype was due to loss of VEGF-A expression.  
These results were anticipated, as abrogation of VEGF-A effects in Mel57-VEGF-A cells 
would indeed be expected to result in a parental Mel57-tumor-like phenotype. However, 
Mel57-VEGF-A tumors were also invisible in Gd-DTPA-enhanced MRI when mice were 
treated from day 10-17 post injection of tumor cells. This illustrates that ZD6474 not only 
prevents, but probably also reverts VEGF-A-induced vascular changes. This is in accordance 
with previous observations that ZD6474 led to regression of certain established subcutaneous 
tumors 21. We did not perform Kaplan-Mayer analysis, and therefore we cannot make definite 
conclusions about effects of treatment on survival. It appeared however that ZD6474 
treatment, despite significant inhibition of tumor angiogenesis and vessel permeability, did 
not delay the appearance of neurological symptoms, presumably because in this experimental 
model Mel57 tumor cells co-opt normal vasculature.  
In a rat model of intracranial glioma it has also been reported that anti-VEGF treatment led to 
conversion of an angiogenic to a co-option phenotype 34. This conversion, brought about by 
treatment with an anti-VEGF antibody, was accompanied by slower tumor growth and 
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prolonged survival. The apparent discrepancy between these results and those reported here 
may be related to the fact that upon injection of tumor cells in the internal carotid artery 
numerous lesions develop, whereas stereotactic tumor cell implantation will give rise to one 
tumor. In the latter case, the effects of anti-VEGF therapy are predicted to result in slower 
growth of one single lesion, since only the tumor-rim has the possibility of outgrowth via 
infiltration/co-option. In our model, all lesions may grow via vessel co-option since upon 
extravasation, tumor cells can directly take profit from the vessels from which they 
extravasated. Therefore, although individual tumors in our brain colonization model are 
smaller in the ZD6474 treated groups,  the overall number of lesions is not different between 
treatment and placebo groups. This may explain our finding that 100 mg/kg ZD6474 
treatment did not delay the onset of neurological symptoms.  
At lower doses, ZD6474 potently inhibited new vessel formation, but did not prevent VEGF-
A-induced vascular leakage. Consequently, tumors treated with 25 or 50 mg/kg of ZD6474 
were still visible by Gd-DTPA-enhanced MRI. Thus, at lower doses ZD6474 appears to have 
differential effects on two VEGF-A-induced effects: increased vascular permeability and 
endothelial proliferation, both activities that are mediated by VEGFR-2 13. This suggests that 
endothelial cell proliferation and vascular permeability are the result of a divergence in cell 
signaling pathways downstream of VEGFR-2. Such a divergence has indeed recently been 
described 35. Permeability depends on a Rac-dependent pathway, while proliferation is 
mediated by Erk1/2. Our data suggest that the Erk1/2 pathway requires a stronger signal from 
VEGFR-2 than the Rac-pathway.  
An intriguing observation from this study was that ZD6474 treatment at 100 mg/kg resulted in  
tumor progression via co-option of pre-existent brain vessels, a process that appears efficient 
since no  hypoxia or necrosis develops in the tumor. In contrast, tumors treated with lower 
doses of ZD6474  often showed central necrosis, while in the same animals necrosis in co-
opting Mel57-EGFP tumors was never observed. These data support the following 
interpretation: ZD6474 at 25 or 50 mg/kg inhibits new vessel formation, but does not prevent 
vascular leakage. Increased vessel permeability presents a potential benefit to the tumor as it 
leads to increased supply of nutrients to the tumor cells, and consequently increased and 
expansive tumor growth. However, because compensating angiogenesis does not occur, due 
to a lack of endothelial cell proliferation, central hypoxia and eventually necrosis develop. 
Interestingly, we found that on the morphological and MRI level there was little or no 
difference between brain tumors in the different groups of mice in which treatment was 
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started from day 1 or day 13 onwards. Possibly this is due to both potent anti-vascular and 
anti-angiogenic activity of ZD6474. 
Differential effects on angiogenesis and vascular permeability have the potential to be 
exploited in brain tumor therapy since it creates the possibility of manipulating the blood-
brain barrier for therapeutic benefit.  For instance, by creating a situation where VEGF-
dependent angiogenesis, but not vascular leakage, is inhibited, combination treatment with  
chemotherapeutic agents may be more effective. Where both processes are inhibited, leading 
to restoration of the blood brain barrier, reduced accessibility of chemotherapy for the tumor 
cells may occur. This subject is currently under investigation in our laboratory.  
ZD6474 has potent activity against VEGFR-2 signaling and has additional activity against 
EGFR. EGFR is upregulated on endothelium and is involved in angiogenesis 36. Since the 
particular vascular phenotype in Mel57-VEGF-A brain tumors is an unambiguous VEGF-A 
effect 29, the ZD6474 effects are likely due to VEGFR-2 antagonism rather than EGFR 
antagonism. 
In animals treated with 100 mg/kg ZD6474, tumor cells still had a high proliferation rate 
(more than 50% of the cells were positive for the proliferation antigen Ki67), while 
endothelial cell proliferation was completely abolished. This provides strong evidence that the 
effects of ZD6474 on the tumor phenotype might be entirely attributed to effects on the 
vasculature and not on the tumor cells. This is in agreement with the fact that Mel57 cells in 
vitro do not respond to VEGF-A, although they express VEGFR-2 similar to other melanoma 
cell lines (data not shown).  
At present in clinical practice, the best non-invasive way to diagnose brain tumors is by CE-
MRI. Our model system indicates that tumors that adopt a vessel co-opting phenotype would 
be invisible by Gd-DTPA-enhanced MRI. If a switch to this phenotype occurred while 
VEGFR-2 was fully antagonized by a treatment regimen, it may falsely suggest tumor 
regression had been induced. However, it is not known if switching to a vessel co-option 
phenotype, as seen in the Mel57-VEGF-A tumor model, will translate widely to the human 
clinical situation. Based on our findings, the use of a low dose treatment regimen of ZD6474 
would allow for a more reliable MRI follow-up. 
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Abstract 
Expression by a tumor of the angiogenic factor Vascular Endothelial Growth Factor-A 
(VEGF-A) correlates with high vascular density and increased metastasis, but how these latter 
two relate mechanistically is unclear. We here report that spontaneous metastasis from 
subcutaneous xenografts is dramatically enhanced when these express recombinant VEGF-A. 
This effect was attributed to the early stage of tumor cell intravasation as VEGF-A expression 
did not result in increased tumor burden after hematogeneous delivery to target organs in 
colonization assays. In contrast to the commonly accepted concept of increased shedding of 
single cells into a condensed vascular bed, the metastatic potential was enhanced by a distinct 
architectural transformation of tumors: VEGF-A-expressing tumors, but not VEGF-A-
negative xenografts, were characterized by a micronodular growth pattern. Multicellular 
micronodules budded into vessel lumina, were covered by endothelial cells and generated 
metastatic tissue embolisms in pulmonary arteries. From mixed xenografts, consisting of both 
VEGF-A-positive and negative cells, polyclonal lung metastases developed, indicating that it 
is VEGF-A-induced organized tumor cell clusters, and not single cells, that are responsible for 
metastasis. This mechanism of metastasis has clinical relevance, as intravascular tumor 
fragments, covered by an endothelial cell layer, were also observed in renal clear cell 
carcinomas, tumors that often express high levels of VEGF. 
These results challenge the hypothesis that metastasis is restricted to a subpopuplation of 
aggressive tumor cells, since angiogenically impotent cells can travel along with VEGF-A-
expressing cells. 
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Introduction 
Development of metastasis in cancer patients and its treatment is a major problem in 
oncology. Metastasis is a complex multistep process. The current view is that by a micro-
evolutionary process, tumor cells in a primary tumor acquire a metastatic phenotype, 
characterized by the capacity to invade blood vessels and, after transport via the blood stream, 
extravasate and grow to clinically relevant lesions at distant sites. As spontaneous metastasis 
models are rare, most investigations in the field have been performed using colonization 
approaches in which tumor cells are hematogenously delivered to the organs of interest 1,2. 
These colonization models, however, lack the initial event of tumor cell entry into the blood 
stream, an important and possibly rate-limiting step.  
The generally accepted concept of intravasation of tumor cells is that they leave the primary 
tumor as single cells by degrading stromal matrix and vascular basement membranes, using a 
repertoire of matrix degradation enzymes and adhesion molecules (for review 3), followed by 
entry into the blood or lymphatic vascular bed. This model predicts that the probability of 
tumor cell entry into the blood increases with tumor vessel density. Indeed, for a number of 
tumor types a correlation between vessel density and poor prognosis was found (for review 
see 4-6). After intravasation, tumor cells may circulate until they adhere to endothelium in 
distant organs, extravasate and grow out. Alternatively, adhering cells may grow initially 
intravascularly 7. Clinical and preclinical data suggest, however, that not the amount of 
circulating single tumor cells but rather that of circulating tumor cell clusters correlate with 
development of metastases 8-11. At this moment it is not clear whether these clusters have a 
single cell origin or are derived from tumor cell aggregates that dissociated from the primary 
tumor and intravasated as such. Support for the latter hypothesis comes from studies showing 
that spontaneous metastases derived from genetically polyclonal tumors were, at least in part, 
also polyclonal 12. 
Angiogenesis in tumors has been recognized as a prognostic feature for tumor progression and 
development of metastases. As discussed before, increased vessel density in tumors 
expressing the angiogenic factor Vascular Endothelial Growth Factor-A (VEGF-A) (for 
review 13) may simply augment the chance that a tumor cell encounters a vessel. Also, a 
tumor that has acquired the capacity to induce angiogenesis will be more successful in 
outgrowing its dormant state after metastatic deposition. These explanations might be 
somewhat oversimplified, however. First, recent reports demonstrated the presence of 
intravascular  endothelium-covered tumor cell clusters in the primary tumor as origin of 
metastasis, suggesting that more complex phenomena play a role 14-16 . Secondly, clinical 17-19 
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and animal 20,21 data show that for part of the metastatic tumors, induction of angiogenesis is 
not a prerequisite as for these tumors co-option of the pre-existent vascular bed can be 
sufficient for tumor blood supply. We previously described that in a mouse model of brain 
colonization, the human melanoma cell line Mel57 efficiently co-opts pre-existent blood 
vessels without induction of an angiogenic switch, consistent with minimal expression of 
angiogenic factors by this cell line 20-22.  
It has been suggested by others that VEGF-A-expression is essential, though not sufficient, 
for metastasis formation in a similar animal tumor model 23. In preliminary experiments, we 
found that expression of transgenic VEGF-A by Mel57 cells did not result in increased brain 
colonization potential, but rather to a change in tumor morphology which was characterized 
by the presence of dilated and leaky vessels 24. This led to increased supply of oxygen and 
nutrients to the tumor cells and consistently to enhanced tumor growth.  
As the exact relationship between VEGF-A expression and metastasis is still not clear, we 
have addressed this issue by investigating the mechanisms of metastasis formation by Mel57 
cell lines in the absence or presence of VEGF-A expression. 
 
Materials and Methods 
Animals  
Specific pathogen-free male (SPF), 6 to 8 weeks old BALB/c nu/nu mice were housed under 
SPF conditions (5 mice/cage, temperature 20-24 °C; relative humidity 50-60%; 15 air changes 
per hour; light-dark periods 14 h/10 h). Water and food were available to the animals ad 
libitum. Experiments were carried out in accordance with the national animal protection laws. 
 
Cell lines and transfections 
pIRESneo vector and pEGFP-IRESneo (EGFP=enhanced green fluorescent protein) were 
obtained from Clontech (Palo Alto, CA). VEGF-A165 cDNA was cloned in the EcoR1-BamH1 
site of pIRESneo (pVEGF-IRESneo) as described 20. Mel57 melanoma cells were transfected 
using Fugene reagent (Roche, Mannheim, Germany) with plasmid pEGFP-IRESneo or 
pVEGF-IRESneo and stable treansfectants were selected by culturing in 400 µg/ml G418. 
VEGF-A expression levels in conditioned media were determined by  ELISA as described 
previously 25 and were 30-50ng/106 cells/24h. Consistent with the fact that neomycin 
resistance was linked via the IRES to expression of the cDNA of interest, close to 100% of 
Mel57-EGFP cells expressed EGFP as determined by fluorescence microscopy in vitro, and in 
vivo by immunohistochemistry on brain sections of mice, carrying Mel57-EGFP brain lesions 
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(see below). Conversely, using in situ hybridization for VEGF-A on Mel57-VEGF-A brain 
lesions, we could demonstrate that all of these cells, but not parental or EGFP expressing 
Mel57 cells, expressed VEGF-A. There was no difference between growth rates of the 
different cell lines in vivo. 
 
Colonization and metastasis models  
Colonization models: 
Equal numbers (5x104) of  Mel57-VEGF-A and Mel57-EGFP cells were co-injected into the 
internal carotid artery for induction of brain metastases as described previously (n=11) 20,26 . 
Similarly, 6x106 Mel57-VEGF and Mel57-EGFP cells (in a 1:1 ratio) were injected into the 
tail vein of nude mice (n=7) to examine homing to lung and brain. Animals were sacrificed 
after two to three weeks when mice developed cachexia or acute neurological defects.  
 
Spontaneous metastasis 
To examine spontaneous lung metastasis, two sets of experiments were performed. 
Subcutaneous tumors were induced in nude mice by injection of a mixture of Mel57-VEGF-A 
and Mel57-EGFP cells into the flank (1x106 cells for each cell line, n=9). Otherwise, two 
separate tumors were induced on the right (Mel57-EGFP) and the left (Mel57-VEGF-A) flank 
(2x106 cells per flank)(n=5). Because VEGF-A-expressing tumors grew faster than Mel57-
EGFP tumors, we injected the Mel57-EGFP cells 5 weeks prior to VEGF-A expressing cells. 
Thus, Mel57-VEGF-A and Mel57-EGFP tumors were of comparable size at the time of 
analysis. 
Mice were sacrificed after development of severe cachexia due to tumor load. In two out of 
five animals carrying tumors on both flanks, Mel57-EGFP tumors had to be removed because 
of severe ulceration after 6 weeks of tumor growth. These mice were still included in the 
analysis of metastatic  composition.  
 
Histological and immunohistochemical analysis 
For (immuno)histochemistry, tissues (subcutaneous tumor, heart, lung, liver, kidney and 
brain) were snap-frozen in liquid nitrogen or fixed in buffered formalin. Brains were 
sectioned in six coronal slices. All six slices of each brain were placed side by side in one 
cassette, and embedded in paraffin. To examine lung metastases, right and left lungs were 
separated from each other and subsequently each lung side was dissected in individual lobes. 
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These lobes were placed side by side in one cassette, and embedded in paraffin. Using this 
protocol a representative overview of each organ in each section is obtained. Sections of 4 µm 
underwent conventional H&E staining or immunohistochemical staining as described before 
20,27 . Antibodies used were anti-EGFP (a kind gift of Dr. E. Cuppen, Dept. of Cell Biology, 
UMCN) to detect Mel57-EGFP cells, anti-murine CD31 and CD34 (Hycult Biotechnology, 
Uden, The Netherlands) and 9F1 20,27 to detect endothelial cells, rabbit anti-mouse Ki-67 
(Dianova, Hamburg, Germany) to identify proliferating murine cells (this antibody does not 
cross-react with human Ki67), mouse anti- α-smooth muscle actin (α-Sm1, Sigma, 
Zwijndrecht, The Netherlands) to detect pericytes and vascular smooth muscle cells, and 
rabbit anti-laminin (Dako, Glostrup, Denmark) to detect basement membranes. To detect 
Mel57-VEGF-A cells, we performed in situ hybridization (ISH) on 10 µm sections using a 
digoxigenin-labelled VEGF-A antisense RNA as probe and the corresponding sense RNA as a 
control, using standard techniques. 
Sections of human renal cell carcinomas or melanoma that had previously been eveluated on 
H&E staining as having intravascular localization, were stained with anti-CD31 to detect 
endothelial cells. 
 
Statistical analysis 
In each mouse, the number of microscopic lesions consisting of EGFP- or VEGF-A-
expressing cells and mixed lesions were counted. From these numbers, ratios of 
monoclonal/polyclonal lesions were calculated. For subcutaneous tumors, volumes were 
determined by multiplying hight x width x depth. The softwareprogram SPSS (SPSS 9.0 for 
Windows, SPSS Inc., Chicago, Illinois, USA) was used for statistical analysis. Differences 
were considered significant when p<0.05, as determined by Wilcoxon signed rank test. 
Analyses were performed both on absolute numbers and ratios, where appropriate. 
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Results 
VEGF-A does not increase metastatic burden in colonization assays  
To investigate whether VEGF-A increased the rate of brain colonization, we injected a 
mixture of equal numbers of Mel57 cells expressing VEGF-A or EGFP (serving as VEGF-A 
negative, readily detectable control cells) into the internal carotid artery of nude mice and 
analyzed distribution and numbers of Mel57-EGFP and Mel57-VEGF-A lesions by anti-
EGFP immunostaining and in situ hybridization (ISH) for VEGF-A, respectively. More than 
85% of the lesions grew by clonal expansion as they consisted of either Mel57-EGFP cells or 
Mel57-VEGF-A cells (p=0.002, Fig. 1A, upper two panels and Fig. 1B; Table 1a). There was 
no significant difference between numbers of EGFP- and VEGF-A expressing lesions (Fig. 
1B; Table 1a), implying that in this colonization model VEGF-A did not enhance metastasis 
formation. To  confirm these data in a second colonization assay, we injected a similar 
mixture of Mel57-VEGF-A and Mel57-EGFP cells into the tail vein of nude mice and 
analyzed tumor formation in various organs. Apart from lung, brain was the only organ in 
which tumor growth could be detected. Again, brain lesions were predominantly formed by 
clonal expansion of single tumor cells (p=0.016) and VEGF-A did not confer a colonization 
advantage upon the tumor cells (Fig. 1C ; Table 1b). Remarkably, while in the brains of these 
animals multiple lesions were always present (Table 1b), no or only few lung lesions were 
detected, indicating a strong preference for the melanoma cells to grow in brain parenchyma. 
To be able to still analyze lung lesions after intravenous injection, we had to inject an 
uncommonly high number of tumor cells (6 million). Intriguingly, in contrast to the brain 
lesions which were monoclonal, 50% of the lung lesions in these same animals had a mixed 
tumor phenotype (Fig. 1D; Table 1b). The polyclonal character of these lung lesions could be 
attributed to outgrowth of cell aggregates that were present in the highly concentrated cell 
suspension that was injected, an observation which was similar to that previously described 
by Yamamoto et al.28. Thus, upon intravenous injection, tumor cell aggregrates were captured 
in the lungs while single cells passed the lung capillary filter and homed to the brain.  
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Fig  1. VEGF-A expression does not facilitate colonization potential in brain upon intracarotid or intravenous injection.  
A: EGFP immunostaining of brain lesions consisting of  Mel57-EGFP, Mel57-VEGF-A or a mixture as indicated. Bar 
represents  0.2 mm. B: Quantification of monoclonal and polyclonal lesions in brain after intracarotid injection of  a 1:1 
mixture of VEGF-A and EGFP cells . Note that VEGF-A did not enhance homing to brain (n=11; see also Table 1a). More 
than 85% of the lesions were homogeneous and thus were likely to have a monoclonal origin. C: Quantification of tumor 
types in brain after intravenous injection into the tail vein (n=7; see also Table 1b). Again, brain lesions had a predominantly 
monoclonal origin. D: Analysis of lung lesions after intravenous injection . See also colour display page 158. 
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Table 1 
a)  Composition of brain metastases in mice, injected with a 1:1 mixture of Mel57-VEGF-A and Mel57-EGFP cells into the 
internal carotid artery.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 b)  Composition of lung and brain metastases in mice, injected with 6 million cells into the tail vein.  
Mouse # days p.i # VEGF- 
lesions in  
lung  (%) 
# EGFP- 
lesions in  
lung (%) 
# sum of 
monoclon
al lung 
lesions 
(%) 
# mixed 
lesions in 
lung(%) 
# all 
lung 
lesio
ns 
# VEGF-
lesions in 
brain (%) 
# EGFP- 
lesions in  
brain (%) 
# all 
monoclonal 
brain lesions 
(%) 
# mixed 
lesions in  
brain (%) 
# all brain 
lesions 
1 16 2  (66,7) 0 (0) 2 (66,7) 1 (33,3) 3 88 (36,6) 141 (58,5) 229 (95,0) 12 (5) 241 
2 16 0  0 0 0 0 1 (50) 1 (50) 2 (100) 0 (0) 2 
3 16 0 (0) 4 (44,4) 4 (44,4) 5 (55,6) 9 37 (39,4) 55 (58,5) 92 (97,9) 2 (2,1) 94 
4 16 6 (31,6) 8 (42,1) 14 (73,7) 5 (26,3) 19 7 (29,2) 17 (70,8) 24 (100) 0 (0) 24 
5 16 6 (9,7) 13 (21,0) 19 (30,7) 43 (69,3) 62 69 (32,4) 129 (60,4) 198 (93,0) 15 (7) 213 
6 23 0 0 0 0 0 2 (33,3) 3 (50) 5 (83,3) 1 (16,7) 6 
7 20 0 (0) 0 (0) 0 (0) 1 (100) 1 27 (42,8) 33 (52,4) 60 (95,2) 3 (4,8) 63 
 mean 2 3,5 5,6 7,9  33 54 87 5  
  P=0.13 P=0.81  P=0.03 P=0.016  
 
 
 
 
 
mouse# days p.i # VEGF-
lesions (%) 
# EGFP- 
lesions (%)  
# sum of 
monoclonal 
lesions (%) 
# mixed 
lesions  
(%) 
# all brain lesions 
1 15 38 (36.9) 53 (51.5) 91 (88.4) 12 (11.6) 103 
2 15 60 (37.3) 81 (50.3) 141 (87.6) 20 (12.4) 161 
3 15 72 (43.4) 81 (48.8) 153 (92.2) 13 (7.8) 166 
4 15 63 (47.0) 63 (47.0) 126 (94.0) 8 (6.0) 134 
5 20 17 (54.8) 14 (45.2) 31 (100) 0 (0) 31 
6 18 26 (40.0) 33 (50.8) 59 (90.8) 6 (9.2) 65 
7 18 23 (54.7) 17 (40.5) 40 (95.2) 2 (4.8) 42 
8 18 16 (43.3) 15 (40.5) 31 (83.8) 6 (16.2) 37 
9 18 38 (59.4) 24 (37.5) 62 (96.9) 2 (3.1) 64 
10 18 48 (47.1) 45 (44.1) 93 (91.2) 9 (8.8) 102 
11 16 33 (34.0) 56 (57.7) 89 (91.7) 8 (8.2) 97 
 mean 39.5  43.8  83.3  7.8  
  P=0.3 (n.s.) P=0.002  
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c)  Composition of lung lesions in mice, carrying subcutaneous ipsilateral Mel57-EGFP tumor and contralateral Mel57-
VEGF-A tumor.  
mouse # day post first 
inoculation 
# VEGF-
lesions in 
lung (%) 
# EGFP-
lesions in 
lung (%) 
# mixed 
VEGF/EGFP 
lesions 
# all lung lesions 
1 67 31 (75,6) 10 (24,4) 0 41 
2 67 13 (76,5) 4 (23,5) 0 17 
3 67 15 (93,8) 1 (6,2) 0 16 
4 67 24 (100) 0 (0) 0 24 
5 67 17 (100) 0 (0) 0 17 
 mean 18 3 0 21 
  P=0.043  
 
d)  Composition of lung lesions in mice, carrying subcutaneous Mel57-EGFP/Mel57-VEGF mixed tumors. 
mouse # days post tumor 
injection 
# VEGF-
lesions in lung 
(%) 
# EGFP-lesions 
in lung (%) 
# sum of 
monoclonal lung 
lesions (%) 
# mixed 
VEGF/EGFP 
lesions (%) 
# all lung 
lesions 
1 26 0 (0) 2 (20,0) 2 (20,0) 8 (80,0) 10 
2 26 0 (0) 3 (18,8) 3 (18,8) 13 (81,2) 16 
3 39 1 (4,35) 1 (4,35) 2 (8,7) 21 (91,3) 23 
4 38 1 (4,8) 2 (9,5) 3 (14,3) 18 (85,7) 21 
5 26 0 (0) 0 (0) 0 (0) 15 (100,0) 15 
6 49 0 (0) 0 (0) 0 (0) 1 (100,0) 1 
7 49 0 (0) 0 (0) 0 (0) 2 (100,0) 2 
8 49 0 (0) 1 (10,0) 1 (10,0) 9 (90,0) 10 
9 49 0 (0) 0 (0) 0 (0) 2 (100,0) 2 
 mean 0.2 1 1.2 9.9  
  P=0.13 (n.s.) P=0.003  
 
 
e) Composition of lung lesions in mice, carrying subcutaneous Mel57-EGFP/Mel57-VEGF mixed tumors.  
P-values were calculated via Wilcoxon-signed rank test based on absolute numbers. When comparing ratio’s, similar p-
values result (see corresponding figure 1). 
mouse # days post 
tumor injection 
# parental-
lesions in lung 
(%) 
# EGFP-
lesions in lung 
(%) 
# sum of 
monoclonal 
lung lesions (%) 
# mixed 
parental/EGFP 
lesions (%) 
# all lung 
lesions 
1 81 0 (0) 1 (25,0) 1 (25,0) 3 (75,0) 4 
2 81 1 (7,1) 4 (28,6) 5 (35,7) 9 (64,3) 14 
3 81 5 (20,0) 2 (8,0) 7 (28,0) 18 (72,0) 25 
4 81 10 (34,5) 4 (13,8) 14 (48,3) 15 (51,7) 29 
5 81 0 (0) 1 (20,0) 1 (20,0) 4 (80,0) 5 
 mean 3.2 2.4 5.6 9.8  
  P=0.94  P=0.06 (n.s.)  
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Morphology of subcutaneous tumors: VEGF-A induced micronodular transformation 
Subcutaneous tumors from either Mel57-EGFP or Mel57-VEGF-A cells were grown and 
characterized on the morphological and immunohistochemical level in at least three 
independent experiments using groups of 5 mice for each tumor type. Parental Mel57 and 
Mel57–EGFP tumors behaved similarly with respect to growth rate (not shown) and had 
comparable phenotypes. They developed relatively slowly and were highly necrotic (Fig. 2A), 
leaving a small rim of viable tumor tissue which was sparsely vascularised as was shown by 
anti-CD31 staining (Fig. 2D). A completely different growth rate and architecture was 
observed with Mel57-VEGF-A xenografts. These grew rapidly to large, histologically viable-
appearing tumors with a distinct morphology (Fig. 2B,C, E-J). Tumors were composed of 
multiple micronodules which were surrounded by a network of endothelial cells and pericytes 
(Fig. 2E-J, see also Fig. 4G). Some of these (smaller) nodules were protruding in large 
sinusoidal vessels (Fig. 2C, E, G and respective insets). Stainings for αSMA and CD34 on 
serial sections revealed a composition in which the endothelial cells were localized at the 
outer edge, while pericytes were on the inside (Figure 2I and J). This is consistent with a 
model of bulging of micronodules into dilated vessels during which process nodules become 
gradually covered by vessel wall elements as previously suggested 15. Sometimes, small 
nodules in the tumor periphery appeared only loosely, if at all, attached to the vessel wall and 
impressed as tumor emboli. The notion that these nodules were not attached to the vessel wall 
was strengthened by further stainings of the same nodule at different levels (not shown). Such 
loose nodules were encountered only occasionally, presumably because these will be carried 
away rapidly by the circulation. Instead of widespread central necrosis, the larger individual 
tumor nodules in the tumor centre showed small areas of central necrosis (compare Fig. 2B 
and 2A). 
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Fig 2.  Histological architecture of Mel57-EGFP (A, D) and Mel57-VEGF-A (B, C, E-J). 
A, B and C: H&E staining. D, E and J: anti-CD34 staining. Note the micronodular structure of the VEGF-A tumor and the 
coverage of these nodules by pericytes and endothelial cells (αSMA-staining in (G) and (I) and CD34 staining in (E) and (J)); 
endothelial identity was confirmed by 9F1 staining (F) and CD31 (H). Note in figures I and J, which are stainings on serial 
sections, that endothelial cells were localized primarily at the outer side of the nodules, whereas pericytes were on the inside 
(arrows in (I) and (J)). Frequently, loose nodules were observed in dilated sinusoidal vessels (C,E and G and inset). In 
contrast, Mel57 tumors were highly necrotic in the tumor center (A). Only the tumor rim consisted of viable cells with few 
vessels (A,D). Bars represent:  1 mm in A-E,G;  0.1 mm in F,H and 0.2 mm in I,J. See also colour display page 159. 
 
 
VEGF-A increases metastatic capacity in a spontaneous metastasis model   
To examine whether VEGF-A increased the efficiency of metastasis, we grew both tumor 
types (Mel57-EGFP and Mel57-VEGF-A) on opposite flanks of the same mouse. Based on 
growth curves of individual tumors obtained from previous experiments (not shown), we 
injected the Mel57-EGFP tumors in groups of mice five weeks prior to injection of Mel57-
VEGF-A tumors to compensate for the difference in tumor growth rates. Metastatic burden 
and the composition of the metastases were examined by anti-EGFP immunostaining and 
VEGF-A mRNA in situ hybridization after nine weeks, when EGFP and VEGF-A tumors had 
C 
D F 
B A 
H 
J I 
E 
G 
Figure 2 
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reached similar sizes (Fig. 3A). In striking contrast to the results obtained in the colonization 
assays, we now found that VEGF-A expression significantly increased the probability of lung 
metastasis formation (p=0.043, Fig. 3B; Table 1c). At least 90% of the lesions consisted of 
Mel57-VEGF-A cells only, despite the fact that Mel57-EGFP tumors had been growing for 5 
weeks longer. No mixed lung lesions were found in this group. In two mice in which the 
EGFP tumors had to be resected due to severe ulceration (at a size of approximately 700 
mm3) and in which consequently EGFP tumors had been growing for 6 weeks instead of 9, 
exclusively VEGF-A lesions were found. Tumors were localized in the larger branches of 
pulmonary arteries (Fig. 3C, arrows), strongly suggesting that these originated from tumor 
embolisms. Brain metastases were never detected in mice carrying subcutaneous xenografts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. VEGF-A enhances spontaneous 
metastasis from subcutaneous tumors.  
A: Growth curves of EGFP (-o-) and VEGF-A 
(……) expressing Mel57 tumors, grown on 
the opposite flanks of mice (n=5). After 9 
weeks, when tumors had reached similar sizes, 
mice were sacrificed (see text). Tumor growth 
was measured weekly using calipers. Tumor 
volumes are expressed as h x w x d. The dip in 
the growth curve at day 45 is caused by the 
excision of Mel57-EGFP tumors in two mice 
due to ulceration. These mice were included in 
the analysis of composition of metastasis. B: 
Lung lesions, consisting of Mel57-VEGF-A or 
Mel57-EGFP cells were counted after EGFP 
immunostaining (see also Table 1c). To 
confirm identity of VEGF-A lesions, VEGF 
mRNA-ISH was performed (not shown). C: 
Representative H&E staining, showing tumor 
emboli located in the larger branches of the 
pulmonary arteries (arrows). Bar represents  0.3 
mm. See also colour display page 158. 
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VEGF-A-induced micronodular growth facilitates the formation of multicellular tumor 
emboli  
To examine in more detail the composition of the tumor emboli in the lungs, we performed 
the following experiment: Mel57-EGFP and Mel57-VEGF-A cells were mixed in a 1:1 ratio 
and injected into the flank of nude mice to establish mixed subcutaneous tumors. The 
resulting tumors had comparable growth profiles and phenotypes as Mel57-VEGF-A 
xenografts (see H&E staining in the inset in figure 4A), consistent with the paracrine activity 
of VEGF-A. Also, polyclonal intravascular loose nodules could be observed in these 
xenografts (see EGFP staining in figure 4M). Analysis of the primary tumors and lung 
metastases thereof by EGFP staining revealed that the composition of lung deposits was very 
similar to that of the micronodules in the primary tumor (compare Fig. 4A and B), which was 
confirmed by VEGF-A-mRNA in situ hybridization (Fig. 4H). Analysis of serial sections 
revealed that VEGF-A in situ hybridization and EGFP stainings were complementary (not 
shown), indicating that transgenic proteins were stably expressed and that no confounding 
loss of expression had occurred. Most lesions were polyclonal, as they were composed of both 
Mel57-EGFP and Mel57-VEGF-A (Fig. 4L; Table 1d). Only a small fraction of the lesions 
was clonal, containing either Mel57-EGFP or Mel57-VEGF-A cells (Fig. 4L; Table 1d). This 
reflected the composition of the primary tumors where occasionally nodules were found that 
consisted of a single cell type, probably also arising by clonal expansion within the primary 
tumor (Fig. 4C, arrowheads). Interestingly, in the right ventricle of the heart of one tumor-
bearing animal we found tumor micronodules of the same mosaic composition as the primary 
tumor and the lung metastases (Fig. 4D and inset). Again, these nodules had tissue 
characteristics as they contained laminin (Fig. 4E) and were covered by proliferating murine 
cells (Fig. 4F: Ki67-staining, Fig. 4G: α-SM staining). From the location of the Ki67-positive 
cells we conclude that these cells consist of both pericytes and endothelial cells (see also 
figures 2I and 2J), although it is difficult to accurately identify each proliferating cell in these 
stainings. 
If  generation of tumor emboli augments metastasis formation, the question arises how the 
parental or EGFP-expressing tumors metastasize. To answer this, we generated subcutaneous 
tumors containing equal numbers of parental Mel57 and Mel57-EGFP cells, and analyzed the 
composition of lung deposits using anti-EGFP immunohistochemistry (Fig. 5A). Most lung 
metastases examined were composed of both EGFP and parental Mel57 cells (Fig. 5B; Table  
1e), implying that these tumors may also metastasize by shedding of tumor cell aggregates 
into the circulation. Although we could not resolve whether these aggregates were also 
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accompanied by primary tumor-derived murine endothelial cells and pericytes, the 
architecture and composition of these primary tumors suggest otherwise. 
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Figure 4  
Analysis of VEGF-A-induced metastatic tissue.  
Subcutaneous mixed tumors containing equal 
numbers of Mel57-EGFP  and Mel57-VEGF-A cells 
were grown on the flanks of nude mice (n=9). A: 
EGFP staining of a subcutaneous mixed tumor and 
(B) a lung lesion from the same animal. The inset in 
(A) shows an H&E overview field (x25) of the same 
tumor, showing the nodular phenotype that is 
characteristic of Mel57-VEGF-A tumors. Note the 
similar composition of lung lesions in (B) and 
subcutaneous tumor micronodules. C: In the primary 
tumor, regions with a homogeneous composition 
could be identified (arrow), consistent with the 
occurrence of small numbers of homogenous lung 
lesions (L). D: EGFP staining of tumor micronodules 
in the right ventricle of the heart. Immunostaining 
showed that nodules were covered by laminin (E), 
proliferating (F) endothelial cells and pericytes (G), 
giving these nodules tissue characteristics. Note that 
in figure F only murine proliferating cells are detected 
with our antibody. To confirm VEGF-A identity of 
EGFP-negative Mel57 cells, VEGF-A in situ 
hybridisations on lung lesions were performed (H); 
sense control hynbridization (K). Bars represent  0.2 
mm. L: Quantification in lungs of mono- and 
polyclonal metastases, derived from mixed 
subcutaenous xenografts (see also Table 1d). M: 
intravascular nodule, derived from a VEGF-A/EGFP 
mixed tumor with a  polyclonal composition, as 
illustrated by EGFP-immunostaining. See also colour 
display page 160. 
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Intravascular endothelial cell-covered tumor fragments are observed in clinical tumors  
To evaluate whether intravascular micronoduli have clinical relevance, we looked in detail at 
renal cell carcinomas, tumors that often have high constitutive expression of VEGF-A due to 
mutations of the Von Hippel Lindau (VHL) protein 29. We found that in tumors that were 
designated by pathologists to have intravascular localization, such endothelium-covered 
nodules could indeed be observed. Figure 5D shows an example of such a nodule, laying 
within a dilated blood vessel which is at some distance of the main tumor mass (arrow). These 
results confirm those obtained by Sugino et al. 16 who recently reported on this phenotype in a 
number of clinical tumor types. The relation of this phenotype to VEGF-A expression is 
currently under investigation in our laboratory.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.  Analysis of metastasis from mixed parental and EGFP-expressing Mel57 subcutaenous tumors.  
A and B: EGFP immunostaining of a subcutaneous mixed tumor containing equal numbers of Mel57-EGFP and parental 
Mel57 cells (n=5) (A) and a derived lung lesion (B). Note that lung metastases are predominantly composed of both cell 
types. C: Distribution in lungs of mono- and polyclonal lesions (see also Table 1e). The low number of homogenously 
appearing lesions may be due to the existence of homogenous areas in the primary tumor, like in Figure 4.  
D: CD31 staining of a section of a clinical renal clear cell carcinoma, showing the presence of an intravascular tumor 
fragment, covered by endothelial cells (arrow). Bars represents  0.3 mm.  See also colour display page 158. 
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Discussion 
Metastasis of tumors is a complex multistep process, requiring intravasation, transport, 
extravasation and outgrowth. Expression of VEGF-A by tumors and concomitant high tumor 
vessel densities have been associated with poor prognosis in a number of cancer types (for 
review see 4,13). This correlation has been attributed to an increasing probability of tumor cell 
intravasation. Obviously, other factors must play a role too, since a correlation between 
numbers of circulating tumor cells and prognosis is lacking (for review see 11). For instance, 
the angiogenic potential of a tumor cell might determine part of its metastatic properties, as an 
angiogenic phenotype will fuel outgrowth of distant metastases beyond a dormant stage 3,30. 
However, we and others recently demonstrated that especially in vessel-dense organs like 
brain, lung, kidney and liver, tumors can grow by vessel co-option in an angiogenesis-
independent fashion 18-21,31,32. 
In our brain colonization models in which mixed populations of tumor cells were injected 
intravenously or into the internal carotid artery, metastases developed predominantly by 
clonal outgrowth of single cells, which is in agreement with observations by others 33. 
Interestingly, upon injection of Mel57 cells into the tail vein, multiple brain lesions but only 
few lung lesions developed, indicating a clear preference of this cell line to colonize brain 
(compatible with the ‘seed and soil’ hypothesis 34). The low preference of Mel57 cells to 
colonize lungs forced us to inject high numbers of tumor cells to establish lung lesions in a 
colonization assay. Unavoidably, tumor cell aggregates were formed in these high-density cell 
suspensions, leading to embolism in the lungs. Therefore, we consider this result as an artefact 
with little or no relevance for the human situation. In fact, this finding was confirmed in a 
recent publication by Yamamoto et al., who showed that intravenous injection of relatively 
small numbers of tumor cells resulted in predominantly monoclonal lung lesions, whereas 
injection of high numbers of cells resulted in polyclonal lesions 28.  
In our colonization models, VEGF-A did not increase tumor burden in brains. In a previous 
report, Yano et al. also described that overexpression of VEGF-A in a panel of carcinoma cell 
lines, did not lead to enhanced metastasis formation in a similar brain colonization model 23. 
However, downregulation of VEGF-A by antisense transfection led to a significantly 
attenuated brain colonization potential, suggesting that a basal level of VEGF-A expression 
by tumor cells was necessary for brain colonization. In contrast, our results showed that the 
parental Mel57 and Mel57-EGFP lines were able to generate brain metastases in the absence 
of significant VEGF-A expression. Apparently, Mel57 melanoma metastases were more 
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successful in incorporating pre-existent brain vessels in the absence of VEGF-A than the cell 
lines used by Yano et al. 
The heterogeneity in numbers of lung lesions in metastasis experiments within groups (see 
also tables 3-5) made it hard to make solid statements about differences in metastatic 
efficacies by just comparing absolute numbers of lung lesions in mice carrying EGFP- or 
VEGF xenografts. The differences in growth rate between EGFP and VEGF-expressing 
tumors would make interpretation even more difficult. Therefore, to compare metastatic 
capacities of VEGF-A and EGFP-expressing xenografts, we chose to establish the respective 
xenografts in the same mice. This enabled us to determine the ratio of EGFP and VEGF-
lesions in the lungs, which is far more reliable than absolute numbers. We found that, in 
striking contrast with the colonization assays, Mel57-VEGF-A tumors metastasized to lungs 
much more efficiently than Mel57-EGFP tumors in mice carrying contralateral EGFP- and 
VEGF-A-expressing tumors. The study of metastatic properties of these tumor cell lines with 
such different growth profiles may seem cumbersome also in this experimental setup. 
However, our data suggest that in this instance the comparison is justified. First, volumes of 
the respective tumors were comparable in each mouse at the end point of analysis. Secondly, 
Mel57-VEGF-A tumors had much less time to metastasize than the Mel57-EGFP tumors, 
evenmore suggesting that VEGF-A expression is the crucial determinant for efficient 
metastasis in this model.  
Our morphological data show that tumor cells did not detach from the primary tumor as single 
cells but rather as tissue fragments, at least partly covered by a basal lamina, endothelium and 
pericytes. These tissue fragments enter the circulation, are captured by the filter of the lung 
capillary bed and grow out. This hypothesis is consistent with the fact that in the primary 
tumors, tumor nodules that ly loose within vasculature are encountered only occasionally. 
Indeed, such nodules will be carried away by the circulation instantly, similar to the model 
proposed  by Sugino et al.15.  
It is unclear how the architecture of the VEGF-A-expressing tumors evolves. Because Mel57 
cells secrete laminin, endothelial cells lining dilated vasculature may be induced by tumor-
derived VEGF-A to proliferate and migrate, using tumor cell-associated laminin as a matrix. 
Indeed, endothelial cells and/or pericytes were in a proliferative state on the surfaces of the 
tumor nodules. VEGF-A expression may also lead to higher laminin expression levels and the 
formation of matrix layers 35. Like angiogenic endothelial cells, Mel57 cells also express 
VEGFR2 (data not shown), leaving open the possibility that an autocrine VEGF/VEGFR2 
loop is involved in the development of this phenotype. Which target genes of VEGF-A, either 
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in stromal cells or tumor cells, are involved in development of metastatic tumor tissue 
nodules, is currently under investigation in our lab.  
Interestingly, brain metastases were never observed in animals carrying subcutaneous tumors, 
favoring the hypothesis that the tumor emboli within the circulation cannot pass the lungs 
efficiently. Our findings with mixed parental/EGFP tumors show that these may also 
metastasize via a mechanism of tumor cell cluster embolism, although much less efficient 
than Mel57-VEGF-A tumors. Importantly, in these tumors we did not detect intravascular 
endothelium-covered nodules, suggesting a potential correlation between endothelial coverage 
and metastatic efficiency. 
Based on our observations, VEGF-A may facilitate the metastatic process by induction of  
irregular vasodilatation, allowing for protrusion of micronodular tumor cell aggregates into 
the vessel lumen. This scheme of events would indeed predict that endothelial cells form the 
outer, and pericytes the inner layer of the nodular cover, just as we demonstrated via stainings 
with anti-CD34 and anti-α-SMA on serial sections. Nodules within the main tumor mass that, 
during tumor growth, become localized suboptimally for intravasation, will remain there and 
grow to large nodules, ultimately  making up the main tumor mass.  
Our data may also provide an explanation for the lack of correlation between circulating 
tumor cells and poor prognosis: PCR-based techniques on whole blood samples do not 
distinguish between tumor cell clusters with metastastic capacity and single circulating tumor 
cells that may not be able to survive because they are not in a ‘tumor-tissue’ context. This 
tissue context, especially the endothelial coverage, may mask tissue factor exposure by tumor 
cells and thereby prevent clot formation in the microenvironment of the primary tumor. It is 
also tempting to speculate that coverage by endothelial cells leads to protection from the 
immune system, thus further increasing the chance of successful metastatic deposition. 
Our study challenges the prevailing view that metastases arise by clonal outgrowth of single 
tumor cells that, due to genetic instability and via a micro-evolutionary process, have acquired 
a metastatic phenotype 1,33,36. In fact, tumor cells like Mel57-EGFP, that intrinsically 
metastasize inefficiently, can successfully travel along with VEGF-A-expressing tumor cells. 
This may explain the occasional presence in cancer patients of metastases that have little 
angiogenic potential although they originated from highly angiogenic primary tumors 17.  
Tumor tissue fragments may have high clinical relevance since these are frequently found in 
lymph- and blood vessels of cancer patients 37,38 and their presence correlates with poor 
prognosis (for review 11). It needs to be established in which human tumors VEGF-A 
expression contributes to generation of metastatic tissue. Interestingly, Von Hippel Lindau 
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(VHL)-associated renal clear cell carcinomas (RCCs), cancers with high VEGF-A expression 
levels, also frequently display intravascular growth, and we indeed could detect intravascular 
RCC nodules, covered with endothelial cells. To what extent intravascularly growing tumors 
contain stromal cells and what their characteristics are, is under investigation in our lab.  
Yet, not all tumor types experience enhanced metastatic dissemination upon VEGF-A 
overexpression 39,40, indicating that the effect of VEGF-A that we describe here must be umor 
type-specific to a certain extent. We consider it unlikely that our observations are the result of 
artificial VEGF-A overexpression, since the levels of recombinant VEGF-A, expressed by 
Mel57-VEGF-A cells, are comparable to those found in for example glioma cell lines 41. 
Recently, in a murine model of metastatic mammary carcinoma the presence in lung of tumor 
cell emboli, covered by an endothelial cell layer, was demonstrated 14,15. Micronodular pattern 
formation in the corresponding primary tumors was attributed to pleiotrophin expression. An 
exclusive role for pleiotrophin in the development of the nodular micro-architecture of 
Mel57-VEGF-A tumors can be excluded since this factor is expressed also in parental Mel57 
cells 27. E-cadherin has been described to be essential for intercellular tumor cell adhesion in 
circulating tumor cell clusters 42,43. In our model, however, neither the parental nor the VEGF-
A expressing cell lines or the derived tumors expressed E-cadherin (unpublished results).  
Anti-VEGF therapy has been considered to be a powerful approach to prevent clinical 
manifestations of metastatic disease in cancer patients. By inhibiting angiogenesis, minute 
metastatic deposits should remain dormant, turning cancer into a chronic disease. However, 
especially in vessel-dense organs the angiogenesis-dependency of tumors is at least 
questionable, since tumors may (partly) thrive by incorporating pre-existent vasculature.  Our 
results, however, point to a possible novel role for anti-angiogenic therapy: anti-VEGF 
therapy in patients with primary cancers might decrease the chance of metastatic spread, not 
simply by decreasing vascular density, but rather by preventing the formation of a 
micronodular architecture that facilitates intravasation. In this regard, it will be important to 
further investigate the clinical relevance of a micronodular growth pattern in other types of 
cancer. An interesting initial study on this has recently been published by Sugino et al who 
demonstrated intravasation of tumor micronodules in a number of tumor types, among which 
RCC 16. Unraveling of  the underlying mechanisms will therefore be of potentially high 
significance in oncology. 
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In chapters 2 to 7 different studies in animal models have been described followed by a 
detailed discussion in each chapter. In this last part of the thesis we place the data presented in 
chapters 2-7 in a broader, partly hypothetical or even speculative context of theories on tumor 
growth and metastasis by returning to the questions asked in chapter 1. 
 
Do tumors depend on angiogenesis? 
As described particularly in chapter 3, tumor growth may occur without angiogenesis. In our 
studies melanoma cells were able to co-opt the pre-existent vasculature of the brain by 
infiltrating the brain parenchyma in the perivascular space. In the human situation this growth 
pattern may be observed in the brain as well; e.g. in melanoma, small cell lung cancer 
metastasis and in cerebral lymphoma1. Macroscopically, brain metastases of epithelial tumors 
often show an expanding (pushing) border, sometimes with central necrosis and viable tumor 
tissue at the rim. This central necrosis indicates the absence of a sufficient (neo)vascular bed 
in the cores of these lesions. Indeed, in this situation the tumoral vessels are often located in 
the remnants of the brain tissue in and around the periphery of the tumor. Morphologically, 
this vasculature often differs from normal brain vessels: it may show a delicate branching 
with the formation of new vessels, that may be embedded in a desmoplastic stroma. In 
addition, these peritumoral microvessels frequently show the pattern that we described with 
Mel57 melanoma cells expressing the VEGF-isoforms 121 (chapters 4 and 5) and 
VEGF165gly-ser (chapter 3): vasodilation with occasional glomeruloid microvascular 
proliferation (mvp). Vasodilation may just be the result of morphological modulation of the 
pre-existing vessels without the formation of a neovascular bed, while glomeruloid mvp may 
be considered as aberrant in situ proliferation of endothelial cells and pericytes, without 
formation of a tubular structure; some studies have already described the patho-physiological 
and anatomical background of such vessels2,3. However, we have to realize that vasodilation 
and mvp are not sprouting or intussuceptive angiogenesis4,5 and may only facilitate sufficient 
blood supply to tumor tissue over short distances. Why is the center of many metastatic and 
primary tumor lesions necrotic? We offer the following hypothesis: tumor cells are thought to 
induce angiogenesis because of hypoxia6, but the upregulation of angiogenic factors 
apparently is too late or otherwise insufficient, to prevent necrosis to occur. The peritumoral 
rim frequently shows dilated (pre-existing?) vessels. Recent findings (own unpublished 
results) indicate that probably only VEGF-isoforms that do not exhibit a strong matrix binding 
capacity can reach more distant (e.g. peritumoral) vessels, while larger VEGF isoforms, that 
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in itself are able to induce angiogenesis (chapter 5) are not able to reach more distant vessels 
because of matrix binding in the direct neighborhood of the VEGF secreting cells. 
The VEGF165gly-ser isoform we used in studies in chapter 3 differs from the wild type 
isoform 165 in its amino terminal end (i.e. exon 8): gly-ser instead of arg-arg. To date, this 
amino terminus, has not been described to be relevant in the VEGF-receptor interaction and 
the VEGF-effect in angiogenesis7. However, we found that differences in the VEGF amino 
terminus do seem to have consequences for the receptor activation program: the 165gly-ser 
isoform of VEGF shows induction of a comparable vasculature as VEGF121, while the 
vasculature induced by VEGF165arg-arg is different. This implicates that presumably not 
only VEGFR2 and NRP-1 play a role as receptor for VEGF, but that other receptors may be 
involved as well to initiate the complete program of induction of a neovascular bed.  
 
Is vascular co-option a phenomenon that is limited to the brain? 
In 1999 Holash et al. reported on the phenomenon of vessel co-option8 using an animal 
glioma model. The authors described that in this model initial co-option of pre-existent 
vessels occurred, followed by vessel regression and finally a neo-angiogenic response.  
Malignant tumors are often characterized by infiltrative growth. Should such infiltration be 
accompanied by complete destruction of the infiltrated healthy tissue, for tumor growth 
angiogenesis would be necessary to replace the pre-existing vessels that are destroyed by the 
tumor. Does this scenario occur in tumors? Sometimes it does, but more frequently the tumor 
border of most types of tumors shows infiltration of tumor cells into the pre-existing tissue 
without complete destruction of its anatomy. Rather, tumors grow along anatomical structures 
such as vessels or nerves. In the last years, vessel co-option has gained a lot attention. The 
phenomenon has now been described in human tumors in different organs (lung, liver, kidney 
and brain) and in different animal models9-15. The phenomenon of vessel co-option itself is of 
course not new. Pathologists are confronted with it in everyday practice while examining 
microscopy slides of infiltrating tumors.  
 
What are the consequences of co-option for the diagnosis and  treatment of cancer? 
As described in chapters 4 and 6, infiltrative tumor cells that co-opt/incorporate the pre-
existing vasculature may escape detection with modern radiological imaging techniques. 
Besides a insensitivity of such cells to anti-angiogenic treatment, this situation will hamper 
correct diagnosis of tumor size and tissue involvement in human cancer. For example, 
glioblastoma multiforme is a tumor in which it is difficult to demarcate the tumor margins 
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because of diffuse infiltrative growth in the surrounding brain tissue. However, in chapter 6 it 
is described that contrast-enhanced MRI, although it fails to detect co-opting tumors with 
conventional contrast agents, may be a suitable instrument to monitor the response to anti-
angiogenic therapy by evaluating the attenuation or complete loss of contrast enhancement 
during therapy.  
 
Why is increased angiogenesis correlated with worse prognosis for most of the 
malignancies17-19? 
For some tumors the simple explanation mentioned in chapter 7 would probably suffice: more 
vessels increase the chance that a tumor cell hits a vessel. Furthermore, an angiogenic 
phenotype of metastatic tumor cells will enhance the growth rate of metastases.  
The data presented in chapter 7 show another aspect of how the angiogenic phenotype of 
tumors facilitates the development of metastases: the microarchitecture in angiogenic tumors 
leads to the formation of  multicellular tumor emboli that escape from the primary tumor. This 
phenomenon may well be the explanation for the pathologist’s experience of the occurrence 
of multicellular tumor emboli within (peri)tumoral vessels and at metastatic sites.  
A crucial finding in this respect is that tumor emboli may be polyclonal (chapter 7). 
Non-angiogenic tumor cells can thus travel along with angiogenic ones, resulting in 
polyclonal metastases (consisting of angiogenic and non-angiogenic tumor cells). 
In Darwinian terms,  this does not fully fit. It is not the selection of the angiogenic fittest 
clone. Some might even speculate about ‘tumoral altruism’ in terms of Darwinian social-
biology (see also later in this chapter for more discussion on this topic). 
 
Is the center of the tumor history and the rim the future?  
In contrast to the tumor rim the tumor center may show both extremes of morphology: on the 
one hand, vital highly vascularized tumor tissue without any recognizable pre-existent healthy 
tissue and, on the other hand, extensive tumor necrosis. The majority of tumors exhibit both, 
reflecting the ability to induce sufficient functional angiogenesis in some areas and failing to 
do so in others. Therefore one could also ask if there are differences between the tumor rim 
and the tumor center in tumor progression. More specifically, are there clonal differences 
between rim and center? Or are the histological differences only the result of different tumor 
micro-environment interactions?  
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If the tumor rim is infiltrative and the center probably expansive and angiogenic, which part 
of the tumor will then be the most dangerous for the patient? We can envisage some 
hypothetical scenarios: 
If there are different subclones with regard to angiogenic phenotype in the tumor center 
versus the rim, it would be more plausible that tumor cells from the center disseminate, 
because they are angiogenic. If, on the other hand one tumor is a single clone, tumor cells 
may disseminate from the rim and the center at random, because tumor cells at the rim are as 
angiogenic as those in the center of the tumor.  
But what about co-opting metastases? These exist as is shown in studies described in chapters 
3-7. Several other groups have also confirmed their presence in the human liver and 
lung11,15,16. Based on these findings one can therefore not conclude that only the angiogenic 
tumor part will successfully metastasize, and the answer to the question which part of the 
tumor (center or rim) will kill the patient still remains open (although for tumors with 
extensive necrosis, the rim of course is the “tumor’s future”). 
 
Is the concept of Darwinian tumor evolution and metastasis right?  
Autonomic growth of a primary tumor can clearly be described as an evolutionary cascade. 
All genetic events that enhance mitotic rate, inhibit apoptosis and increase nutrition supply by 
angiogenesis or infiltration and co-option of pre-existing vessels will select the fittest clones 
in this respect. Bernards and Weinberg have published an interesting letter in which they 
mentioned that there is a conceptual mistake in the current metastasis model20.  The question 
is: what is the selective pressure in the primary tumor for developing a metastatic subclone? 
There is no selective pressure for tumor cells to leave the primary tumor. Selection of tumor 
cell clones on their capacity to form a metastasis takes place at the site of metastasis: can 
tumor cells settle there and cope with the micro-environment21. Bernards and Weinberg, 
therefore, hypothesize that metastasis must occur at random in tumor progression and can be 
an early event in patient tumor history. Both authors state that there are no genes in the tumor 
that are solely involved in the creation of a metastatic phenotype, as there is no selective 
pressure for such an event. The capacity of tumor cells to leave the primary tumor can then be 
considered as an epiphenomenon in neoplastic evolution: the same genes that initiate 
autonomous growth, including that of invasive behavior, are responsible for the fact that 
tumor cells leave the primary tumor and form metastases. Recent findings in microarray tests 
comparing the genetic profile of metastases and their primary tumors revealed that they were 
identical22,23. This means that no definite clonal differences between metastasis and primary 
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tumor were detectable. Thus, no additional metastasis gene was identifiable in the metastasis 
that would qualify the metastasis as a more malignant subclone of the primary tumor. The 
data presented in chapter 7 fit in very well with this point of view on the development of 
metastasis: The genetic event creating an angiogenic phenotype (mimicked by VEGF gene 
transfection) obviously increases the growth rate of the primary tumor but is simultaneously  
accompanied by an increased rate of metastasis. In evolutionary perspective, cells with such 
an angiogenesis gene can be selected in the primary tumor because it enhances tumor growth, 
but not because it enhances metastatic rate. In fact, the latter phenomenon can be considered 
as an epiphenomenon caused by a different vascular architecture! 
The discussion by Bernards and Weinberg still continues among researchers24-29 and the 
dogma of evolutionary selection of a metastatic phenotype in primary tumor growth30,31 is still 
a sensitive spot in the Darwinian cancer concept. 
 
What about the seed and soil hypothesis? 
This hypothesis describes that a metastatic tumor cell is selected by its capacity to settle at a 
metastatic site and to grow out32. As already mentioned in chapter 1, many tumor types are 
known for their tendency to spread preferentially to particular organs, a phenomenon which is 
partially independent of the anatomical situation defined by vascular supply and delivery. 
Dissemination of melanoma frequently results in brain metastasis33. Our data clearly illustrate 
this phenomenon: when injected intravenously, melanoma cells showed a preference for CNS 
metastasis and not lung metastasis, while the lung is the first organ which is reached by the 
tumor cells after i.v. injection (chapter 7). This phenomenon might (partially) be explained by 
the embryological, i.e. neuroectodermal background of these cells, which may provide them 
with a phenotype that makes them “feel at home”in the CNS micro-environment. 
Interestingly, the metastatic patterns can be different between different melanoma cell lines 
not only in organ preference21,34 , but also in subregions of  a certain organ. As described in 
chapter 2, some cell lines show a preference for metastases in the meninges, whereas others 
show preferential parenchymal involvement. This must be dependent on selective adhesion 
between tumor cells and local vasculature, as a pure anatomical (embolism!) or micro-
environmental background could be ruled out (chapter 2). The successful outgrowth of 
metastatic tumors in particular organs can thus be considered as evolutionary selective step in 
line with the seed and soil hypothesis. 
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Some final remarks on animal models 
In this thesis, studies are presented in which human tumor cells are investigated in mouse 
models. The question is how relevant these data are for clinical practice. As mentioned in 
chapter 1, we have to bear in mind the sentence: ‘mice tell lies’. Investigators must have a 
clear idea about what they want to investigate. In studies on tumors this background 
implicates the use of an animal model that on the one hand mimics the human situation as 
closely as possible, while at the other hand the harm done to the animals is limited as much as 
possible.  Profound knowledge of pathology, biochemistry and patho-physiology in humans 
and animals are therefore essential prerequisites.  
Many disappointing results with anti-angiogenic therapies in patient trials could probably 
have been avoided when ‘relevant‘ animal models were used from the start instead of ‘a 
priori’ biased tumor models in which tumors were in fact selected for their angiogenesis 
dependency (see also discussion chapter 3). 
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Samenvatting 
 
Kanker is een levensbedreigende ziekte en in westerse landen een frequente en (o.a. vanwege 
de “vergrijzing” van de bevolking) zelfs toenemende oorzaak van ziekte en overlijden. Vooral 
de behandeling van gemetastaseerde (uitgezaaide) kanker vormt een groot probleem. De 
gebruikelijke chirurgische, chemotherapeutische en radiotherapeutische behandelingen 
schieten in zo’n situatie uiteindelijk vaak te kort. Een nieuwe benadering ter bestrijding van 
kankergezwellen is er op gericht om de bloedvoorziening van het gezwelweefsel te 
onderbreken en zo de tumor als het ware “uit te drogen”. Een gezwel heeft, net als normaal 
weefsel, een functionerend vaatbed nodig om vitaal te blijven en te kunnen groeien. Hiertoe 
vormen veel gezwellen nieuwe vaatjes, een proces dat angiogenese wordt genoemd. De 
belangrijkste angiogene factor is Vascular Endothelial Growth Factor (VEGF).  Anti-
angiogene therapie zou door het remmen van angiogenese de tumor mogelijk verhinderen 
verder te groeien of zelfs kunnen doen krimpen. Een bijkomend voordeel van deze benadering 
zou kunnen zijn dat tumorcellen minder makkelijk de bloedbaan bereiken en daardoor minder 
uitzwermen in het lichaam. De toepassing van anti-angiogene therapie bevindt zich tot nu toe 
nog in experimenteel stadium. 
 
Het melanoom van de huid is een van de meest kwaadaardige tumoren bij de mens. Genezing 
van deze tumor is vaak slechts mogelijk als het gezwel wordt verwijderd in een vroeg stadium 
waarin de tumor nog niet dieper in de huid is gegroeid. Bij dieper groeiende melanomen is de 
kans namelijk groot dat reeds tumorcellen zijn uitgezaaid naar andere organen. De metastasen 
worden in eerste instantie vaak aangetroffen in lymfklieren in de buurt van de tumor, maar 
vervolgens ook meer op afstand in organen als longen, lever en hersenen. Hersenmetastasen 
komen bij patienten met maligne melanoom relatief frequent voor, mogelijk heeft dit te 
maken met het feit dat melanoomcellen wat betreft herkomst verwantschap tonen met 
hersenweefsel. 
  
Om het biologisch gedrag van tumoren te kunnen bestuderen en nieuwe therapeutische en 
diagnostische mogelijkheden te ontwikkelen en te testen is wetenschappelijk onderzoek 
noodzakelijk. Voor meer basale of onrijpe klinische vraagstellingen wordt vaak 
dierexperimenteel onderzoek verricht, al dan niet met met gebruik making van 
patientenmateriaal (bijv. weefsel dat o.a. is verkregen voor pathologisch onderzoek). De meer 
uitgewerkte onderzoeksvragen kunnen vervolgens in klinische trials worden onderzocht. Een 
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groot voordeel van dierexperimenten is dat hierbij een zeer gestandaardiseerde opzet mogelijk 
is met nauwkeurige manipulatie van verschillende facetten van het te onderzoeken fenomeen. 
Ook diagnostische technieken kunnen in principe vaak in dierexperimentele setting worden 
getest. 
 
In dit proefschrift wordt dierexperimenteel onderzoek in zogenaamde “naakte muizen” 
beschreven. Deze muizen heten zo omdat zij nauwelijks behaard zijn, samenhangend met een 
gestoorde immuunafweer. Deze gestoorde immuunafweer maakt het ook mogelijk om in 
dergelijke muizen tumoren van de mens te laten groeien zonder dat deze worden afgestoten. 
In hoofdstuk 2 wordt de ontwikkeling van een geschikt diermodel voor hersenmetastasering 
beschreven. In dit model wordt gebruik gemaakt van humane melanoomcellijn(en). De 
invloed van de aanwezigheid van het eiwit αvß3 integrine (dat o.a. binding bewerkstelligt 
tussen cellen onderling en hun omgeving) op tumorcellen en de rol van individuele 
tumorcellen versus groepen van tumorcellen op het metastase-gedrag in de hersenen werden 
onderzocht. Wij vonden dat het patroon van metastasering (in hersenvliezen versus in het 
hersenweefsel zelf) niet werd beinvloed wordt door de aanwezigheid van αvß3 integrine op 
melanoomcellen. Ook maakte het voor het metastaserings-patroon niet uit of individuele 
tumorcellen of tumorcelclusters in de bloedstroom van de proefdieren gebracht werden. 
 
Hoofdstuk 3 vermeldt onderzoek (met behulp van het in hoofdstuk 2 ontwikkeld model) naar 
de groeiwijze van metastasen in het eigenlijke hersenweefsel. Wij tonen aan dat metastasen 
van melanoomcellen die de angiogene factor VEGF niet produceren in hersenweefsel kunnen 
groeien zonder nieuwe vaten aan te maken. Dergelijke tumoren maken gebruik van reeds 
bestaande bloedvaten in de hersenen (zogenaamde vaat-coöptie). Als dezelfde tumorcellen 
echter kunstmatig zo worden veranderd dat ze wel VEGF gaan produceren dan leidt dit tot 
vorming van nieuwe vaten en tot vaatverwijding en verhoogde permeabiliteit van pre-
existente bloedvaten (hoofdstukken 3 en 5). Verschillende isovormen van VEGF bleken 
hierbij verschillende effecten te hebben op het vaatpatroon in en rond de tumoren.  
 
De diagnostische consequenties van vaat-coöptie in hersentumoren worden in hoofdstuk 4 
besproken: tumoren zonder angiogenese en zonder VEGF-productie zijn niet goed te 
herkennen op basis van MRI onderzoek met conventionele contrastmiddelen. Het gebruik van 
nieuwe, op ijzeroxide gebaseerde contrastmiddelen kan in zo’n geval van nut zijn. Deze 
laatste contrastmiddelen blijven in het vaatstelsel van normaal en door tumor ingenomen 
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hersenweefsel, maar ter plaatse van de tumor zijn de preexistente vaten vaak uiteengedrukt en 
wordt daardoor minder contrast gevonden dan in normaal  hersenweefsel. 
 
Hoofdstuk 6 beschrijft onderzoek waarbij wordt aangetoond dat antiangiogene behandeling 
van tumoren die VEGF maken inderdaad leidt tot het sterk verminderen of ontbreken van 
angiogenese en vaatlekkage. Deze tumoren blijven echter wel groeien, maar dan door 
preexistente vaten te incorporeren. Omdat deze groeiwijze niet goed meer zichtbaar is te 
maken met behulp van de conventionele MRI diagnostiek bestaat het gevaar dat de anti-
angiogene behandeling ten onrechte als zeer succesvol wordt beschouwd.   
 
VEGF productie door tumorcellen leidt ertoe dat metastasen sneller groeien (hoofdstukken 3 
en 5). De vraag is of zulke tumoren ook eerder metastasen geven als tumoren die niet 
angiogeen zijn. In hoofdstuk 7 wordt onderzoek beschreven waarbij in verschillende 
diermodellen wordt gekeken  naar de kans op metastasering van melanoomcellen in relatie 
hun VEGF-productie. Uit dit onderzoek bleek dat de kans dat melanoomcellen in de 
bloedbaan geraken vanuit de oorspronkelijke tumor duidelijk hoger is wanneer de tumor 
VEGF maakt. Het “landen” van melanoomcellen in diverse organen (de kolonisatie) werd 
echter niet beinvloed wordt door de aan- of afwezigheid van VEGF op tumorcellen. De 
grotere kans op uitzwermen van tumorcellen in de bloedbaan in VEGF producerende tumoren 
lijkt niet alleen te verklaren door een relatief hoge vaatdichtheid en daardoor een hogere 
trefkans voor tumorcellen om in een bloedvat te geraken. Wij menen dat ook andere, door 
VEGF geinduceerde miro-architecturele veranderingen in de tumor hierbij een rol spelen: in 
VEGF producerende tumoren werden regelmatig tumorcel-clusters gevonden die deels 
uitpuilden in het lumen van bloedvaatjes en soms zelfs als multicellulaire emboli op afstand in 
de bloedbaan werden aangetroffen. Hierbij bleek binnen deze tumoremboli een heterogene 
populatie van (o.a. meer en minder VEGF producerende) tumorcellen aanwezig te zijn, 
hetgeen begrijpelijk maakt dat vanuit dergelijke emboli zelfs niet-angiogene metastasen 
kunnen ontstaan. 
 
Samenvattend komen in dit proefschrift nieuwe inzichten naar voren in de mogelijkheid van 
tumoren om in hun bloedvoorziening te voorzien door middel van vaat-coöptie en in de 
consequenties van een dergelijke groeiwijze voor radiologische beoordeling van bijv. het 
effect van anti-angiogene behandeling. Daarnaast bevat het dierexperimenteel werk 
beschreven in dit proefschrift aanwijzingen dat de door VEGF productie in tumoren teweeg 
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gebrachte microarchitecturele veranderingen o.a. aanleiding kunnen geven tot vorming van in 
vaatlumina uitpuilende, multicellulaire tumorcel-aggregaten die vervolgens los geraken en tot 
metastasen op afstand aanleiding geven. Verder onderzoek in humaan tumorweefsel is 
inmiddels gestart om na te gaan of, en zo ja, hoe vaak dit fenomeen bij de mens voorkomt. De 
eerste indruk hierbij is dat dit fenomeen bij bijv. heldercellig niercelcarcinoom relevant is. 
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Zusammenfassung 
 
Krebs ist eine lebensbedrohliche Krankheit und ist eine häufige Ursache für Krankheit und 
Tod in westlichen Ländern. Gerade die Behandlung von Krebsmetastasen stellt ein großes 
Problem dar. Die gängigen chirurgischen, chemotherapeutischen und radiotherapeutischen 
Behandlungsschemata sind in diesen Fällen häufig nicht effizient genug. Deshalb wird 
versucht, neue Wege zur Behandlung zu finden: ein neuer Ansatzpunkt zur Krebsbehandlung 
zielt darauf die Gefäßversorgung der Krebsgeschwulst zu unterbinden und somit den Tumor 
„auszuhungern“. Das Konzept dahinter ist die Hypothese, daß Krebsgeschwülste, wie 
normales Gewebe auch, zur Aufrechterhaltung eines vitalen Status eine Blutgefäßversorgung 
nötig haben, die Tumoren durch den Prozeß von Angiogenese (Gefäßneuformung) selbst 
induzieren. Eine Antiangiogene Therapie würde damit das Wachstum eines Tumors 
verhindern und vielleicht sogar die Metastasierung hemmen, da Tumorzellen den primären 
Tumor häufig via die Blutbahn verlassen und damit der Ursprung von Metastasen sind. Die 
Erprobung van antiangiogener Therapie befindet sich zurzeit noch in experimentellen Studien 
und ist noch nicht etablierte Standardtherapie innerhalb der Onkolgie. 
 
Das Melanom der Haut ist eines der bösartigsten Krebserkrankungen des Menschen, dessen 
Heilung nur möglich ist, wenn der Tumor in einem frühen Stadium vollständig exzidiert wird. 
Ist das Melanom tiefer in die Haut infiltriert, ist die Wahrscheinlichkeit auf 
Metastasenformung deutlich erhöht. Erste Metastasen werden häufig in regionalen 
Lymphknoten, später auch in anderen Organen wie Lunge, Leber und Gehirn angetroffen. 
Hirnmetastasen sind beim metastasierten Melanom im Vergleich zu anderen Tumoren relativ 
häufig.  
 
Um die biologische Eigenschaften und neue therapeutische und diagnostische Ansätze zu 
entwickeln, ist weitere Forschung von Nöten. Basale und noch präklinische Fragestellungen 
werden hierbei in erster Linie durch tierexperimentelle Studien, flankiert durch Analyse von 
Patientenmaterial (Material aus pathologischen Archiven) angegangen. Bei schon ausgereiften 
Konzepten werden klinische Studien an Patienten durchgeführt. Der Vorteil 
tierexperimenteller Studien ist die Möglichkeit der Standardisierung der 
Versuchsbedingungen und die Möglichkeit bestimmte Mechanismen der Tumorbiologie 
durch Manipulation in definierten Stoffwechsel/Gen-Mechanismen zu verändern und damit 
Einsichten zu Wirkmechanismen zu erlangen.  
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In dieser Dissertation werden tierexperimentelle Studien mit „nackten Mäusen“ beschrieben. 
Diesen Mäusen fehlt neben einer regulären  Behaarung auch ein kompetentes zelluläres 
Immunsystem, sodaß es möglich ist, in diese Mäuse menschliche Tumorzellen zu 
transplantieren, ohne daß diese durch eine Immunreaktion abgestoßen werden.  
 
In Kapitel 2 wird die Entwicklung eines Tiermodells von Hirnmetastasen beschrieben; hierbei 
werden humane Melanomzellen verwendet. Die Rolle der Integrin αvß3 -Expression durch die 
Tumorzellen und die Rolle von individuellen Tumorzellen versus Tumorzellaggregaten bei 
der Metastasierung wurden untersucht. Unsere Ergebnisse zeigten, daß das 
Metastasierungsmuster (Gehirnparenchym versus Hirnhäute) ebenso wenig beeinflußt wird 
durch die Integrin αvß3 -Expression wie durch die An- bzw. Abwesenheit von 
Tumorzellaggregaten.  
 
Kapitel 3 untersucht das Wachstumsverhalten der Melanomzellen im Hirngewebe. Wir 
zeigen, daß Melanomzellen, die den Blutgefäßwachstumsfaktor VEGF (Vascular Endothelial 
Growth Factor) nicht produzieren, im Hirngewebe wachsen ohne überhaupt neue Blutgefäße 
zu induzieren, da diese Tumorzellen vom preexistenten Gefäßsystem Gebrauch machen (engl. 
co-option). Produzieren diese Tumorzellen jedoch einen der verschiedenen Isoformen von 
VEGF (dies kann durch genetische Manipulation der Tumorzellen erreicht werden), so 
können neben Gefäßdilatation und erhöhte Permeabilität  auch Gefäßneubildungen beobachtet 
werden (Kapitel 3 und 5); hierbei zeigt sich jedoch ein Unterschied zwischen den einzelnen 
VEGF-Isoformen.  
 
Die diagnostischen Konsequenzen der Gefäß-cooption von Hirntumoren wird in Kapitel 4 
beschrieben: Tumore die keine Gefäßneubildung zeigen bzw. kein VEGF produzieren sind 
fast unsichtbar in kernspintomographischer Bildgebung (MRI) mit gewöhnlichen 
Kontrastmitteln. Neuere Kontrastmittel, basierend auf kleinen Eisenoxidpartikeln und in erster 
Linie im Gefäß verbleibend, können aber solche Tumoren demarkieren, da diese durch eine 
relative Abnahme der Gefäßdichte innerhalb des Tumors weniger Kontrastanreicherung 
zeigen als das vergleichbare umgebende Hirngewebe. 
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In Kapitel 6 wird gezeigt, daß eine anti-angiogene Behandlung von VEGF-produzierenden 
Tumoren tatsächlich einhergeht mit einer Hemmung der Angiogenese und der Gefäßleckage. 
Tumore können aber dennoch weiter wachsen durch den Gebrauch preexistenter Gefäße, ohne 
daß diese Tumoren noch sichtbar sind im MRI. Hierin liegt dann auch die Gefahr, daß bei 
antiangiogener Therapie zu unrecht eine Tumoreradikation angenommen wird. 
 
Die Sekretion von VEGF durch Tumorzellen erhöht die Wachstumsrate der Tumoren (Kapitel 
3 und 5). Die Frage ist, ob VEGF-produzierende Tumorzellen nicht nur schneller wachsende 
Metastasen formen können, sondern auch die tatsächliche Anzahl der Metastasen erhöhen 
kann. In Kapitel 7 konnten wir mit Hilfe unterschiedlicher Tumormodelle zeigen, daß eine 
VEGF-Sekretion durch Tumorzellen auch die Inzidenz von Metastasen erhöht. Dies wird 
verursacht durch einen mikroanatomischen Umbau des primären Tumors, der zu einer 
Gefäßarchitektur führt, in der innerhalb der Gefäße (intravaskulär) 
Tumorfragmente/Tumornoduli gelegen sein, die in der Blutbahn weiter verschleppt und so zu 
Metastasen werden können. Diese Tumornuduli können heterogen sein bezüglich der VEGF-
Produktion, was dazu führen kann, daß selbst Tumorzellen metastasieren können, die kein 
VEGF sekretieren.  
 
Zusammenfassend beschreibt diese Dissertation neue Einsichten über die Möglichkeiten der 
Gefäßversorgung von Tumoren, hierbei zu nennen die Gefäß-cooption. Die radiologischen 
und therapeutischen Konsequenzen derartiger Tumorcharakteristiken werden aufgezeigt. 
Daneben wird in dieser Arbeit ein alternatives Konzept zur Entstehung van Metastasen 
beschrieben, dessen Ursache die angiogene Eigenschaft eines Tumors ist. Hierbei spielt die 
Entstehung van intravaskulären Tumornoduli/Tumoremboli eine entscheidende Rolle. Erste 
Untersuchungen in humanem Patientenmaterial zeigen, daß dieses Phänomen auch beim 
Menschen zu beobachten ist, z.B. beim klarzelligen Nierenzellkarzinom. 
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